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Summary  
The CHO-K1 cell line is the most common expression system for therapeutic proteins in the 
pharmaceutical industry. Due to the nature of economics, the cell lines and the vector design are 
subject to constant change to increase product quality and quantity. During the cultivation, the 
production cell lines are susceptible to decreasing productivity over time. Often the loss of 
production can be associated with a reduction of copy number and the silencing of transgenes. 
During cell line development, the most promising cell lines are cultivated in large batch culture. 
Consequently, the loss of a stable production cell line can be very cost-intensive. For this reason I 
developed different strategies to avoid a reduced productivity. Instability of production cell lines can 
be predicted by the degree of CpG methylation of the driving promoter. Considering that the DNA 
methylation is at the end of an epigenetic cascade and associated with the maintenance of the 
repressive state, I investigated the upstream signals of histone modifications with the assumption to 
obtain a higher predictive power of production instability. For this reason I performed a chromatin 
immunoprecipitation of the histone modifications H3K9me3 and H3K27me3 as repressive signals 
and H3ac as well as H3K4me3 as active marks. The accumulations of those signals were measured 
close to the hCMV-MIE at the beginning of the cultivation and were then compared with the loss of 
productivity over two month. I found that the degree of the H3 acetylation (H3ac) correlated best 
with the production stability. Furthermore I was able to identify an H3ac threshold to exclude most 
of the unstable producers. 
In the second project I aimed to improve the vector design by considering epigenetic mechanisms. 
To this end I designed on the one hand a target-oriented histone acetyltransferase to enforce an 
open and active chromatin status at the transgene. On the other hand I point-mutated methylation-
susceptible CpGs within the hCMV-MIE to impede the maintenance of inactive heterochromatin 
formation. Remarkably, the C to G mutation located 179 bp upstream of transcription start site 
resulted in very stable antibody producing cell lines. In addition, the examination of cell pools 
expressing eGFP showed that G-179 promoter variants were less prone to a general methylation and 
gene amplification, which illustrates the dominating effect in epigenetic mechanisms of one single 
CpG.  
The last project was performed to localize stable integration sites within the CHO-K1 genome. In so 
doing I could show that the transfection leads predominantly to integration into inactive regions. 
Furthermore I identified promising integration sites with a high potential to induce stable 
expression. However, those results are preliminary and must be viewed with caution. Further 
examination needs to be done to confirm these results. 
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Considering the results of all three projects, I propose that the interplay of metabolic burden and 
selection pressure at an early time point of cultivation plays an important role in cell line 
development. Small alterations of selection pressure can lead to a decisive change of cell properties. 
Therefore, stable cells are less susceptible than weak producers. The increase of selection pressure 
leads to compensatory effect by gene amplification in the instable cell lines. The resulting 
adjustment of productivity masks the truly stable cells, which precludes the selection of the right cell 
lines. For this reason the selection pressure, the copy number as well as the growth rate should be 
considered to minimize repressive effects. 
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Zusammenfassung 
Die CHO-K1 Zelllinie ist das am häufigsten verwendete Expressionssystem für therapeutische 
Proteine innerhalb der pharmazeutischen Industrie. Aus wirtschaftlichen Gründen wird die 
verwendete Zelllinie sowie die eingesetzten Vektoren ständig verbessert um die Produktqualität und 
-quantität zu erhöhen. Während der Kultivierungsphase neigen Produktionszelllinien dazu an 
Produktivität zu verlieren. Dabei wird der Produktivitätsverlust häufig mit einer Reduktion der 
Kopienzahl oder dem Silencing von Transgenen assoziiert. Während der Zelllinienentwicklung 
werden vielversprechende Zelllinien ausgewählt und im großen Ansatz kultiviert. Ein 
Produktivitätsverlust innerhalb solcher Zellen ist somit sehr kostenintensiv. Um diese Gefahr zu 
minimieren entwickelte ich unterschiedliche Stategien, welche darauf abzielen den 
Produktivitätsverlust zu vermeiden. 
Produktionsinstabilität konnte von unserer Gruppe schon anhand des CpG Methylierungsgrades am 
CMV Promoter vorhergesagt werden. Die DNA Methylierung wird wahrscheinlich zur 
Aufrechterhaltung eines inaktiven Chromatinstatus benötigt und steht am Ende einer epigentischen 
Kaskade. Im Gegensatz dazu erscheinen Histonmodifikationen früher in der Signalkaskade und 
könnten deswegen eine höhere Aussagekraft über die Stabilität haben. Aus diesem Grunde wurden 
von mir Histonemodifkationen am hCMV-MIE Promoter und Enhancer zu Beginn der 
Kultivierungsphase gemessen. H3K4me3, H3ac sind Histonmodifikationen die mit Expression 
assoziiert werden wohingegen H3K27me3 und H3K9me3 grundsätzlich mit einem inaktiven 
Chromatinstatus in Verbindung gebracht werden. Der Grad der unterschiedlichen Modifikationen 
wurde mit dem über zwei Monate entstehenden Produktivitätsverlust verglichen. Dabei stellte sich 
heraus, dass der Grad der Histon H3 Acetylierung die höchste Korrelation mit der Stabilität aufwies. 
Des Weiteren konnte ich einen Grenzwert für die H3 Acetylierung definieren der einen Ausschluss 
der meisten instabilen Produktionszelllinien ermöglicht. 
Im zweiten Projekt wurde das Vector Design unter epigenetischen Aspekten verändert. Ich erstellte 
eine zielgerichtete Histonacetyltransferase, um in dem Chromatinbereich des Transgenes einen 
offenen und aktiven Status zu induzieren. Desweiteren mutierte ich methylierungsanfällige CpGs des 
hCMV-MIE Promoters und Enhancers um eine Methylierung und daraus folgend einen inaktiven 
Chromatinstatus zu verhindern. Die C zu G Konversion an dem 179 Basenpaar oberhalb der 
Transkriptionsstartstelle führte zu einer bemerkenswert stabilen Antikörperexpression in klonalen 
Zelllinien. Desweiteren konnte ich bei gleicher Promotervariante in eGFP exprimierenden Zellpools 
eine geringere Methylierung und Genamplifikation feststellen. Somit konnte zum ersten Mal die 
Effektsensitivität eines einzelnen CpGs verdeutlicht werden. 
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Im letzten Projekt wurde die Expressionsstabilität abhängig von der Integrationsstelle des 
Transgenes untersucht. Dabei konnte ich zeigen, dass die standardmäßig durchgeführte zufällige 
Integration entweder bevorzugt in inaktiven Bereichen des Euchromatin stattfindet oder dass die 
Selektionsdruck induzierte Genamplifikation hauptsächlich im Heterochromatin stattfindet. 
Weiterhin vermute ich, dass beide Ereignisse hintereinander geschaltet sind, bei der die geringe 
Aktivität des Transgenes im inaktiven Euchromatin die Genamplifikation im Heterochromatin 
fördert. Bei der Untersuchung der Chromatinlandschaft und den enthaltenden Transgenen konnte 
ich vielversprechende aktive Regionen identifizieren, die wahrscheinlich die Stabilität der Expression 
fördern. Jedoch müssten diese Ergebnisse in weiteren Experimenten bestätigt werden. 
Bei der Betrachtung der drei Projekte zeigt sich, dass das Wechselspiel zwischen der Belastung des 
Stoffwechsels der Zelle und dem Selektionsdruck in der frühen Kultivierungsphase ausschlaggebend 
ist für deren weitere Entwicklung. Dabei können kleine Veränderungen des Selektionsdruckes die 
Zellen maßgebend beeinflussen. Stabil exprimierende Zellen sind dabei weniger angreifbar als 
schwach exprimierende Zellen. Bei einer Erhöhung des Selektionsdruckes kompensieren die 
schlechteren Produktionszelllinien ihren Nachteil durch Genamplifikation. Die Anpassung der 
Produktivität überdeckt die stabilen Zellen welches die richtige Auswahl erschwert. Aus diesem 
Grunde sollte der Selektiondruck, die Kopienzahl, sowie die Wachstumsrate in den 
Selektionskriterien mit einbezogen werden, um reprimierende Effekte zu minimieren. 
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1 Introduction 
 
1.1 Chromatin 
1.1.1 Organization of chromatin 
Deoxyribonucleic acid (DNA) is a macromolecule that encodes the instructions of all known living 
organisms (Avery, Macleod & McCarty, 1944). In human cells DNA has a length of approximately two 
meters and is predominantly stored in the nucleus which has a diameter of 10 µm (Turner, 2002). To 
organize this amount of information the DNA needs to be highly compacted. A group of conserved, 
small basic proteins called histones in complex with DNA generate an ordered and compact 
structure termed `chromatin`. Histones were first described in 1911 by Albrecht Kossel. Those 
positively charged proteins interact with the negatively charged phosphodiester backbone of the 
DNA double helix (Alberts B, 2002; Meyers, 2012a; Olins, 2003). The four “core” histones H2A, H2B, 
H3 and H4 combine with DNA to form the basic repeating unit of chromatin, called the nucleosome 
(Thomas & Kornberg, 1975). The 225 kDA nucleosome core structure consists of approximately 147 
bp of DNA wrapped around a histone octamer, comprising two H2A/H2B dimers and a H3/H4 
tetramer in 1.67 left-handed superhelical turns (Figure 1) (Arents et al., 1991; Arents & 
Moudrianakis, 1993; Richmond, 1999). Linker DNA of 10 to 80 bp connect consecutive nucleosomes 
(Widom, 1992). A fifth histone called linker histone H1 can bind to the linker DNA and thereby 
induces further compaction by altering the entry/exit angle of the DNA (Allan et al., 1984). 
Nucleosomes with bound H1 are often referred to as chromatosomes comprising approximately 
166 bp of two full turns of DNA (Allan et al., 1984; Wu, Bassett & Travers, 2007). 
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Figure 1: Organization of chromatin: Schematic overview of chromatin structure depicting major levels of histone 
mediated compaction. Modified from (Tonna et al., 2010). 
 
Repeating nucleosomes build a long chain, which gives the appearance of beads on a string called 
10 nm fiber (Olins & Olins, 1974). In addition the linker histone H1 induces further compaction into a 
secondary structure called 30 nm fiber (Thoma, Koller & Klug, 1979; Wu et al., 2007). The structure 
of the 30 nm fiber remains unresolved due to the limited visualization of the individual nucleosome 
within the fiber (Tremethick, 2007). Solenoid and zig-zag structures are reported as models for the 
30 nm fiber, whereas the preferred architecture can be influenced by linker length between 
neighboring nucleosomes (Robinson & Rhodes, 2006; Routh, Sandin & Rhodes, 2008). Recent studies 
showed that 10 nm fibers were the only regular chromatin structures in vivo and that further 
compaction was rather achieved by densely packaged 10 nm fiber than by folding into regular 
structures like the solenoid or zig zag model (Chen & Dent, 2014). Folding at the tertiary level 
probably requires non-histone proteins known collectively as Chromatin Architectural Proteins 
(CAPs). The highest level of compaction is represented by mitotic chromosome with 1.4 µm fiber 
diameter (Woodcock & Ghosh, 2010).  
 
1.1.2 Euchromatin versus heterochromatin 
Depending on the accessibility of DNA, chromatin is distinguished into two types. Highly compacted 
heterochromatin, which is less accessible for transcription, and loosely-packed transcriptionally-
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active euchromatin. Condensed chromatin is subdivided into constitutive and facultative (inducible) 
heterochromatin. Constitutive heterochromatin mainly comprises repetitive genetic elements and is 
thought to act as a chromosome stabilizer. Heterochromatin formation can spread into non-
repetitive, gene-containing adjacent regions – this mechanism is known as position-effect-
variegation. Facultative heterochromatin can form anywhere in the nucleus, often localized to 
promoters, and is established either in a developmentally regulated manner or in response to 
environmental triggers (Chen & Dent, 2014). Euchromatin, due to its open structure, is more 
accessible for RNA polymerases. Therefore, genes that are located in euchromatin are often actively 
transcribed (International Human Genome Sequencing, 2004). 
Specific sequence elements known as insulator or boundary elements act either to block the effect 
of enhancers on promoters, or to prevent heterochromatin spreading into euchromatin areas by 
forming barriers. Thereby, respective genes are shielded from the influence of their position within a 
specific nuclear environment (Gaszner & Felsenfeld, 2006; Henikoff, 1990). 
 
1.1.3 The dynamic of chromatin structure – epigenetic marks 
During the last decades of research it has been demonstrated that chromatin is highly dynamic. 
Changes occur at all compaction levels from mitotic chromatin condensation to the individual 
nucleosome (Meyers, 2012a). Alterations of the chromatin structure can result from the 
incorporation of histone variants (Greaves et al., 2007; Hake & Allis, 2006; Santenard & Torres-
Padilla, 2009), histone modifications (Chen & Dent, 2014), binding of chromatin architectural 
proteins (Luger & Hansen, 2005) or ATP-dependent remodeling factors (Clapier & Cairns, 2009), non-
coding RNAs (Mercer & Mattick, 2013; Peschansky & Wahlestedt, 2014; Zhou, Hu & Lai, 2010) and 
DNA methylation (Smith & Meissner, 2013). The dynamics of chromatin interaction can be very 
different. While histone H1 association and dissociation can occur within seconds, histones H3 and 
H4 typically remain bound over several cell generations (Kimura & Cook, 2001; Kimura, Hieda & 
Cook, 2004; Lever et al., 2000; Steffen, Fonseca & Ringrose, 2012). Likewise, the post-translational 
modifications of histones are highly dynamic (Barth & Imhof, 2010). Cytosine methylation of DNA is 
in contrast considered to be a long-lasting modification (Otto & Walbot, 1990; Smith & Meissner, 
2013). Considering the various possibilities of structure modulation at all stages of the cell cycle, it 
seems plausible why no consistent higher-order structures have been observed in vivo (Woodcock & 
Ghosh, 2010). 
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Figure 2: Epigenetic mechanisms involved in chromatin modifications. Five mechanisms for alteration of chromatin 
structure are known: Chromatin remodeling, insertion of histone variants, histone modification, effects of non-coding 
RNAs (ncRNAs) and DNA methylation. Ac, acetyl; Me, methyl; P, phosphate: adopted from (Dulac, 2010). 
 
1.1.4 Inheritance of epigenetic marks 
Epigenetic marks can be heritable and can be passed to daughter cells to preserve cellular identity 
(Chen & Dent, 2014). In particular, DNA methylation and H3K9 methylation are stable markers, 
which for instance can hinder the reprogramming of somatic cells into induced pluripotent stem 
cells (Papp & Plath, 2013). While it is widely accepted that symmetrical CpG methylation is passed on 
daughter cells involving semi-conservative segregation and template copying during DNA replication, 
inheritance mechanisms of histone modifications are still subject to investigation (Chen & Dent, 
2014). In at least some cases proteins with specific recognition sites for post translational 
modifications rather than the histone marks persist through DNA replication at specific chromatin 
locations to establish histone modifications in daughter cells, which questioned the epigenetic 
inheritance of histone modifications (Francis et al., 2009; Petruk et al., 2012). However a recent 
study in fission yeast demonstrates true inheritance of H3K9 methylation independent of sequence 
specific recruitment (Ragunathan, Jih & Moazed, 2015). 
 
1.2 Histone variants 
Canonical histones H2A, H2B, H3 and H4 are conserved from yeast to mammals and are encoded by 
multiple gene copies, clustered in repeat arrays in higher eukaryotes. The transcription occurs 
mainly in S-phase during the cell cycle and is tightly coupled to DNA replication (Talbert & Henikoff, 
2010). The canonical histones are incorporated in a replication coupled manner, whereas histone 
variants are expressed throughout the cell cycle and replace canonical histones when nucleosomes 
are evicted (Weber & Henikoff, 2014). Those histone variants differ in primary amino acid sequence 
from their canonical paralogues and are usually encoded by a single copy gene (Bernstein & Hake, 
2006; Meyers, 2012a). In contrast to canonical histones, the non-canonical histones can be 
incorporated by replication-coupled and replication independent mechanisms. It has been observed 
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that the incorporated histone variant composition correlates with the functional status of the 
chromatin, regardless of the mechanism. Non-canonical histones have roles in DNA repair, meiotic 
recombination, chromosome segregation, transcription initiation and termination, sex chromosome 
condensation and sperm chromatin packaging (Talbert & Henikoff, 2010). 
The H2A histone variants are well examined. Although the variants can be very different to the 
canonical H2A on the amino level, the structures are often quite similar. Within the core, the L1 loop 
as well as the docking domain of the C-terminus are often structurally different, which leads to 
variation of H3-H4 respectively H2A-H2B interaction (Weber & Henikoff, 2014). In addition 
internucleosomal and higher-order associations are influenced by alteration of the acidic patch of 
H2A. For instance H2A.Z and MarcoH2A are associated with compaction, whereas H2A.Bbd is 
associated with decompaction of chromatin structure (Bonisch & Hake, 2012). Furthermore the 
combinations of non-canonical and canonical subtypes of histones like H2A.Z/H2A can be associated 
with specific biological processes, which increases complexity of signal pattern (Nekrasov et al., 
2013). 
 
1.3 Histone modifications 
Histones can be modified in many different ways, mainly occurring along the residues of the  
N-terminal amino acid sequence which range from amino acids 13 to 40. The large number of 
modifications even increases due to the fact that some modifications, like lysine methylation, 
comprise up to three different states (Kouzarides, 2007). More than 100 histone modifications have 
been discovered and new modifications might be found within the next few years (Zentner & 
Henikoff, 2013). This complexity provides enormous potential for structural and functional 
responses. Acetylation and methylation of histone H3 and histone H4 tail residues are the best 
studied modifications. Overall, 14 distinctive types of modifications have been found (Dawson & 
Kouzarides, 2012) and are listed in Table 1. 
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Chromatin 
Modifications 
Modified Residues Chromatin 
Modifications 
Modified Residues 
Acetylation K-ac Proline isomerization P-cis> P-trans 
Methylation (lysines) K-me1, K-me2, K-me3 Crotonylation K-cr 
Methylation 
(arginines) 
R-me1, R-me2a, R-me2s Propionylation K-pr 
Phosphorylation S-ph, T-ph Butyrylation K-bu 
Ubiquitylation K-ub Formylation K-fo 
Sumoylation K-su Hydroxylation Y-oh 
ADP ribosylation E-ar O-GlcNAcylation  
(serine and threonine) 
S-GlcNAc; T-GlcNAc 
Deimination R>Cit   
 
Table 1: K, lysine; R, arginine; S, serine; T, threonine; E, glutamic acid; P, proline; Ac, acetylation; me, methylation; Cit, 
citrulline; P, proline; cr, crotonylation; pr, propionylation; bu, butyrylation; fo, formylation; oh, hydroxylation; a, 
asymmetric; s, symmetric; >, conversion; Cit, citrulline. Adopted from (Dawson & Kouzarides, 2012). 
 
The combination of those modifications, termed as PTM motifs are rather associated with functions 
than the individual marks. Research into combination of modifications suggests more than 200 
different PTM motifs (Feller et al., 2015). Modifications are reversible and controlled by proteins 
which are according to their function as “writers”, “erasers” and “readers”. Writers are enzymes 
which modify specific histone loci by adding a post-translational modification, such as histone 
acetyltransferases (HATs), whereas erasers are enzymes with the opposite function (Baker, Allis & 
Wang, 2008; Borrelli et al., 2008). Readers are proteins with specific domains which recognize post-
translational modifications. For instance bromodomains recognize acetylation whereas 
chromodomain target the threefold methylation of H3K9 (Taverna et al., 2007). Thus, some histone 
acetyltransferases can act simultaneously as readers and writers. 
 
1.3.1 Histone methylation 
1.3.1.1    Location in context with function of specific histone lysine methylations 
Methylations of histone amino acids are best-characterized for lysine (K) and arginine (R) residues. 
The prominent sites for lysine methylation are H3K4, H3K9, H3K27, H3K36, H3K79 and H4K20. The 
appearance and frequency of methylated residues are dependent on their location and function. 
H3K4, H3K36 and H3K79 methylated residues are typical for active chromatin, whereas H3K9, H3K27 
and H4K20 methylation are often found in heterochromatin (Dawson & Kouzarides, 2012). The 
active mark H3K4me2/3 is especially enriched at the transcription start sites of active genes 
(Ruthenburg, Allis & Wysocka, 2007), the appropriate gene bodies are broadly enriched with 
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H3K36me3 (Zentner & Henikoff, 2013). Repressive marks have different spatial distributions: the 
H3K27me accumulates on the inactive X-chromosome, whereas H3K9me is enriched in the 
pericentromeric heterochromatin (Barski et al., 2007; Kouzarides, 2007). Furthermore, H3K9me3 as 
well as H3K27me3 can be found in the promoter region of silenced genes (Allan et al., 2012; 
Rougeulle, Navarro & Avner, 2003; Trojer & Reinberg, 2007). 
 
1.3.1.2    Establishing of histone lysine methylation and demethylation 
Methylation of histone residues is performed by the writers; lysine methyltransferases (KMTs) or 
protein arginine methyltransferases (PRMTs). The first lysine methyltransferase to be identified was 
SUV39H1 (Rea et al., 2000), followed by a varying number of characterized KMTs. The vast majority 
of KMTs contain a conserved SET domain catalyzing the transfer of a methyl group from  
S-adenosylmethionine (SAM) to lysine ε-amino groups (Meyers, 2012a). There are numerous histone 
lysine methyltransferases as well as demethylases which are highly specific enzymes that target 
specific lysines depending on their methylation status (Klose & Zhang, 2007; Xiao et al., 2003). In 
mammals at least eleven H3K4 methyltransferases have been described (Gu & Lee, 2013). The 
recruitment of these methyltransferases can be initiated by specific transcription factors and/or 
RNAs (Figure 3). Both are proposed as initiation mechanisms, followed by maintenance mechanisms 
(Ruthenburg et al., 2007). 
 
Figure 3 Mechanisms of H3K4 methyltransferase targeting specific genes exemplified by the MLL family. Recruitment is 
conducted by sequence specific DNA binding factors (A), by basal transcriptional machinery (B), by histone modification 
readers (C) or by RNA (D). Adopted from (Ruthenburg et al., 2007). 
 
Lysine demethylases were first identified in 2004 (Shi et al., 2004). The lysine specific demethylase 1 
(LSD1) is able to demethylate di- and mono-methyllysines via an amine oxide reaction (Klose & 
Zhang, 2007; Ng et al., 2009). Depending on the associated complex LSD1 can act either as repressor 
or activator by demethylating H3K4 or H3K9 (Klose & Zhang, 2007). Tri-methyllysines require a 
specific class of demethylases for degradation to occur. The first enzyme was discovered in 2006 and 
A B C D 
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termed JMJD2 (Whetstine et al., 2006). Degradation is carried out by an oxidative mechanism in 
which iron and α-ketoglutarate catalyze hydroxylation, forming a carbinolamine intermediate which 
readily breaks down into formaldehyde and a lysine lacking one methyl group (Mosammaparast & 
Shi, 2010; Whetstine et al., 2006). 
 
1.3.1.3    Mode of action 
Histone methylation neither influences the overall charge nor is it likely to influence the structure of 
the molecule. Considering this, methylation of residues indirectly affect the chromatin state by 
attributing binding sites for functional proteins instead of inducing a direct allosteric change 
(Meyers, 2012a). A number of protein domains were found which specifically binds to methylated 
lysines in histones. The Tudor, PWWP and MBT domains comprise a four ß-stranded core region 
while the chromodomain comprises a three-stranded ß-barrel with a C-terminal α-helix (Shimojo et 
al., 2008) as recognition site for methylated lysines within histones (Kim et al., 2006). PHD fingers 
can also act as recognition sites for methylated lysines, depending on protein context (Champagne & 
Kutateladze, 2009; Gozani et al., 2003). Those protein domains are part of downstream effector 
proteins, which are able to execute specific independent functions after binding histone 
modifications (Kim et al., 2006; Shi et al., 2006; Wysocka et al., 2006). The fact that a variety of 
proteins with different functions can bind the same histone modification (e.g. 5 of 6 MLL family 
proteins on H3K4me3), this led to the conclusion that there are primary recruiting events such as 
site-specific transcription or RNA, followed by the stabilizing effect of specific histone modification 
(Filippakopoulos et al., 2012; Ruthenburg et al., 2007). 
 
1.3.2 Histone acetylation 
1.3.2.1    Location in context with function of specific histone lysine acetylations 
Acetylation was discovered in 1961 as the first histone modification (Phillips, 1963). Early studies 
associate actively transcribed genes with the hyperacetylation of histones, which indicates a 
function of acetylation in the transcription process (Allfrey, Faulkner & Mirsky, 1964). During S-phase 
a global increase of acetylation sites, such as H3K56ac, was observed followed by a decrease during 
G2-phase. This led to the conclusion that histone acetylation might facilitate the incorporation of 
newly synthesized histones (Miller, Maas & Toczyski, 2006). In addition to their global role during 
DNA replication, histone acetylation forms specific genomic patterns correlating with active 
transcription; where heterochromatin regions are hypoacetylated and transcriptionally active genes 
are highly acetylated (Kouzarides, 2007). Acetylation peaks are found at specific sites in the 
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promoter close to transcription start sites (TSS) and with tendencies to spread toward the gene 
body, depending on the acetylation mark and the gene (Wang et al., 2008). The lysine residues of 
the N-terminal tail of H3 at position 4, 9, 14, 18 and of H4 at lysines 5, 8, 12 and 16 are prone to 
acetylation (Zentner & Henikoff, 2013). Taken together, regulation of gene expression, DNA 
replication, repair and recombination are influenced by different acetylation states of histones 
(Dawson & Kouzarides, 2012). 
 
Figure 4: Exemplified modification of histone N-tails. The residues are numbered starting from the N-termini and 
proceeds towards the core histone body. H3K4 represents the 4th amino acid. Adopted from (Graff & Mansuy, 2008).  
 
1.3.2.2    Establishment of histone lysine acetylation and deacetylation 
Histone acetyltransferases (HATs) generally mediate gene expression and transcriptional activation 
(Cheung, Allis & Sassone-Corsi, 2000). Functional HATs which were examined in vivo, can be grouped 
into three families, based on their structural homology:  
∑ (I) p300-CBP (CREB Binding Protein) coactivator family  
∑ (II) GCN5-related N-acetyltransferases (GNATs); and 
∑ (III) MYSTs (named after its four founding members MOZ, Ybf2, Sas2, and Tip60) (Meyers, 
2013; Sun et al., 2012)  
 
The CBP/P300 group only exists in metazoans and regulates a large number of physiological 
functions (Kalkhoven, 2004; Sun et al., 2012). In vitro studies suggested non-specific acetylation of 
multiple lysines of all core histones (Kouzarides, 2007). Although some in vivo studies demonstrate 
some specificity of CBP (Jin et al., 2011; McManus & Hendzel, 2003; Valor et al., 2011), a recent 
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study employing mass spectrometry to identify alteration of acetylation code suggests that CBP 
influences many acetylation sites (Feller et al., 2015). 
The GNAT group is a large family of N-acetyltransferases: their conserved structure is a set of  
three-dimensional (3-D) structural motifs, comprising several α–helices and β–strands (Vetting et al., 
2005). PCAF is a well-studied member of the GNAT family which can induce growth arrest by 
interaction with the cell cycle regulator p53 or to cellular proliferation by interacting with E2F 
(Timmermann et al., 2001). Furthermore it has been reported that PCAF acetylates specific lysines 
on H3 (Meyers, 2012b). 
The MYST HATs are a closely related family of five human genes termed according to their yeast 
homologs (MOZ, YBF2 (SAS3), SAS2, and TIP60) (Pillus, 2008). The acetylation of specific histone tail 
lysines is influenced by MYSTs. For example H4K16 acetylation in MYST1 knockout mice is greatly 
reduced in early embryo blastocysts, while the acetylation of the remaining H4 and H3 residues 
remains unaffected, leading to peri-implantation lethality in mouse embryos (Thomas et al., 2008). 
Furthermore, MOF (the drosophila MYST1 paralog) overexpression suggests that H4K16ac 
counteracts chromatin compaction mediated by the ISWI ATPase (Corona et al., 2002). MYST3 also 
acetylates H4K16, whereas MYST4 might only affect H3 acetylation (Kraft et al., 2011; Paggetti et al., 
2010). 
Three potential mechanisms for HAT enzymatic activity have been proposed: creation of a ternary 
complex between acetyl-CoA and substrate lysine or generation of an intermediate with the  
acetyl-CoA through a cysteine followed by attacking the target lysine (Hodawadekar & Marmorstein, 
2007) and a more complex “hit and run” mechanism (Liu et al., 2008). HATs are usually found in 
large macromolecular complexes comprising the additional components that confer specificity and 
genomic localization; their function have proven very difficult to dissect (Meyers, 2012a). 
In contrast to this, the erasers like histone deacetylases (HDACs) remove acetyl groups, which 
strengthens the histone-DNA interactions and modify the nucleosome fiber to the closed and 
transcriptionally inactive heterochromatin conformation (Lee & Workman, 2007). The HDACs can be 
grouped into four classes dependent on the sequence homology. Class I, II and IV share a related 
catalytic mechanism requiring a zinc metal ion but no cofactors (de Ruijter et al., 2003). The class III 
enzyme employ a distinct catalytic mechanism that is NAD+ dependent (Saunders & Verdin, 2007). 
 
1.3.2.3    Mode of action 
The acetylation of histone residues has a direct effect which leads to the neutralization of the 
positive charge located at the ε amino group of lysines, which are located along the histone tails 
(Brownell & Allis, 1996). The interaction of negatively charged DNA backbone and the N-terminal 
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histone tails is influenced by the ionization state and acetylated chromatin tends to adopt a relaxed 
euchromatin structure. For instance, targeting H4K16ac to a promoter in vitro or in yeast can lead to 
a robust derepression of transcription (Akhtar & Becker, 2000). A recent study propose the 
redundancy of some acetyltransferases for the overall histone acetylation levels. This suggests a key 
role in genomic stabilization by maintenance of global charge neutralization (Feller et al., 2015). In 
addition the alteration of the ionization state, histone acetylation has been shown to exhibit at least 
two additional functions: 
Acetylated lysines can be bound by bromodomains specifically, which enables protein recruitment 
like the chromatin remodeling complexes (Mujtaba, Zeng & Zhou, 2007). Hence the acetylation motif 
can influence the binding affinity of bromodomains (Filippakopoulos et al., 2012). Furthermore, the 
tandem plant homeodomain (PHD) fingers in the BAF chromatin remodeling complex member 
DPF3b are also able to bind acetyl-lysine motifs (Zeng et al., 2010).  
In addition to recruitment of proteins, acetylation of histones can hinder binding of proteins to 
chromatin, in particular it has been shown that an acetylation of lysine 4 on H3 reduces the affinity 
of spChp1 to H3K9me (Schalch et al., 2009; Xhemalce & Kouzarides, 2010). Overexpression of the 
acetyltransferase MOF in Drosophila melanogaster leads to a loss of the ISWI chromatin remodeler, 
indicating that H4K16ac might interfere with ISWI remodeling activity (Corona et al., 2002; Zentner & 
Henikoff, 2013). 
 
1.4 DNA methylation 
1.4.1 Location in context with function of DNA methylations 
DNA methylation is a repressive well-studied epigenetic modification and has a profound impact on 
gene expression, genome stability and development (Jaenisch & Bird, 2003; Smith & Meissner, 
2013). Methylation patterns can be associated with the developmental stage and cell type-specific 
epigenetic memory (Bird, 2002). Methylation of cytosine at the fifth position of the pyrimidine ring is 
a conserved epigenetic mark from fungi, plants to animals (Feng, Jacobsen & Reik, 2010). In 
mammals 5-methylcytosine (5mC) is predominantly 5´located to guanine and is primarily restricted 
to palindromic cytidine-phosphate-guanosine (CpG) dinucleotides (Ramsahoye et al., 2000; Ziller et 
al., 2011). Due to the mutagenic properties of methylcytosine to deaminate into thymine (Coulondre 
et al., 1978), CpG dinucleotides are depleted in mammalian genomes (Deaton & Bird, 2011). The 
human genome has approximately 28 million CpGs, of these 60-80% are generally methylated in 
somatic cells (Smith & Meissner, 2013). 
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In pericentromeric repeats the CpG methylation maintains the centromere-proximal 
heterochromatin, which is essential for cell division. Transposable elements are constitutively 
hypermethylated to repress the activity of their strong promoters except in specific phases of 
embryogenesis; Also parent-specific imprints are propagated by CpG methylation of germline 
imprint control regions (ICRs) (Smith & Meissner, 2013).  
Ten percent of the CpGs are accumulated in CpG-dense regions, termed CpG islands. Those islands 
are frequently located at transcription start sites of housekeeping and developmental regulator 
genes (Deaton & Bird, 2011), in a predominately nonmethylated state (Figure 5) (Illingworth et al., 
2010). Orphan CpG islands are located in intergenic and intragenic regions. They tend to be more 
frequently methylated, compared to CpG islands at common transcription start sites.  
 
 
Figure 5: Distribution of CpGs. Empty cycles represent unmethylated CpGs whereas filled cycles display methylated 
CpGs. Accumulation of CpGs is termed CpG island which occurs predominately at transcription start sites. Orphan CpG 
islands which are located at intra and intergenic regions, represent the half of all CpG islands (Illingworth et al., 2010). 
Adopted from (Deaton & Bird, 2011). 
 
1.4.2 Establishing of DNA methylation and demethylation 
DNA methylation is performed by DNA methyltransferases which catalyze the transfer of a methyl 
group (CH3) from S-adenosylmethionine (SAM) to the C5 position of cytosine (Wu & Zhang, 2014). 
Three conserved enzymes, DNA methyltransferase 1 (DMNT1), DNMT3A and DNMT3B are 
responsible for the establishment and maintenance of methylation and are essential for normal 
development (Li, Bestor & Jaenisch, 1992; Okano et al., 1999). 
De novo DNA methylation patterns are established by the DNA methyltransferases DNMT3A and 
DNMT3B, which are in turn supported by the DNMT3L (Okano et al., 1999). The maintenance 
methyltransferase DNMT1 with its obligate partner UHRF1, is responsible for passing the global CpG 
methylation pattern on to the daughter cells by transferring a methyl group to the hemi-methylated 
newly replicated DNA (Bostick et al., 2007; Hermann, Goyal & Jeltsch, 2004; Sharif et al., 2007). 
DNMT1 is the key player of methylation maintenance, but DNMT3A and DNMT3B also contribute 
(Jones, 2012). 
DNMT1 has a low affinity and catalytic activity for nonmethylated DNA. Therefore the de novo 
methylation by DNMT1 is limited (Jeltsch, 2006; Song et al., 2011). In embryonic stem cells (ESCs) 
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DNMT1 can be supported by DNMT3 to maintain DNA methylation at LINE (long interspersed 
elements) and LTR (long terminal repeat) element promoter sites (Liang et al., 2002). De novo 
methylation strongly correlates with the activity of close-by transcription factors. Depletion or 
truncation of the binding site for the common transcription factor SP1 within CpG islands leads to 
heritable accumulation of CpG methylation (Brandeis et al., 1994; Jones, 2012; Macleod et al., 1994). 
Furthermore, CpG methylation can influence the binding affinity of appropriate binding factor, as it 
has been shown for MYC (Jones, 2012). Examination of global transcription factor binding in context 
of DNA methylation supports the dominant role of transcription factors (Stadler et al., 2011). After 
transcription factor binding, an order of recruitment is frequently proposed, where chromatin 
remodeler LSH is followed by linker histone H1, heterochromatin protein HP1, H3K9 
methyltransferases and de novo DNA methyltransferases (Smith & Meissner, 2013). 
Though the mechanism of DNA methylation is well understood, the demethylation mechanism in 
mammalians remains ambiguous. DNA demethylation occurs either passively or actively (Wu & 
Zhang, 2014). Passive demethylation occurs when maintenance DNA methyltransferase DNMT1 is 
not able to fulfill its function. 5mC loss is thus achieved by successive cycles of DNA replication 
(Bostick et al., 2007; Sharif et al., 2007). A main mechanism for active demethylation involves 
oxidation of 5mC (Wu & Zhang, 2014).  
The oxidation of 5mC provides a biochemical mechanism of DNA demethylation (Wu & Zhang, 2014). 
Here 5mC is oxidized by enzymes of the TET family to 5-hydroxymethylcytosine (5hmC) (Kriaucionis 
& Heintz, 2009; Tahiliani et al., 2009), which gets successively oxidized to 5-formylcytosine (5fC) and 
5-carboxycytosine (5caC) (He et al., 2011; Ito et al., 2011; Pfaffeneder et al., 2011). TET proteins use 
a base-flipping mechanism to flip the target base out of the duplex DNA into the catalytic site to 
oxidate the 5-methylgroup in an α–ketoglutarate (α-KG) dependent way (Hashimoto et al., 2014;  
Hu et al., 2013). From this the CpGs can be demethylated by passive dilution or by active excision of 
modified 5mC (Wu & Zhang, 2014). 
 
 
Figure 6: Methylation and demethylation of cytosine. 5-cytosine methylation is catalyzed by DNMTs which uses  
S-adenosylmethionine (SAM) as methyl donor, resulting in 5mC and S-adenosylhomocysteine (SAH). Methylated C5 can 
be oxidized by TET enzymes to 5-hydroxymethyl-,5-formyl- and 5-caboxy-cytosine. Adopted from (Wu & Zhang, 2014). 
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1.4.3 Mode of action 
CpG islands can be methylated during development, leading to a stable silencing of the associated 
promoter (Jones, 2012; Mohn et al., 2008; Payer & Lee, 2008; Stein, Razin & Cedar, 1982). It has 
been proposed that the silencing effect is promoted by direct inhibition of transcription factor 
binding to methylated DNA or by methyl-binding domain (MBD) proteins that recruit chromatin 
modifying activities (Cedar & Bergman, 2009; De Carvalho, You & Jones, 2010; Klose & Bird, 2006). 
Recent studies suggest that DNA methylation is not an initial step towards silencing, but rather acts 
to lock the silent state (Lee & Bartolomei, 2013; Okamoto & Heard, 2009; Payer & Lee, 2008). In 
mammals it has been proposed that stable promoter silencing requires H3K9 methylation as well as 
DNA methylation, in which H3K9me might initiate heterochromatin formation and DNA methylation 
ensures long term stability (Epsztejn-Litman et al., 2008; Myant & Stancheva, 2008; Myant et al., 
2011). Also in female X chromosome inactivation the DNA methylation is downstream of a 
repressive histone modification (H3K27me3) which indicates that DNA methylation predominantly 
occurs at the end of a silencing cascade as a stabilizing signal (Smith & Meissner, 2013). 
 
1.5 Repressive chromatin 
Repressive chromatin can be divided in constitutive and facultative heterochromatin. Constitutive 
heterochromatin is characterized by consistently inactive regions across all cell types of a species, 
which indicates a role in the maintenance of genome stability. Sometimes, repressive epigenetic 
marks like H3K9me3 may spread into adjacent euchromatin regions. This is known as Position Effect 
Variegation (PEV). The facultative heterochromatin differs between cell types of a species and is 
therefore associated with differentiation and morphogenesis. Famous key players are the polycomb 
proteins (Almouzni & Probst, 2011; Oberdoerffer & Sinclair, 2007).  
 
1.5.1 Constitutive heterochromatin 
A sequential pathway is required to establish constitutive heterochromatin. Although the initial 
events of constitutive heterochromatin formation still need to be clarified, studies in mouse propose 
that transcription factors bind major satellite repeats in the pericentric region and attract the 
histone methyltransferase Suv39h (Dambacher, Hahn & Schotta, 2013; Saksouk N, 2015). This leads 
to an establishment of H3K9me3 at pericentric heterochromatin. The effect can be strengthened by 
premethylated H3K9me1 transferred from a cytoplasmic pool and generated by histone 
methyltransferases Prdm3 and Prdm16. The established H3K9me3 marks results in the attraction of 
heterochromatin protein HP1. HP1 is followed by a Suv4-20h2 accumulation. The histone 
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methyltransferase Suv4-20h2 recruits cohesin to the pericentric heterochromatin and catalyzes 
H4K20 thimethylation, which finally results in a highly condensed form of chromatin (Dambacher et 
al., 2013). In addition to histone methylation, DNA methylation also strongly correlates with the 
constitutive heterochromatin and is responsible for maintaining genomic integrity (Smith & 
Meissner, 2013). 
 
1.5.2 Position-effect variegation 
A phenomenon of gene silencing adjacent to constitutive heterochromatin was originally observed 
in Drosophila mutants, bearing a radiation-induced chromosome rearrangement that places the 
white gene close to centromere heterochromatin (Muller, 1930). The mosaic mutants had some 
white (mutant) and some red (normal) patches, which indicates a variegated gene silencing. 
Profound examinations showed that chromosomal rearrangements induced the silencing via 
translocation of white genes close to the pericentric heterochromatin. From this the 
heterochromatin marks H3K9me3 and H4K20me3 spread into neighboring regions and lead to 
transcription repression (Almouzni & Probst, 2011; Wang et al., 2014). Depending on the region, 
different proteins induce the downstream signals of H3K9me3 and H4K20me3 (Dambacher et al., 
2013; Wang et al., 2014). Additionally it was observed that the counteracting activation marks H3ac 
and H4ac correlate negatively with distance of constitutive heterochromatin to transgene, which 
suggest heterochromatinization-dependent inhibition of histone acetylation (Yin et al., 2012). 
 
 
Figure 7: Position-effect variegation. Translocation of white genes close to heterochromatin results in silencing mediated 
by spreading of heterochromatin marks. Adopted from (Festenstein & Chan, 2012). 
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Although constitutive heterochromatin is consistent within a species, silenced genes within those 
regions can be activated rapidly (Bannister, Schneider & Kouzarides, 2002). This indicates the high 
dynamic nature of chromatin structure. Methylated H3K9 is a permanent and heritable mark which 
attracts HP1/Swi6 with higher affinity than the unmethylated H3K9. From this it can be determined 
that HP1/Swi6 is presented in steady state equilibrium of dynamic association and dissociation. 
Considering this, euchromatin with less methylated H3K9 has lower binding affinity than  
H3K9me3-rich heterochromatin, leading to increased HP1/Swi6 mediated cross-link of adjacent 
nucleosomes in heterochromatin. This process is favored by further compaction by enhanced 
HP1/Swi6 interaction. Therefore a stochastic model for short-term heterochromatin, also known as 
mass action phenomena is proposed in Drosophila, yeast and mammals (Cheutin et al., 2004; 
Dambacher et al., 2013; Henikoff, 1996). Observed binding of transcription factors in “closed” 
constitutive heterochromatin regions as well as the need for higher activation signals to derepress 
genes in constitutive heterochromatin compared to elsewhere repressed regions, support the theory 
of a stochastic model (Aparicio & Gottschling, 1994; Sekinger & Gross, 2001). 
 
1.5.3 Silencing through polycomb complexes 
The polycomb group (PcG) complexes are a family of transcriptional repressors subdivided in two 
forms of multiprotein complexes, the polycomb repressive complex 1 (PRC1) and 2 (PRC2) (Gil & 
O'Loghlen, 2014). The PRC2 comprises the core proteins Suz12, Eed, and the lysine 
methyltransferase Ezh2 or its homolog Ezh1. Both KMTs catalyze the H3K27 methylation, a common 
hallmark of facultative heterochromatin (Di Croce & Helin, 2013; Mozzetta et al., 2014).  
Time-dependent expression of differentiation genes is induced by alleviating PC-mediated 
repression to ensure correct differentiation of adult stem and progenitor cells (Margueron & 
Reinberg, 2011). During differentiation pluripotency genes are repressed by polycomb. In this way 
targeted chromatin fibres were folded into small discrete nuclear compartments, termed Pc nuclear 
foci (Cheutin & Cavalli, 2014). The PRC1 can bind with its subunit chromobox-domain (CBX) protein 
to H3K27me3. The bound PRC1 induces monoubiquitination of H2A on K119 by activity of E3 ligases 
RING1a and RING1b (Di Croce & Helin, 2013). From this a complex comprising of the protein RYBP 
and the catalytic subunit RING1B of PRC1, catalyzes the ubiquitination of H2A (Tavares et al., 2012). 
In both cases the histone H2A ubiquitination is proposed to repress transcription factor binding and 
inhibit the RNA polymerase (Zhou et al., 2008). Furthermore, H2A ubiquitination leads to a positive 
feedback loop by the promotion of H3K27 methylation (Kalb et al., 2014). 
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Figure 8: Silencing by polycomb complexes. The canonical pathway requires recognition of H3K27me3 (A) whereas in the 
noncanonical pathway the affinity of KDM2B for the CpG island enables the binding of the RYBP-PRC1 complex (B). The 
bound PRC1 induces monoubiquitination of H2A on K119 by activity of E3 ligases RING1a and RING1b. Adopted from (Di 
Croce & Helin, 2013). 
 
The methylation of H3K9 can be indirectly induced by the interaction of PRC2 with G9a and GLP 
(H3K9 KMTs), which demonstrates a crosstalk between both epigenetic silencing pathways 
(Mozzetta et al., 2014). 
 
1.5.4 Heritable epigenetic silencing; positive feedback loops between different self-
reinforcing repressive principles 
Two major epigenetic marks for the maintenance of the epigenetic status are H3K9 methylation and 
DNA methylation. Both marks are embedded in positive feedback loops, as exemplified in the fission 
yeast and Arabidopsis models. 
Constitutive heterochromatin in fission yeast is marked with H3K9me3 and comprises various 
numbers of repeat units. Those repeats can be transcribed into double stranded (ds) RNA and 
further processed into small interfering (si) RNA by Dcr1 (Volpe et al., 2002). The RNA-dependent 
RNA polymerase complex (RdRC) produces dsRNA and siRNA from Argonaute (Ago) 1-targeted 
transcripts by interaction with Dcr1 and Ago1. Also Ago1 is a component of the RNA-induced 
transcriptional silencing complex (RITSC), which guides to nascent pericentromeric non-coding RNA 
(ncRNA) transcripts if loaded with appropriate siRNA. Furthermore, RITSC binds H3K9me3 with the 
chromodomain protein Chp1 (Verdel et al., 2004). This reinforce H3K9 methylation by recruitment of 
the cryptic loci regulator complex (CLRC), which contains the H3K9 KMT Clr4 (Zhang et al., 2008a). 
The target base pairing of siRNA has therefore an important role in the heterochromatinization and 
creates a positive feedback loop between siRNA generation, RITSC localization and H3K9 
methylation (Castel & Martienssen, 2013). 
In Arabidopsis an analogical reinforcing positive feedback loop was discovered whereas 24 nt small 
interfering RNAs guides a DNA methyltransferase to a specific genomic loci. Here RNA-dependent 
RNA polymerase 2 (RDR2) associates with RNA Pol IV on repetitive heterochromatic loci to produce 
dsRNA (Law et al., 2011). Those dsRNA are cleaved by DICER-LIKE 3 (DCL3) into small interfering RNA 
(Kasschau et al., 2007). Subsequently, Ago4 is loaded with the siRNA in cytoplasm and transferred 
A B 
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into the nucleus (Wierzbicki, Haag & Pikaard, 2008; Wierzbicki et al., 2009; Ye et al., 2012). In the 
nucleus, either Ago4 can bind nascent RNA Pol V transcripts to form the RNA-directed DNA 
methylation complex, or associates with RDM1 to activate the de novo DNA methyltransferase 
DMR2 (Gao et al., 2010; Wierzbicki et al., 2008; Wierzbicki et al., 2009). 
In addition to the self-reinforcing feedback loops, different models propose crosstalks between the 
epigenetic pathways. Two models are depicted below for the maintenance of genome integrity, 
mediated by repressive heritable marks. 
 
 
Figure 9: Crosstalk of epigenetic pathways. (A) Model I H3K9me3, hemimethylated DNA and PCNA are recognized by 
Uhrf1 which recruits Dnmt1 and H3K9 methyltransferase (G9a) directly. In addition Setdb1 is attracted to methylated 
DNA through interaction with Mbd1, which lead to maintenance of the H3K9 methylation. (B) In model II at first Uhrf1 
ubiquitylates H3K23 after PCNA, H3K9me3 and DNA methylation recognition, than Dnmt1 gets recruited. 
 
As described in section 1.4, DNA methylation is maintained through the interaction of Dnmt1 with 
Uhrf1. In model I PCNA, H3K9me3/me2 and hemimethylated DNA are recognized by Uhrf1 at the 
replication forks followed by the recruitment of Dnmt1 and H3K9 methyltransferase to copy the 
methylation pattern onto the newly synthesized daughter strand. In addition Setdb1 is attracted to 
methylated DNA, maintaining the H3K9 methylation. In model II Uhrf1 induces the ubiquitylation of 
H3K23, which in turn attracts Dnmt1 (Rose & Klose, 2014).  
 
1.5.5 X chromosome inactivation in mammals  
Gene dosage compensation relates to the fact that species with heteromorphic sex chromosomes 
frequently have different numbers of sex chromosomes. For example, female mammals females two 
X chromosomes, but males have only one. So the X chromosome inactivation (XCI) compensates for 
the dosage difference between both sexes. However, recent studies suggest that rather a partial 
A 
B 
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dosage compensation of dosage sensitive genes occurs in mammals than the observed global dosage 
compensation of Drosophila (Pessia, Engelstadter & Marais, 2014). 
The X-inactivation center (Xic) controls XCI, whereby the XCI is randomly chosen in somatic cells of 
eutherian mammals resulting in mosaic females (Lee & Bartolomei, 2013). The Xic is associated with 
lncRNAs and the “X-interactive-specific transcript” (XIST/Xist) contains a 17-20 kb RNA, which covers 
the X-chromosome during XCI (Clemson et al., 1996). Hereby Xist RNA binds PRC2 and guides it to 
the Xi (Zhao et al., 2008) as long as the cis-expressed Xist antisense partner Tsix is down-regulated 
(Jeon & Lee, 2011). PRC2 is attracted by strong binding sites along the future inactive X. The resulting 
H3K27me3 gradually spreads from strong binding sites into neighboring clusters with more 
moderate binding affinity. Hierarchical spreading of XCI depends on Xist RNA and sites with a high 
frequency of polycomb proteins (Lee & Bartolomei, 2013). Xist is controlled by other lncRNAs. For 
instance Tsix acts as a repressor and coordinates X chromosome pairing (Bacher et al., 2006; Xu et 
al., 2007; Xu, Tsai & Lee, 2006), recruits DNA methyltransferase (Dnmt3a) towards Xist, which leads 
to DNA methylation (Sado, Hoki & Sasaki, 2005; Sun, Deaton & Lee, 2006; Zhao et al., 2008) and 
blocks PRC2 binding to Xist. The deletion of the trans-acting Jpx RNA or RepA RNA lead to a reduced 
Xist activation, which indicates both RNAs as potential activators of Xist (Lee & Bartolomei, 2013).  
 
1.5.6 Imprinting in mammals 
The coordinated regulation of a specific gene domain according to the parental origin is termed 
“genomic imprinting” and affects both male and female offspring. Consequently genomic imprinting 
is a result of parental inheritance and not of sex (Barlow & Bartolomei, 2014). Around five to ten 
percent of all genes in the mammalian genome are influenced by imprinting. Imprinted genes are 
commonly distributed in clusters of 20 to 3,700 kb range (Barlow, 2011). Besides protein coding 
genes the clusters contain noncoding RNAs (ncRNAs), which can be subdivided in micro-, sno- and 
lncRNAs oftentimes close to or within imprinting control region (ICR). The ICRs contain the parent-of-
origin-specific epigenetic modifications which are responsible for the specified regulation. A well-
known mechanism for imprinting includes the expression of lncRNAs in cis following similar schemes 
as has been observed for X inactivation, although the mechanism of cis-induced silencing by lncRNA 
remains unclear. A possible mechanism proposes that the lncRNA overlaps in a sense-antisense way 
with adjacent imprinted genes, which causes transcriptional interference in the overlapped region 
(Pauler, Barlow & Hudson, 2012). From this an accumulation of repressive chromatin follows and 
spreads throughout the cluster (Latos et al., 2012). In addition, many imprinted lncRNAs such as Gt2 
and Nespas can attract polycomb proteins and act thereby in a manner reminiscent of Xist (Pandey 
et al., 2008; Zhao et al., 2010). Further experiments with lncRNAs like Airn and Kcnq1ot1 suggest 
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that besides the attraction of polycomb proteins, also an actively recruitment of repressive histone 
modifications takes place (Nagano et al., 2008; Pandey et al., 2008; Terranova et al., 2008). In 
conclusion, genomic imprinting can be a result of direct interaction of lncRNA within the controlled 
region or the induction of epigenetic signal cascades. 
 
1.5.7 Silencing of ribosomal genes in mammals 
Ribosomal gene transcripts are the RNA component of ribosomes and are therefore of pivotal 
importance in the cell metabolism. These genes are located at the nucleolar organizer regions 
(NORs) and clustered in tandem repeats on five acrocentric chromosomes (Grummt & Langst, 2013). 
The transcription of rRNA genes depends on the cell status and is in general active in 50% of all rRNA 
genes (Conconi et al., 1989; Lucchini & Sogo, 1995). 
Silent ribosomal RNA genes are indicated by the typical heterochromatin marks like DNA 
hypermethylation, H4 hypoacetylation, H3K9me3, H4K20me3 and H3K27me3 (Earley et al., 2006; 
Lawrence et al., 2004; Santoro, Li & Grummt, 2002; Zentner et al., 2011; Zhou, Santoro & Grummt, 
2002). Induced hypomethylation of rRNA genes results in genomic instability. Apparently many rRNA 
genes are deeply embedded into repressive chromatin structures, which are typically excluded from 
the cellular recombination machinery (Kobayashi, 2008; Peng & Karpen, 2007). Transcriptional 
silencing can be promoted by DNA methylation which reduces the protein-DNA binding affinity. For 
instance, a single methylation located 133 bp upstream of TSS within the upstream control element 
(UCE) of the rDNA promoter hinders the binding of the basal transcription factor UBF (Santoro & 
Grummt, 2001). In addition methylation might repress rDNA transcription through attraction of 
histone deacetylases, as mediated by methyl-CpG-binding proteins or MBD proteins (Brown & Szyf, 
2007; Ghoshal et al., 2004; Klose & Bird, 2006). This suggests that only specific positions of DNA 
methylation have a direct effect on UBF. 
In general epigenetic silencing mechanisms for rRNA genes are well known, but the targeting 
mechanism of specific copies is still unclear. NORs contain in a ratio of 2:1 evenly distributed 
canonical repeats and non-canonical rDNA repeats, which are indicated by their palindromic 
structures (Caburet et al., 2005). In addition rRNA genes can differ in number and location of single 
nucleotide polymorphisms (SNPs) and length of enhancer elements (Guetg et al., 2010; Qu, Nicoloso 
& Bachellerie, 1991; Santoro et al., 2010; Shiao et al., 2011; Tseng et al., 2008). From this chromatin 
structure- and transcription- variation might be explained. Once the epigenetic states are 
accomplished the status is inherited through cell division and stably propagated towards daughter 
cells (Schlesinger et al., 2009). 
32 
 
A key regulator of rRNA gene transcription is the multifunctional protein TTF-I. TTF-I can bind to 
specific terminator elements, for instance 170 bp upstream of the transcription start site (To). From 
this TTF-I can either promote transcription by interaction with activating chromatin modifiers like 
CSB/G9a (Langst, Becker & Grummt, 1998; Langst et al., 1997) or mediate silencing by attraction of 
repressive chromatin remodeling complex NoRC. (Santoro et al., 2002; Strohner et al., 2001; Zhou et 
al., 2002). In addition TTF-I can support DNA loop formation by self-assembly of proteins linked to 
distant terminator elements. The loop facilitates activation by concentrating relevant transcription 
factors (Denissov et al., 2011; Nemeth et al., 2008; Nemeth & Langst, 2011; Sander & Grummt, 1997; 
Shiue, Arabi & Wright, 2010; Shiue, Berkson & Wright, 2009). The repressive epigenetic state is 
promoted by the ATP-dependent chromatin remodeling machines NoRC, which comprises the  
DNA-dependent ATPase SNF2h and the TTF-I interacting protein 5 (TIP5) (Strohner et al., 2001). After  
TTF-I-mediated NoRC-rDNA binding, NoRC induces nucleosome remodeling, histone modification 
and DNA methylation (Grummt & Langst, 2013; Li, Langst & Grummt, 2006). Nucleosomes are then 
relocated predominantly to a silent position that does not allow the formation of the transcription 
complex comprising UBF and TIF-IB/SL1 (Li et al., 2006). In particular, NoRC recruits histone 
deacetylases (HDAC), H3K9 histone methyltransferases (HMT) SET-DB1 and DNA methyltransferases 
(DNMT) to establish the heterochromatin state, which is propagated through cell cycle progression 
(Grummt & Langst, 2013). 
 
1.5.8 Silencing of transposons and retrotransposons 
46% of the human and 37.5% of the mouse genome consists of repetitive sequences, located within 
and between genes (Lander et al., 2001; Mouse Genome Sequencing et al., 2002). These repeat 
elements can be distinguished in four groups: DNA transposons, long interspersed elements (LINEs), 
short interspersed elements (SINEs) and long terminal repeats (LTRs) (Ohms & Rangasamy, 2014). Of 
these the LINE-1 elements are the most active retrotransposons (Brouha et al., 2003). 
Retrotransposons, as well as DNA transposons, are DNA sequences that can relocate within the 
genome, mutate and duplicate themselves. Retrotransposons are first transcribed into RNA followed 
by a reverse transcription into DNA, whereas the underrepresented DNA transposons do not require 
an RNA intermediate to jump within the genome (Lander et al., 2001; Mouse Genome Sequencing et 
al., 2002). Retrotransposition affects genomic integrity by generating dsDNA breaks and insertion of 
pseudo-genes or retro-genes (Esnault, Maestre & Heidmann, 2000; Gasior et al., 2006; Gualtieri et 
al., 2013). Thus the fitness of the cell depends on the silencing of retrotransposons. Especially the 
repetitive sequences are mostly silenced in differentiated cells whereas embryonic stem cells harbor 
non-repressed retrotransposons, which may be explained by an overall open chromatin formation 
33 
 
(Efroni et al., 2008). Silencing of retrotransposons is mediated by DNA methylation, histone 
modifications and small RNAs (Ohms & Rangasamy, 2014). Small RNAs are integral to various 
silencing mechanisms and can be grouped into microRNAs (miRNAs), endogenous small interfering 
RNAs (endo-siRNAs), small nucleolar RNAs (snoRNAs) and Piwi-interacting RNAs (piRNAs) (Ambros & 
Chen, 2007; Ghildiyal & Zamore, 2009; Peng & Lin, 2013). siRNAs suppresses retrotransposition by 
binding endogenous mRNAs in a sense-antisense manner (Faulkner et al., 2009; Ghildiyal et al., 
2008; Watanabe et al., 2006; Yang & Kazazian, 2006). From this complementary siRNA is generated 
by folding back of inverted repeats, bidirectional transcription sites and expressed antisense 
transcripts of retrotransposons and peudogenes or by multiple Dicer cleavages of long precursor 
dsRNAs (Okamura et al., 2008; Tam et al., 2008). piRNAs induces retrotransposon silencing by a  
Piwi-interacting RNA-mediated mechanism and are Dicer independently produced from 
retrotransposon derived dsRNA (Aravin et al., 2007; Carmell et al., 2007; Girard et al., 2006; Ross, 
Weiner & Lin, 2014). 
After the initial regulation of repetitive elements by RNA in mouse embryos, the loss of activation 
marks occurs prior to the accumulation of repressive histone modifications (Fadloun et al., 2013). 
 
1.5.9 Silencing of transgenes in culture cells 
Integrated recombinant genes tend to get lost by chromosomal disruption/ rearrangement 
mechanisms (Kim et al., 2011) and are prone to silencing. They are often inserted as multiple copies, 
which resembles retrotransposon arrangements. Observed epigenetic repressions include promoter 
methylation (Yang et al., 2010a), histone methylation and histone deacetylation (Mutskov & 
Felsenfeld, 2004). Especially in CHO cell lines, a simultaneous decrease of H3 acetylation and 
transgene expression was observed in long term culture (Paredes et al., 2013). The initiation of 
transgene silencing is proposed to be associated with the transgene sequence, their susceptibility to 
form tandem repeats, and the integration site into the host genome (Kaufman et al., 2008). 
Integration site-dependent silencing is mediated by the position effect, which influences the stability 
of recombinant gene expression (Lattenmayer et al., 2006; Yin et al., 2012). For this reason 
potentially stable integration sites are extensively studied (Akhtar et al., 2013).  
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1.6 Cell line development of therapeutic protein producers 
1.6.1 CHO cell line development 
The mammalian cell culture rose to be the main production system in the pharmaceutical industry, 
since the first therapeutic protein was expressed from recombinant mammalian cells in 1986 (Kim, 
Kim & Lee, 2012). Alternative expression systems such as microbial (e.g. E.coli), insect, cells, plant 
cells or transgenic animals are also in use, but for the expression of therapeutic proteins such as 
immunoglobulins and other multimeric or glycosylated proteins, mammalian cells are the preferred 
producers (Osterlehner, Simmeth & Gopfert, 2011; Walsh, 2010). 
Despite the variety of available mammalian cell lines, the Chinese hamster ovary (CHO) cells produce 
nearly 70% of all recombinant therapeutic proteins (Jayapal & Wlaschin, 2007). In regard to the 
specific demands on therapeutic proteins, the CHO cells have some attributes which make them 
suitable for recombinant protein expression. CHO cells are a well-established system, supplying 
therapeutic proteins over the last 20 years which might facilitate the approval by regulatory 
agencies. Furthermore the usual low specific productivity (q) of protein production in mammalian 
cells can be overcome by gene amplification in CHO cells. Dihydrofolate reductase (DHFR)-mediated 
or glutamine synthetase (GS)-mediated (e.g. CHO-K1 SV) selection systems are available in CHO cells 
to compensate for low q by selective exclusion of low copy number cell lines or to maintain a specific 
production level, which is dependent on selection agent concentration. Also CHO cells can efficiently 
conduct post-translational modifications to produce, for instance, glycosylated forms of recombinant 
proteins, which are essential for biologic functionality and compatibility in human (Wurm, 2004). At 
last, CHO cells proliferate well in serum-free (SF) suspension, which is preferred from the regulatory 
authority and therefore used in large scale cultures (Kim et al., 2012; Landauer, 2014). 
The demand for biopharmaceutics is increasing constantly, resulting in the current market with an 
average yearly growth of 35% since 2001 (Altamirano et al., 2013). Although the development of 
CHO cell culture over the past two decades has resulted in a 100-fold yield improvement of titer, the 
highly competitive market of biopharmaceutical drugs requires a constant development of producer 
cell lines (Kim et al., 2012). Besides the development of serum-free medium and optimized feeding 
strategies, achievements in cell- and vector-engineering make CHO cell lines highly productive  
(Kim et al., 2012). 
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1.6.2 Loss of productivity in CHO cell lines 
Economic cell lines are required to provide high productivity and stable production levels during 
propagation from small to large scale. Decrease of productivity during scale-up constitutes a serious 
risk during cell line development (Barnes, Bentley & Dickson, 2003). One main reason for production 
instability is a reduction of copy numbers over time, which might be attributed to chromosomal 
disruption/rearrangement as an inherent characteristic of CHO cells (Kim et al., 2011) and/or an 
induction by gene amplification (Kaufman, Sharp & Latt, 1983). The decrease of mRNA at a constant 
number of copies of recombinant genes is another major cause of productivity drop (Barnes, Bentley 
& Dickson, 2004; Chusainow et al., 2009; Strutzenberger et al., 1999). A reasonable explanation for 
this occurrence is epigenetic silencing by promoter methylation (Osterlehner et al., 2011; Yang et al., 
2010b) and histone modifications as typified by deacetylation and specific methylation (Mutskov & 
Felsenfeld, 2004; Paredes et al., 2013). Also, the recombinant sequence itself, the formation of 
tandem repeats of sequence and the genomic location of transgene are proposed initiators for gene 
silencing (Kaufman et al., 2008). From this the influence of adjacent chromatin onto integration sites 
is termed ‘position effect’ (Lattenmayer et al., 2006; Yin et al., 2012). 
 
1.6.3 Silencing of hCMV-MIE promoter  
The promoter upstream of the recombinant gene initiates gene transcription and is able to affect 
gene expression level and stability (Kaufman et al., 2008). The major immediate early gene promoter 
of the human cytomegalovirus (hCMV-MIE) is commonly used to drive recombinant expression in 
mammalian cells for research and manufacturing to obtain high expression levels in transient and 
stable transfections (Boshart et al., 1985; Chapman et al., 1991; Foecking & Hofstetter, 1986; Wright 
et al., 2005). Although the hCMV-MIE promoter provides high gene expression levels, many studies 
have reported a decrease of productivity over long-term culture (Bailey et al., 2012; Barnes, Bentley 
& Dickson, 2001; He et al., 2012). The silencing of the hCMV-MIE promoter is (in addition to the loss 
of copy numbers) largely attributed to epigenetic events of promoter DNA methylation and histone 
modification (Brooks et al., 2004; Kim et al., 2011; Osterlehner et al., 2011; Paredes et al., 2013; 
Yang et al., 2010b). 
36 
 
1.7 Aims 
CHO cell lines are the main production cell lines in the pharmaceutical industry to produce 
therapeutic/diagnostic proteins (Kim et al., 2012). In addition to the demand for high protein titer, 
cell lines needs to be stable, to maintain the production level during the cell line development. To 
accomplish this, three independent epigenetic strategies were pursued. 
 
Early exclusion of instable cell lines by an epigenetic prediction marker: 
Finding an optimized prediction marker which indicates stable production in cell lines will reduce 
costs and increase efficiency in the cell line development. The epigenetic modification of CpG 
methylation of the strong hCMV-MIE promoter was successfully used as an indicator for long-term 
production stability (Osterlehner et al., 2011). However, other epigenetic marks such as histone 
modifications are also well known for their association with active or inactive chromatin, frequently 
proposed as events prior DNA methylation. Depending on epigenetic pathways, the loss of active 
marks or the accumulation of specific repressive marks are early events of a silencing cascade (Chen 
& Dent, 2014; Fadloun et al., 2013). In order to cover the most prominent pathways, I examined 
general lysine acetylation (H3ac) as well as the trimethylation of lysine 4, 9 and 27 of H3 (H3K4me3, 
H3K9me3, H3K27me3) as potential prediction markers of long-term transgene silencing. 
 
Vector modification to impede silencing of transgenes: 
Histone modification and DNA methylation are important steps in the activation and repression of 
genes. In general, CpG methylation of promoter DNA is proposed to maintain the repressed status, 
whereas the loss of methylation is associated with activation (Smith & Meissner, 2013). CpGs within 
the hCMV-MIE promoter were observed to comprise a position-dependent methylation pattern 
(Osterlehner et al., 2011). Considering this, I point-mutated three predominantly methylated CpGs 
from cytosine to guanine to investigate the resulting effect on long term production stability. In 
contrast to DNA methylation, the histone acetylation is associated with an open chromatin 
formation. H4K16 acetylation especially is a strong activation mark in the dosage compensation of 
Drosophila (Prestel et al., 2010). Thus, I constructed a vector for coexpression of a reporter and a 
modified histone acetyltransferase MOF, which is target oriented to UAS sites upstream of  
hCMV-MIE. This should lead to acetylated H4K16 close to the transgene promoter and an activation 
of the target region. Both strategies were executed to promote stable production in CHO cell line; 
either by preventing of transgene repression, or by forcing chromatin into an open formation. 
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Discovery of potential stable integration sites in the CHO-K1 genome: 
It is a common approach in the pharmaceutical industry to develop production cell lines by random 
integration of transgene. However many cell lines need to be discarded during the cultivation phase 
in regard to their loss of productivity. Although the selection phase prefers cells with transgene 
expression, the possibility for a position effect like heterochromatinization increases over time. A 
target integration in constantly active genomic regions minimizes the risk of silencing. The chromatin 
of CHO-K1 cells was mapped for active (H3ac, H3K4me3, H3K36me3) and inactive (H3K9me3) 
regions and compared with the integration sites of cell pools of high or low productivity. The analysis 
of those sites in combination with the epigenetic landscape might lead to the identification of stable 
integration sites; those stable integration sites can then be used for prospective cell line 
developments. 
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2 Materials and methods 
 
2.1 Material sources 
2.1.1 Laboratory chemicals and biochemicals 
Acrylamide (Rotiphorese Gel ® 30) Roth, Karlsruhe 
Agar-Agar Probio, Eggenstein 
Agarose (ME, LE GP and low melting) Biozym, Hessisch Oldendorf 
Ampicilin Roth, Karlsruhe 
Bacto Agar BD, Fance 
BSA (Bovine serum albumin) Sigma, Taufkirchen 
ß-Mercaptoethanol Sigma, Taufkirchen, Germany 
Casein Roche, Penzberg, Germany 
Chloroform/Isoamylalcohol (24:1) Roth, Karlsruhe 
Chloramphenicol Roth, Karlsruhe 
Coomassie Serva, Heidelberg 
DTT Roth, Karlsruhe 
5-aza-2deoxycytidine (DAC) Sigma, Taufkirchen 
EDTA Sigma, Taufkirchen 
EGTA Sigma, Taufkirchen 
Ethidium bromide Sigma, Taufkirchen 
Fetal bovine serum Sigma, Taufkirchen 
IPTG Roth, Karlsruhe 
NP40 (Igepal CA-630= Invitrogen, Karlsruhe 
Orange G Sigma, Taufkirchen 
Paraformaldehyde Sigma, Taufkirchen 
Phenol Sigma, Taufkirchen 
Phenol-chloroform Sigma, Taufkirchen 
PMSF (Phenylmethansulfonyl fluoride) Roth, Karlsruhe 
Ponceau S solution Sigma, Taufkirchen, Germany 
SDS (Sodium dodecyl sulfate) Serva, Heidelberg 
Roche Complete  Roche, Penzberg 
rAPID alkaline phosphatase (Cat.no. 04898133001, 
Roche, Germany) 
Roche, Penzberg 
Roti®Phenol/Chloroform/Isoamylalcohol (25:24:1)   Roth, Germany 
Tris Invitrogen, Karlsruhe 
Triton X-100 Sigma, Taufkirchen 
Tween 20 Sigma, Taufkirchen 
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2.1.2 Enzymes 
DNA Polymerase I, Large (Klenow) Fragment New England BioLabs GmbH, Frankfurt 
(a.M), Germany 
Proteinase K Roche, Mannheim, Germany 
Restriction endonucleases New England BioLabs GmbH, Frankfurt 
(a.M), Germany 
RNAse, DNAse Roche, Mannheim, Germany 
Taq DNA Polymerase Invitrogen, Darmstadt, Germany 
T4 DNA Ligase  New England BioLabs GmbH, Frankfurt 
(a.M), Germany 
ZymoTaq™DNA polymerase premix  ZymoResarch, Freiburg, Germany 
 
2.1.3 Antibodies 
Rabbit IgG, Purified, PP64B,  Millipore, Darmstadt, Germany 
Rabbit H4K16ac-ab 07-329 Millipore, Darmstadt, Germany 
Mouse GFP G 6539 Sigma, Taufkirchen, Germany 
Mouse Flag F 3165 Sigma, Taufkirchen, Germany 
Rabbit Gal4(DBD+O1679) Sc-577 Santa Cruz Biotech 
Mouse Alpha-tubulin T 9026 Sigma, Taufkirchen, Germany 
Goat anti rabbit 12-348 Millipore, Darmstadt, Germany 
Goat anti mouse Millipore, Darmstadt, Germany 
ChIP grade Antibodies  
ChIPAb+ Trimethyl-Histone H3 (Lys4)  Millipore, Darmstadt, Germany 
ChIPAb+ Trimethyl-Histone H3 (Lys27)  Millipore, Darmstadt, Germany 
Anti-Histone H3 (tri methyl K9) antibody Abcam 
Anti-Histone H3 antibody Abcam 
Anti-acetyl-Histone H3 Millipore, Darmstadt, Germany 
Histone H3K4me3 antibody (pAb) Activemotif, La Hulpe, Belgium 
Anti-acetyl-Histone H3 Antibody Millipore, Darmstadt, Germany 
ChIPAb+ Trimethyl-Histone H3 (Lys9) Millipore, Darmstadt, Germany 
ChIPAb+ Trimethyl-Histone H3 (Lys27) Millipore, Darmstadt, Germany 
Anti-Histone H3 antibody Abcam 
 
2.1.4 Organisms 
E.coli NEB 5 alpha (NEB, Germany New England BioLabs GmbH, Frankfurt 
(a.M), Germany 
XL10 Gold ultracompetent cells Agilent Technologies, Oberhaching Germany 
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2.1.5 Oligonucleotides and plasmids  
Primers: Sequence: 
Primer for bisulfite converted CMV 
UG_730_Bisul_CMV1 F1 GATATTGATTATTGATTAGTTATTAATAGTAATTAA 
UG_731_Bisul_CMV1 R1 CAAATAAAAAAATCCCATAAAATCATATACTAA 
UG_732_Bisul_CMV2 F2 TTAGTATATGATTTTATGGGATTTTTTTATTTG 
UG_733_Bisul_CMV2 R2 TTCTAATACTAAACTCCTCTCCCAA 
iPCR primer 
UG_574_16110 BtsI_rev CTGTCATGCCATCCGTAAGATGCT 
UG_575_16110 BtsI_for GCGGCCAACTTACTTCTGACAACG 
UG_576_16110 AceIII_rev AAGGCGAGTTACATGATCCCCCAT 
UG_577_16110 AceIII_for CACCACGATGCCTGTAGCAATGG 
Vector design primer 
UG_362_CMV_G-508F CGTTACATAACTTAGGGTAAATGGCCCGCC 
UG_363_CMV_G-179F AATGGGCGTGGATAGGGG TTTGACTCACG   
UG_364_CMV_G-41F GTAGGCGTGTAGGGTGGGAGGTCTATATAAG 
UG_404_Linker_ClaI-UAS-
SpeIF AAAAAAATCGATCAATTGGATATCGTCGACGGATCGGAGTACTGT 
UG_405_Linker_ClaI-UAS-
SpeIR TTTTTTACTAGTCAATAATCAATGTCAACGCGTGGATCCGCTCGGAGGAC 
UG_406_Linker_AgeI-UAS-
SspIF AAAAAAACCGGTGTCGACGGATCGGAGTACT 
UG_407_Linker_AgeI-UAS-
SspIR TTTTTTAATATTAGCGCTGATCCGCTCGGAGGACA 
UG_408_Linker_BclI-GFP-
BsiWIF AAAAAATGATCAAGGCTAGCGCCGCCACCATGGTGAGCAA 
UG_409_Linker_BclI-GFP-
BsiWIR TTTTTTCGTACGCTCCTTAGGTTAACGGTCCATCCCGCTCTCCTG 
UG_415_Rec._GFP-PolyAF TGTCTTGTGCCCAGGAGAG 
UG_416_Rec._GFP-PolyAR TGAGTTTGGACAAACCACAAC 
UG_417_Linker_BclI-GFP-
BsiWIF 
AAAAAATGATCAGCACTGAACACAGAGGAAGCTAGCCGCCACCATGGTG
AG 
UG_418_Linker_Bsu36I-
IRESF AAAACCTAAGGAGGGATATCGCGGCCGCG 
UG_419_Linker_IRES-BsiWIR TTTCGTACGATATTTAAATCTGGCCGAGGCGGCCAGGATCCATCGTGTTT
TTCAAAGG 
UG_420_Linker_SfiI-MOF F AAAAAAGGCCGCCTCGGCCTCTGA 
UG_421_Linker_MOF-SwaIR TTTTTTATTTAAATCTATTTGTCGTCGTCGTCT 
UG_422_Linker_MluI-CMVF AAAAAAACGCGTTGACATTGATTATTGACTAGTTAT 
UG_423_Linker_CMV-NheIR AAAAAAGCTAGCTTCCTCTGTGTTCAGT 
ChIP primer 
UG_386_Chip_GusbF2 CAGGGTGGGATGCTCTTC 
UG_387_Chip_GusbR2 GCCGGTTTTCCGAGAAGT 
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UG_388_Chip_RhoF1 AGCCTCGGTCTCTATTGACG 
UG_389_Chip_RhoR1 CGTTGGAGAAGGGCACATAA 
UG_396_Chip_CMVF3 TACATCAATGGGCGTGGATA 
UG_397_Chip_CMVR3 AAGTCCCGTTGATTTTGGTG 
UG_431_CHIP_Eif3iF1 GTTCCCGGCACTGACACT 
UG_432_CHIP_Eif3iR1 ACTTGATCTGCGTGATGGAC 
UG_445_CHIP_CMVF7 CATTATGCCCAGTACATGACCTT 
UG_446_CHIP_CMVR7 AAACCGCATCACCATGCTA 
UG_468_CHIP_Gata5 F1 CACCTACCCCATCCTGTCTG 
UG_469_CHIP_Gata5 R1 GAGGAGGTGAAGGCAAAGTCT 
UG_474_CHIP_UNC13c F1 GGGTGCTTTACGGAAACTGA 
UG_475_CHIP_UNC13c R1 GCTTCTTATGCCCCAGGTTT 
UG_484_CHIP_Foxa2 F1 ATCACCCGTACTGCTGCTCT 
UG_485_CHIP_Foxa2 R1 GAGGCTTCTGGGGATCTCTT 
 
2.1.6 Other materials and kits 
Kits  
AllPrep DNA/RNA Mini Kit (50)  Qiagen, Hilden, Germany 
Dnease Blood & Tissue Kit  Qiagen, Hilden, Germany 
EZ-96 DNA Methylation-Lightning TM Kit (deep-
well format) 
ZymoResarch, Freiburg, Germany 
High Pure PCR Product Purification Kit  Roche, Penzberg, Germany 
LightCycler®480 SYBR Green I Master Roche, Penzberg, Germany 
Lock Gel™ Light tube (Cat.no. 0032005.101,) Eppendorf, Hamburg, Germany 
Lumi-LightPLUSWester blotting system  Roche, Penzberg, Germany 
(NuPAGE®Novex® 10% Bis-Tris Gel 1.0mm x 12 
well, Cat. No. NP0302BOX 
Invitrogen, Darmstadt, Germany 
20x NuPAGE MOPS SDS Running Buffer, Cat.No. 
NP0001, 
Invitrogen, Darmstadt, Germany 
4xNuPAGE LDS-Samplebuffer Invitrogen, Darmstadt, Germany 
Pierce®BCA Protein Assay Kit,  Thermo Scientific, Rockford, USA 
Protein A Agarose slurry  Roche, Mannheim, Germany 
QIAquick® Gel Extraction Kit  Qiagen, Hilden, Germany 
Quiagen Blood & Cell culture DNA prep. Midi Kit  Qiagen, Hilden, Germany 
Qiagen Plasmid Maxi Kit Qiagen, Hilden, Germany 
Qiagen Plasmid Mini Kit Qiagen, Hilden, Germany 
QuikChange Multi Site-Directed Mutagenesis Kit Agilent Technology, Waldbronn, Germany 
Rapid DNA Ligation Kit  Roche, Mannheim, Germany) 
Platinum PCR SuperMix High Fidelity  Invitrogen, Germany 
Other materials  
Branson Sonifier B15 Branson, Dietzenbach, Germany 
Branson Sonifier 45,  Branson, Dietzenbach, Germany 
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Flash-gel, FlashGel™systems Lonza, Cologne, Germany 
Cellavista CV3.1 Synentech Bio Services GmbH, Munich, 
Germany 
Centrifuge 5415D Eppendorf, Hamburg, Germany 
Centrifuge 5417 R Eppendorf, Hamburg, Germany 
Centrifuge HeraeusMultifuge 35R+ Termo Scientific 
Flowcytometer FACSCalibur BD-Bioscience, Heidelberg, Germany 
Flowcytomerter BD-FACSCanto II BD-Bioscience, Heidelberg, Germany 
gel documentation system INTAS Intas Science Imaging Instruments GmbH, 
Göttingen, Germany 
gel documentation system Roche Lumi-Imager F1 Roche, Mannheim, Penzberg 
Incubator LabTerm-LT-XC Kuhner AG, Birsfelden, Switzerland 
Nanodrop 2000 PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
PCR cycler GeneAmp(r) PCR system 9700 PE Applied Biosystems, Darmstadt, Germany 
PCR cycler LightCycler®480 Instrument II System Roche, Mannheim, Germany 
Plate reader Tecan infinite M200 Pro Tecan Group Ltd., Crailsheim, Germany 
Power device Consort E802 Sigma, Taufkirchen, Germany 
Mastercycler nexus X1 Eppendorf, Hamburg, Germany 
Marker SeeBlue Marker prestained,  Invitrogen, Darmstadt, Germany 
Marker MagicMark XP anti IgG Invitrogen, Darmstadt, Germany 
Salmon Sperm DNA  Invitrogen, Darmstadt, Germany 
Xcell II Blot-Modul  Invitrogen, Darmstadt, Germany 
 
2.1.7 Buffers and solutions 
CHIP Cell lysis buffer (Gonzani lab.) Stock Vol for 1 L 
20 mM TrisHCl pH 8.0 1M 20 ml 
85 mM KCl 3 M 28 ml 
0.5% NP40 (Nonident P-40/ 
octylphenolpolyethoxyethanol) 
10% 50 ml 
ddH2O  883 ml 
Nuclei Lysis buffer (Gonzani lab.) Stock Vol for 1L 
50 mM TrisHCl pH 8.0 1M 50 ml 
10 mM EDTA pH 8.0 0.5 M  20 ml 
1% SDS 10% 100 ml 
ddH2O  830 ml 
1 tablet Roche Complete per 10 ml   
Low salt wash buffer (Gonzani lab.) Stock Vol. for 1 L 
0.1% SDS 10% 10 ml 
1% Triton X 100 10% 100 ml 
2 mM EDTA 0.5 M 4 ml 
20 mM Tris-CL pH 8.0 1 M 20 ml 
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150 mM NaCl 4 M 37.5 ml 
ddH2O  828.5 ml 
High salt wash buffer (Gonzani lab.) Stock Vol. for 1 L 
0.1% SDS 10% 10 ml 
1% Triton X 100 10% 100 ml 
2 mM EDTA 0.5 M 4 ml 
20 mM Tris-CL pH 8.0 1 M 20 ml 
500 mM NaCl 4 M 125 ml 
LiCl wash buffer (Gonzani lab.) Stock Vol. for 1 L 
0.25 M LiCl ( Villagra et al. CHIP) 1 M 250 ml 
1% NP40 10% 100 ml 
1% docycholate (deoxycholic acid)  10 g 
1 mM EDTA 0.5 M 2 ml 
20 mM Tris, pH 8.0 1 M 20 ml 
ddH2O  ad to 1 L 
TE buffer Stock Vol. 1 L 
10 mMTrisHCl pH 8.0 1 M 10 ml 
1 mM EDTA 0.5 M 2 ml 
(IP) Elution buffer (Farnham lab.) Stock Vol for 5 ml 
50 mM NaHCO3 1 M  0.25 ml (or 21 mg direct) 
1% SDS 10% 0.5 ml 
ddH2O  Ad to 5 ml 
IP Dilution buffer (Farnham lab.) Stock Vol for 5 ml 
0.01% SDS 10% SDS 0.5 ml 
1.1% Trition X 100 10% Trition X 100 0.5 ml 
1.2 mM EDTA 0.5 M 12 µl 
16.7 mM Tris-HCl pH 8.1 (8.0) 1 M Tris-HCl pH 8.0 83.5 µl 
167 mMNaCl 4 M NaCl 209 µl 
H2O  4.196 ml 
IP Blocking buffer  Volume for 10 ml 
IP Dilution buffer  10 ml 
BSA  50 mg 
Salmon Sperm DNA  1 mg 
Roche Complete Protease Inhibitor  1 tablet  
 
 
Triton X-100 lysis buffer Concentration 
Tris-HCl (pH 7.5)  50 mM 
Triton X-100  0.5% 
NaCl  137.5 mM 
Glycerol 10% 
Roche Complete EDTA (1 tab/10ml) 
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2.2 Methods 
2.2.1 Methods for DNA preparation and analysis 
2.2.1.1    Agarose gel electrophoresis 
Agarose gel electrophoresis was performed to analyze the quality, size and amount of linear DNA 
fragments (Chong, 2001). According to the size of DNA fragments, agarose solutions of 1% w/v were 
dissolved in 1 × TAE by boiling. Gels contained a final concentration of 0.5 μg/ml ethidium bromide. 
Samples were prepared by adding 1/6 v/v of 6 × DNA loading dye. A DNA ladder was used as a size 
standard. Electrophoresis was performed in 1 × TAE by applying 10 V/cm gel length (not more than 
250 V). After separation, DNA was examined under UV light (254-366 nm) in a gel documentation 
system (Intas Science Imaging Instruments GmbH, Göttingen, Germany). 
 
2.2.1.2    Gel extraction 
After Agarose Gel Electrophoresis, the gel slice with the favored band was excised by scalpel and the 
gel slice was further extracted by QIAquick® Gel Extraction Kit (Qiagen, Hilden, Germany). Following 
this, three volumes of Buffer QG were added to one volume of gel (100 mg ~ 100 µl) and incubated 
for ten minutes at 50°C. One gel volume of isopropanol was added to the dissolved gel and mixed. 
DNA fragments adhered to QIAquick spin column by one minute centrifugation at 13,000 rpm and 
were washed by 0.75 ml Buffer PE and subsequent centrifugation (13,000 rpm, one minute). Second 
wash in another collection tube removed the residual wash buffer. Finally DNA was eluted in 30 µl 
RNAse-free H2O into a sample tube by centrifugation (13,000 rpm, one minute). DNA can be 
checked on Flash-gel (FlashGel™systems, Lonza, Cologne, Germany). 
 
2.2.1.3    DNA quantification 
NanoDrop 2000 (PEQLAB Biotechnologie GmbH, Erlangen, Germany) was used to quantify DNA 
concentration by measuring the optical density (OD) at a wavelength of 260 nm. The purity of the 
DNA can be judged by the ratio OD 260/280 and 260/230. Pure DNA preparations should possess a 
ratio ≥ than 1.8 and 2.0. 
 
2.2.1.4    Transformation of competent bacteria 
45 µl of chemically competent E.coli NEB 5 alpha (NEB, Germany) were thawed on ice for 
ten minutes and incubated with 1 pg – 100 ng of plasmid DNA (1 -5 µl) for 30 minutes on ice. The cell 
suspension was heat shocked at 42°C for 45 seconds and immediately chilled on ice for five minutes. 
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950 µl of room tempered SOC or LB was added and suspension was incubated at 37° for 60 minutes 
being agitated (250 rpm). Transformed bacteria were plated on pre-warmed agar plates containing 
ampicillin. Plates were incubated overnight at 37°C. 
 
2.2.1.5    Plasmid preparation 
Plasmids were prepared using the Qiagen Plasmid Mini and Maxi Kits (Qiagen, Hilden, Germany) 
following the manufacturer´s instructions. 
 
2.2.1.6    DNA purification 
Genomic DNA was isolated and purified with the AllPrep DNA/RNA Mini Kit (50) (Cat.no.80204, 
Qiagen, Hilden, Germany) and the Dnease Blood & Tissue Kit (Qiagen, Hilden, Germany) according to 
manufacturer´s recommendations. Purification of fragments was done with the High Pure PCR 
Product Purification Kit (Roche, Penzberg, Germany) by following recommended protocol. 
 
2.2.1.7    Phenol-chloroform extraction 
Plasmid concentration and purification was done by Phenol/Chloroform extraction. All steps were 
performed under a chemical hood. 500 µl of linearized plasmid was mixed with 1 volume 
Roti®Phenol/Chloroform/Isoamylalcohol (25:24:1) (Cat.no.A156, Roth, Germany) and vortexed for 
30 seconds. Short spin removes liquid from lid and emulsion was transferred in precentrifuged Phase 
Lock Gel™ Light tube (Cat.no. 0032005.101, Eppendorf, Hamburg, Germany) for centrifugation 
(13,000 rpm, one minute, Eppendorf table centrifuge). Upper aqueous phase was transferred into 
new tube and extraction was repeated. Thereafter the upper aqueous phase was mixed with 500 µl 
Chloroform/Isoamylalcohol (24:1) and extraction steps were repeated once. The upper phase was 
transferred into a new tube and mixed with 0.1 start volume of 3 M NaAc (pH 4.8-5.2) and 0.7 start 
volume of 100% isopropanol (20-30°C) by inverting tube 4-6 times. 20 minutes incubation at -80°C 
followed by centrifugation (13,000 rpm, 30 minutes at 4°C) resulted in DNA precipitation and 
sedimentation. Supernatant was discarded. Pellet was washed with chilled 1 ml 70% EtOH, 
centrifuged (13,000 rpm, five minutes at 4°C) and supernatant was discarded. Wash step was 
repeated under sterile conditions and residual supernatant was completely removed. Pellet was 
dried for five to ten minutes on sterile air and subsequently up taken in 0.5 start volume ddH2O.  
 
46 
 
2.2.1.8    Transgene copy number determination 
Determinations of transgene copy number as well as methylation rate of C-179 of hCMV-MIE 
promoter were performed by Silke Simmeth and Tobias Scherzinger according to the 
recommendations of Osterlehner (Osterlehner et al., 2011). 
Relative Copy number (rCN) was calculated by two to the power of the substraction of the Cq value 
of the reference input sample (e.g. Gusb) from the Cq value of the target input sample hCMV-MIE 
promoter. 
 
 
 
 
Figure 10: Comparison of relative copy number of transgene and the calculated copy number by standard curve. Y-axis 
represents the relative copy number and x-axis displays the sample numbers. 
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2.2.1.9    Cloning of reporter constructs 
All transfection vectors were designed with the p5532 backbone as exemplified above. Depending 
on assay UAS sites, GFP-PEST, IRES and Gal4BD-MOF were integrated into backbone (Figure 12). 
 
 
Figure 11: Plasmid design for measuring hCMV-MIE promoter strength by expression of secretory alkaline phosphatase 
(SEAP). 
 
Figure 12: Cloning strategy for transfection vectors. UAS sites, GFP-Pest, IRES and Gal4BD-MOF were integrated into 
vector backbone. Testing CpG point mutations of hCMV-MIE was done in a vector without IRES and Gal4BD-MOF. 
 
5548 bp 
TATA box 
origin 
murine DHFR 
recomb. SEAP 
Ampicillin resistance gene 
SV40 early polyadenylation signal shortened 
SV40 early polyadenylation signal 
SV40 promoter and origin 
hCMV-MIE 
pUC origin 
TATA 
5'UTR-IGHV3-33 SP-IGHV102 
tramscription start 
p5532-pUG-5'UTR-IGHV3-33 SP-IGHV102 SEAP 
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The sequences for UAS and Gal4BD-MOF were kindly provided by Prof. Dr. Peter Becker (Adolf 
Butenandt Institute, Munich, Germany). The EV71-IRES DNA as well as the eGFP and Pest DNA were 
kindly provided by the in-house groups of Dr. Peter Hülsmann and Dr. Gwendlyn Kollmorgen (Roche, 
Penzberg, Germany). Fragments were amplified by PCR, according to integration sites, primers were 
equipped with appropriate cutting sites. Digestion of integrates and backbone was done with the 
appropriate restriction enzymes (NEB, Germany) according to manufacturer´s protocol. 
Dephosphorylation of vectorbackbones was done with rAPID alkaline phosphatase (Cat.no. 
04898133001, Roche, Germany). Thereby 30 µl linearized vector (< 1 pmol) were incubated with 
3.6 µl 10x Dephosphorylation buffer and 2 µl (1 Unit) alkaline Phosphatase for ten minutes at 37°C, 
followed by 15 minutes at 65°C and chilling on ice. Ligation of fragments was done with Rapid DNA 
Ligation Kit (Cat.no. 1635379, Roche, Germany) according to manufacturer´s protocol. Ligation was 
then performed at a ratio 1:3 (backbone:insert) for standard and 1:5 for sticky ends. The number of 
copies was calculated with the following formula: 
 
 
 
All constructs were verified by digestion analysis and sequencing (Sequiserve GmbH, Vaterstetten, 
Germany). After verification of correct sequence, plasmids were amplified in E.coli and purified with 
Qiagen Plasmid Mini and Maxi Kits (Qiagen, Hilden, Germany). 
 
2.2.1.10    Site directed mutagenesis 
Influence of major methylated CpG sites of the hCMV-MIE promoter was investigated by C to G point 
mutation of predominately methylated CpG sites in various combinations. 
Mutation of CpG sites of the hCMV-MIE promoter was done by QuikChange Multi Site-Directed 
Mutagenesis Kit (Cat.no 200514-12, Agilent Technology, Waldbronn, Germany). The hCMV-MIE 
promoter was mutated at C-508, C-179 and C-41 upstream of transcription start site with following 
primers in various combinations. 
 
Primer number Position of point mutation Primer sequence 
1 C-508 CGTTACATAACTTAGGGTAAATGGCCCGCC 
2 C-179 AATGGGCGTGGATAGGGG TTTGACTCACG   
3 C-41 GTAGGCGTGTAGGGTGGGAGGTCTATATAAG 
 
Table 1: Primer sequences for C to G mutation of hCMV-MIE promoters to investigate DNA methylation dependent 
silencing effects 
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Mutation was done according to manufacturer´s protocol: 
Mutant strand synthesis was performed by thermal cycling to denature DNA template, anneal the 
mutagenic primers (primers bind same strand) and extend primers and ligate nicks with the 
QuikChange Multi enzyme blend. The following digestion of template was executed to digest 
methylated and hemimethylated DNA with restriction enzyme DpnI. The mutated ssDNA was 
transformed into XL10 Gold ultracompetent cells. 
 
 
Figure 13: Overview of the QuikChange Multi Site-Directed Mutagenesis method. Adapted from Agilent technologies 
protocol. 
 
Position of C to G mutations upstream of TSS Code 
-508, -179, -41 GGG 
-508, -41 GCG 
-179 CGC 
-508 GCC 
-41 CCG 
 
Table 2: Combinations of C to G point mutations of hCMV-MIE. Those variations were used to investigate DNA 
methylation dependent silencing effects. 
 
Transformed E.coli colonies were picked, incubated and plasmids were prepared. Finally plasmids 
were sequenced by Sequiserve (Sequiserve GmbH, Vaterstetten, Germany) and hCMV-MIE 
promoters with desired combinations (displayed in Table 2) of point mutations were used for further 
investigations of silencing effect. 
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2.2.1.11    Chromatin immunoprecipitation 
CHO cells lines were harvested with a viability of greater than 97% to obtain comparable results. 
Before fixation, agarose beads for preclearing and precipitation were prepared. Preclearing beads 
were generated by washing (one hour, RT while rotation) of 15 µl Protein A Agarose slurry (Roche, 
Mannheim, Germany) two times in 120 µl Dilution buffer followed by incubation with 2 µl Rabbit 
IgG, Purified (PP64B, Millipore, Germany) in 120 µl ChIP Dilution Buffer per sample. Two Wash steps 
with 120 µl of ChIP Dilution Buffer were done for purification and agarose beads were resuspended 
in 85 µl ChIP Dilution buffer. In addition 15 µl Agarose A Beads slurry for precipitation were blocked 
in 1 ml ChIP Dilution buffer with 5 mg/ml BSA (Roche, Penzberg) and 100 µg/ml of preheated Salmon 
Sperm DNA (ten minutes at 95°C and five minutes on ice; Cat no. 15632-011, Invitrogen, Germany). 
Resuspended pellet were incubated for four to five hours at 4°C while rotation and subsequently 
washed three times and mounted in 40 µl of ChIP Dilution Buffer.  
1.10^7 cells per sample were fixed by adding formaldehyde into media up to a final concentration of 
3.7% and incubated for ten minutes at RT as described previously (Beneke et al., 2012). Fixation was 
stopped by adding glycine up to a one fold solution. After two wash steps with ice cold PBS, and 
centrifugation at 2,000 g for three minutes, pellet was resuspended in 1 ml PBS plus protease 
inhibitor Roche Complete (Roche, Penzberg, Germany). The suspension was pelleted by 
centrifugation (3,000 g, five minutes, 4°C) and supernatant was discarded. 
Lysation of pellet was done by adding 1 ml cell lysis buffer plus Roche Complete (Roche, Penzberg, 
Germany) and incubation on ice for ten minutes. Centrifugation (2,300 g, four minutes, 4°C) resulted 
in nuclei pellet which was resuspended in 300 µl Nuclei Lysis Solution and sonicated (Output 5, Duty 
cycle 90%, 15 seconds sonication followed by two to three minutes incubation on ice for six cycles; 
Branson Sonifier B15,Dietzenbach, Germany). 700 µl of Nuclei Lysis Solution were added to 
sonicated nucleis followed by centrifugation (13,000 rpm, 15 minutes, 4°C). The supernatant 
contents the chromatin and was transferred into a new tube for storage at -80°C until use. 
Sonification grade was tested after protein digestion on an agarose gel (Figure 14). 
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Figure 14: Sonification efficiency test. CHO-K1 M chromatin was sheared with three and six repeats to obtain the optimal 
fragment size. 
 
Chromatin was precleared with 80 µl prepared protein A agarose slurry by incubation (two hours at 
4°C while rotation) and centrifugation (13,000 rpm, six minutes, 4°C , Eppendorf 5417R, Eppendorf, 
Hamburg, Germany). Supernatant was transferred into new tube and protein concentration was 
determined (Pierce®BCA Protein Assay Kit, Thermo Scientific, Rockford, USA). 25-100 µg of 
chromatin per immunoprecipitation (IP) were mounted in 200 µl Nuclei Lysis buffer and added to 
300 µl ChIP Dilution buffer comprising 3 µg of appropriate antibody. Immunoprecipitation was done 
overnight at 4°C while under rotation. Undiluted input samples were stored at -20°C. After overnight 
incubation, 40 µl of blocked Protein A Agarose beads were added to IP solution and incubated  
(one hour at 4°C while rotating). Precipitation was washed with 2 x low-, 1x with high-salt wash 
buffer, 1 x with LiCl wash buffer and additional with 1x TE wash buffer. Each wash was done in 1 ml 
buffer for five minutes on rotating platform followed by centrifugation (500 g, 30 seconds, 4°C). 
After the last wash step beads were centrifuged with 500 g for one minute. Bead pellets were 
combined with 200 µl IP Elution buffer, while simultaneously 25-100 µg chromatin input sample 
were filled up to 200 µl with IP Elution buffer and incubated for 30 minutes at 65°C while shaking. 
Subsequently tubes were incubated for 30 minutes at 37°C after adding 0.5 µl RNAse DNAse free 
(Roche, Germany) to each tube. For final protein digestion 10 µl 4 M NaCl (final conc. 0.2 M) and 2 µl 
Proteinase K (final conc. 100-200 µg/ml, Roche Germany) were added to the reaction samples and 
incubated for 1.5 hours at 65°C. DNA was purified by Roche PCR purification Kit (Roche, Germany). 
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2.2.1.12    Bisulfite conversion 
For conversion of unmethylated cytosines into uracil the EZ-96 DNA Methylation-Lightning TM Kit 
(deep-well format) (ZymoResarch, Freiburg, Germany) was used according to manufacturer´s 
instructions. In brief, gDNA was extracted with Dnease Blood & Tissue Kit (Qiagen, Hilden, Germany) 
and concentration was measured with NanoDrop 2000 (PEQLAB Biotechnologie GmbH, Erlangen, 
Germany) to set concentration at 350 ng gDNA in 20 µl ddH2O. 20 µl gDNA were mixed with 130 µl 
of Lightning Conversion Reagent in a Conversion Plate, afterwards were incubated at 98°C for eight 
minutes, then at 54°C for 60 minutes and finally temporarily stored at 4°C. A Zymo-Spin™ I-96 
Binding Plate containing 600 µl of M-Binding Buffer per well, was mounted on a Collection Plate. 
Samples from the Conversion Plate were added to the Zymo-Spin™ I-96 Binding Plate, mixed and 
centrifuged (3,000 g for five minutes). Plates were washed with 400 µl fo M-Wash Buffer and 
centrifuged (3,000 g, five minutes). 200 µl of L-Desulphonation Buffer were added to each well, 
incubated (20-30°C, 20 minutes) and subsequently centrifuged (3,000 g for five minutes). An 
additional wash step was completed with ten minutes centrifugation at 3,000 g and converted DNA 
was eluted in 30 µl M-Elution buffer. Converted DNA was stored at -20°C until use. 
 
Amplification of converted and integrated hCMV-MIE promoter: 
For investigation of CpG methylation of hCMV-MIE promoter, primer pairs for distal (F1 & R1) and 
proximal (F2 & R2) promoter region were designed as follows: 
 
UG_730_Bisul_CMV1 F1 gatattgattattgattagttattaatagtaattaa 
UG_731_Bisul_CMV1 R1 caaataaaaaaatcccataaaatcatatactaa 
UG_732_Bisul_CMV2 F2 ttagtatatgattttatgggatttttttatttg 
UG_733_Bisul_CMV2 R2 Ttctaatactaaactcctctcccaa 
 
Table 3: Primers for amplification of distal and proximal hCMV-MIE promoter region. 
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10 pmol of each primer (0.5 µl) were added to 12.5 µl ZymoTaq™DNA polymerase premix 
(ZymoResarch, Germany), 3 µl gDNA template and filled up to 25 µl with ddH2O. Polymerase chain 
reaction (PCR) was done with Mastercycler nexus X1 (Eppendorf, Hamburg, Germany), PCR 
conditions were as follows: 
 
95°C 10 min   
94°C 30 sec 
 49°C 2 min 2 cycles 
68°C 2 min 
 94°C 30 sec 
 
54°C 2 min 
34-43 
cycles 
68°C 2 min 
 72°C 10 min  
4°C Œ   
 
Table 4: Adjustment of Mastercycler nexus X1 conditions. 
 
Amplicons were purified with Roche PCR Purification Kit (Roche, Germany) in 30-40 µl Elution buffer. 
Concentration was defined with NanoDrop 2000 (PEQLAB Biotechnologie GmbH, Erlangen, 
Germany) and size of amplicons were displayed by agarose gel electrophoresis. 
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2.2.1.13    Inverse PCR 
The inverse Polymerase Chain Reaction (iPCR) is a method to determine integration sites of a 
randomly integrated vector. From this the known vector-sequence near the cutting site will be used 
to generate primers of at least 20 bp length. Those primers are oriented in opposite directions.  
The genome was digested with frequently cutting enzymes (4 bp cutter) which did not cut between 
the primer binding sites and at the linearization site of the vector. The resulting fragments are 
ligated at very dilute conditions so as to favor intramolecular ligation. The circularized sequence can 
now be amplified with the inverse primers. 
 
Figure 15: Schema of inverse PCR. Adapted from (Papapetrou & Sadelain, 2011). Well-chosen restriction enzymes cut in 
a defined region of vector sequence near the integrations site and in the unknown area of genome. Self-ligation under 
highly diluted condition is favored. Primers bind the known vector sequence and amplify the circularized fragment. 
Sequencing of amplicons leads to the identification of integration sites. 
 
Genomic DNA was isolated with Quiagen Blood & Cell culture DNA prep. Midi Kit (Qiagen, Hilden, 
Germany) out of 2x10^7 cells (~90 µg DNA) per condition (genomic DNA can be stored at -20°C for 
several months) and dissolved in 90 µl ddH2O. 
The isolated genomic DNA was digested with differing restriction endonucleases at the appropriate 
working temperature for a minimum of 16 hours (overnight). For the digestion of gDNA the Enzymes 
CviQI, MseI and MspI for the iPCR upstream of PvuI integration site and the enzymes MseI, BfaI and 
MluCl for the iPCR downstream of the PvuI integration site were used. 10 µg genomic DNA were 
used per digestion (3,8x10^6 copies). 
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Digestion: 
Component  Volume / 80μl  Final amount  
gDNA template  x μl 10 μg 
NEBuffer 10×  8 μl 
BSA 10× (if required)  8 μl 
ddH2O  Add to 80 μl 
Restriction endonuclease  x μl 50 U*  
 
Table 5: Digestion of gDNA for inverse PCR. Long incubation increases change of complete digestion. 
 
The digested DNA was purified with the Roche PCR-purification kit and eluted in x µl (200 µl) Elution 
buffer. The high dilution grade of DNA favors intramolecular ligation. 
 
Ligation: 
Neb T4 DNA Ligase (M0202S) for iPCR 
Digested DNA 20 µl (1 µg) (3,8x10^5 copies) 
Ligation buffer, 10x 50 µl 
T4 DNA ligase (400 Uµl^-1) 1 µl 
WFI (ddH2O) 429 µl 
 
Table 6: Ligation of digested gDNA. High Dilution leads to preferred self-ligation. 
 
In order to generate circular DNA fragments, the digested DNA was ligated overnight at 16°C using 
T4 DNA ligase (NEB, Frankfurt/Main,Germany). Ligated DNA was eluted in 50 µl Elution buffer of the 
High PurePCR Purification Kit (Roche, Penzberg, Germany). Phenol-chloroform extraction is not 
recommended by GATC guidelines. For iPCR of circularized fragments, 10 µM of each primer (574 & 
575 or 576 & 577) and 45 µl of Platinum PCR SuperMix High Fidelity (Invitrogen, Germany) were 
added to 10 ng template DNA. As a control group, untransfected gDNA for CHO cell line was 
investigated. 
 
Primer Sequence Location  
UG_574_16110 BtsI_rev CTGTCATGCCATCCGTAAGATGCT 5`PvuI Integration Site  
UG_575_16110 BtsI_for GCGGCCAACTTACTTCTGACAACG   
UG_576_16110 AceIII_rev AAGGCGAGTTACATGATCCCCCAT 3`PvuI Integration Site  
UG_577_16110 AceIII_for CACCACGATGCCTGTAGCAATGG   
 
Table 7: Primer for inverse PCR. Appropriate forward and reverse Primer are in opposite direction. Circularization of 
template DNA results in amplification. 
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The iPCR for 5´iPCR conditions are described as follows: 
Initial Denaturation 94°C 7 min   
Denaturation 94°C 45 sec 
 Annealing 60°C 45 sec 28 cycles 
Elongation 68°C 4 min 
 Final Elongation 68°C 7 min  
Short storage 4°C Œ   
 
Table 8: iPCR conditions. Extended elongation time minimize the loss of amplification according to fragment length. 
 
5 µl of PCR fragment was mixed with Orange G (5 µl) and ddH2O (10 µl) and loaded on agarose-gel 
to verify the distribution of fragments. For 5´iPCR of MseI and MluCI cutted fragments good results 
were obtained and no unspecific band in control lanes was detected. 
 
 
Figure 16: 5`iPCR of stable CHO pools after eGFP sort. Pools were randomly transfected with eGFP reporter plasmid and 
MTX selected. After one month of cultivation, pools were positive and negative eGFP sorted and integration sites were 
examined with iPCR. No unspecific amplifications were obtained in untransfected CHO control cells using 5´integration 
site primers.  
 
5´amplicons of each sample (cut with MseI and MluCI) were combined and purified with High Pure 
PCR Purification Kit (Roche, Penzberg, Germany) in 40 µl Elution buffer. Sequencing of fragments 
was done by GATC-Biotech (Konstanz, Germany). 
 
2.2.1.14    Quantitative real-time polymerase chain reaction 
For detection of relative amounts of a target sequence the quantitative real-time polymerase chain 
reaction (qPCR) is the method of choice. Based on the principle of PCR, a target sequence is 
amplified by target specific primers. In addition, each amplification cycle is measured in real time. 
For each qPCR the non-specific fluorescent dye LightCycler®480 SYBR Green I Master in the 
LightCycler®480 Instrument II System (Roche, Penzberg, Germany) was used. The LightCycler®480 
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System is a high-performance, medium- to high-throughput PCR platform (96- or 384-well plates) 
that can be integrated as a robotically controlled, automated high-throughput solution. SYBR Green 
is excited using blue light (λmax = 488 nm) and it emits green light ( λmax = 522 nm). The SYBR 
Green dye binds to all double-stranded DNA in PCR. As a result the fluorescence intensity and the 
amount of DNA product increase simultaneously, which can be detected by the LightCycler® System 
after each cycle. For quantification the fluorescence was plotted against the number of cycles on a 
logarithmic scale. Slightly above the emitted background the threshold for detection of DNA-based 
fluorescence was set by the LightCycler®System. The number of cycles at which the fluorescence 
pass the threshold is termed quantification cycle (Cq) (Bustin et al., 2009). During the exponential 
amplification phase a doubling of target DNA is expected in every new cycle. However, the efficiency 
of amplification is often variable among primers and templates. Analysis of the melting temperature 
of amplified DNA fragments gives first hints of the specificity of used primer pairs and the amount of 
primer dimers. 
An efficiency of primer template combination can be assessed by a titration experiment to create a 
standard curve or by efficiency calculation program like LinRegPCR. The program uses non-baseline 
corrected data from the LightCycler®System, performs a baseline correction on each sample 
separately, determines a window-of-linearity and then uses linear regression analysis to fit a straight 
line through the PCR data set. From the slope of this line the PCR efficiency of each individual sample 
is calculated (Ruijter, Velden & Ilgun, 2009). 
For relative quantification the amount of target sequence were compared to a reference sequence, 
by subtracting Cq (target) from Cq (reference). This normalization is termed ∆Cq-method (Schefe et 
al., 2006).The reference sequence has to have very stable values, considerably higher than the 
background values (Mock).Therefore for each reference sequence, the average and the coefficient of 
variation of all samples within one project was calculated and compared to background levels. Cq 
values of the different conditions were displayed as % of the Input Sample, visualizing the distance 
to mock control. 
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Regarding the large number of samples, all qPCR were accomplished in 384 well plates. In each well 
following ingredients were transferred. 
 
Volume (µl) 384 wellplate Solution 
5 Sybr Green MasterMix 
0.5 Primer (10 pM) for. 
0.5 Primer (10 pM) rev. 
1.5 H2O 
2.5 DNA (X ng/µl) 
10 Total 
 
Table 9: qPCR mix. DNA template has normally a concentration around 1 ng/µl. ChiP samples have a low number of 
target sequences. Therefor concentration could not be estimated. 
 
The qPCR program was designed as follows: 
Appliance Temperature (°C) Time Degree (°C/sec) Cycles 
Pre-Denaturation 95 10 min 4.8 1 
 
Amplification 
95 10 sec 4.8  
40 60 5 sec (single) 2.5 
72 15 sec 4.8 
 
Melt curve 
95 5 sec 4.8  
1 70 1 min 2.5 
95 (continuously)  
Cooling     
 
Table 10: qPCR program of ChIP samples accomplished in the LightCycler®System. Number of amplification cycles can 
vary between 40-45. All Cq values scratching 40 cycles cannot be trusted anymore, because of the increase of unspecific 
amplification. 
 
In the special case of the relative quantification of histone modifications, the normalization of 
sample (treated) to input sample (untreated) is directly replaced by the normalization of treated 
target sequence to treated reference sequence. Further calculation of histone modification per 
histone makes the normalization to input sample redundant. 
The relative amount of specific histone modification close to human CMV major immediate-early 
promoter/enhancer fragment were estimated with the Livak method, also known as delta delta Cq 
(∆∆Cq) method (Livak & Schmittgen, 2001), as long as primer-template efficiencies are close to 2 and 
close to each other (< 2% difference of Cq mean). 
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The method can be used for relative quantification of a target regarding to a reference. In this 
example the relative quantification of H3 acetylation and H3 levels close to human CMV major 
immediate-early promoter/enhancer fragment were normalized to the histone 3 acetylation and the 
histone 3 levels close to reference gene in two steps. First ∆Cq was calculated as follows: 
 
  
 
∆Cq is the distance of quantification cycles (Cq) between control (e.g. ChIP sample value of Gusb) 
and target (e.g. ChIP sample value of hCMV-MIE) of the same sample, amplified with different 
primer pairs. To identify the level of H3 modification per H3, the ∆∆Cq method was used.  
 
  
 
2.2.1.15    Sequencing methods 
Sanger sequencing was performed by the company Sequiserve (Sequiserve GmbH, Vaterstetten, 
Germany). Next generation sequencing was performed by GATC (GATC-biotech, Konstanz, Germany) 
and Active Motif (La Hulpe, Belgium) and in house by myself using Illumina Sequencing technology. 
 
2.2.1.16    Sequencing of amplicons after bisulfite conversion 
I performed sequencing of bisulfite converted amplicons by employing the MiSeq system (Illumina, 
Inc., San Diego, USA). At first amplicon concentration was measured with the Qubit system (Life 
Technologies GmbH, Darmstadt, Germany) and library was generated according to the TruSeq Nano 
DNA Library Prep Guide (Part # 15041110 Rev. C, Illumina, Inc., San Diego, USA)) using 100 ng per 
amplicon. Library quality was checked with the Agilent 2100 bioanalyzer (Agilent Technologies, 
Waldbronn, Germany) using a 1/100 dilution of dsDNA with the High Sensitivity DNA Assay (Agilent 
Technologies, Waldbronn, Germany) (Figure 17). 
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Hence in each sample two clear peaks were observed. Those peaks are the result of the combined 
distal and proximal hCMV-MIE amplification and demonstrate the quality of each sample. After 
verification of quality, all 56 amplicons were pooled in equal shares and mixed with 10% PhiX before 
run. 
 
 
Figure 17: Electropherogram of one sample including the proximal and distal amplicons of bisulfite converted hCMV-
MIE. The clear peaks between 400 and 600 base pairs confirm the good quality of the library. 
 
Reads were mapped with the Bismark software (Krueger & Andrews, 2011) which uses Bowtie2 
(Langmead & Salzberg, 2012) for alignment. Bismark was performed with the following commands: 
/data64/sequencing/LMR_IntegrationSite_BenjaminMoritz/bisulfit_data/bismark/bismark_v0.14.3/
bismark --non_directional --bowtie2 -o $(dirname $file1) -p 8 $reference -1 $file1 -2 $file2 
For this purpose following alignment parameters for non-directional reads were used according to 
the manual and calculation was performed by Matthias Barann. The output of the 
bismark_methylation_extractor includes --include_overlap, --bedGraph, --cytosine_report and --
report 
 
2.2.1.17    Analyses of next generation sequencing data 
Alignment of reads and mapping was performed by Matthias Barann. Reads of the integration sites, 
generated by inverse PCR, and the ChIP sequencing reads for H3K36me3, H3ac, H3K4me3 and 
H3K9me3 were aligned to the CHO-k1 genome (genBank Assembly ID GCA_000223135.1), employing 
the Burrow-Wheeler alignment tool BWA (Li & Durbin, 2009) 
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BWA was performed with the following commands:  
reference=/data64/sequencing/LMR_IntegrationSite_BenjaminMoritz/reference/cricetulus_griseus_
merged.fasta 
/apps64/bidev/ngs/bwa/bwa-0.7.10/bwa aln -t 12 $reference $file1 > $(basename $file1).sai 
/apps64/bidev/ngs/bwa/bwa-0.7.10/bwa samse $reference $(basename $file1).sai $file1 > 
$(basename $file1).sam 
samtools view -b  $(basename $file1).sam >  $(basename $file1).bam 
samtools sort $(basename $file1).bam $(basename $file1)_sorted 
samtools index $(basename $file1)_sorted.bam 
 
The analysis of ChIP peaks was performed with MACS2 (Zhang et al., 2008b) and the subsequent 
commands were given: 
callpeak-t /path….file.name(H3K36me3) .bam –c /path…file.name(Input control).bam –f BAM-g hs 
(genome size) –n file.name(output H3K36me3).bam –outdir /path…/(broad)—buffer-size 10000  
 
The command broad was only added for H3K36me3 and H3K9me3 reads. 
 
The arguments were as follows: 
∑ name = 2_2578Roche_CHO_K1_M_rep_H3K36me3_i81_sorted.bam 
∑ format = AUTO 
∑ ChIP-seq file = [´/path…file.name(H3K36me3).bam`] 
∑ control file = [´/path…file.name(Input control).bam`] 
∑ effective genome size = 2.7e+09 
∑ band width = 300 
∑ model fold = [5,50] 
∑ and the quality values were 
∑ qvalue (minimum false discovery rate FDR ) cutoff for narrow/strong regions = 5.00e-02, or 
1.00e-01 for broad/weak regions respectively. 
∑ Larger dataset will be scaled towards smaller dataset 
∑ Broad region calling is on for H3K36me3 and H3K9me3 whereas it is off for H3ac and 
H3K4me3. 
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2.2.2 Methods for protein analysis 
2.2.2.1    Protein quantification 
Protein concentrations were estimated in comparison to a protein standard with the Pierce®BCA 
Protein Assay Kit (Thermo Scientific, Rockford, USA). 
 
2.2.2.2    Protein fractionation in compartiments 
Proteins were fractionated in membrane/cytoplasmic and nuclear proteins (Misawa Y, 2006). 
Following this CHO cells (1x 10^7 cells per sample) were sedimented by centrifugation (300 g, three 
minutes at 4°C) and the pellet was washed twice in ice-cold PBS + Roche Complete (Roche, Penzberg, 
Germany). Washed pellet was lysed with 1 ml 0.5% Triton X-100 lysis buffer and incubated on ice for 
15 minutes. Insoluble nuclei were separated by centrifugation (13,000  rpm, 15 minutes at 4°C) with 
Eppendorf table centrifuge (Eppendorf, Hamburg, Germany). Membrane/cytoplasma containing 
supernatant was transferred into a new tube and chilled on ice. Nuclear pellet was rinsed with lysis 
buffer once and resuspended in 300 µl lysis buffer containing 0.5% SDS followed by sonication (five 
seconds, Output 2, duty cycle 90%, Branson Sonifier 450, Dietzenbach, Germany). 700 µl lysis buffer 
were added and sample was centrifuged at 13,000 rpm, 15 minutes at 4°C with an Eppendorf table 
centrifuge. Nuclei containing supernatant were transferred into new tube and protein fractions were 
stored at -80°C. 
 
2.2.2.3    SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Denaturing SDS polyacrylamide gels were used for protein separation according to their molecular 
weight. To accomplish this, the NuPAGE gels (4-12%) were used (NuPAGE®Novex® 10% Bis-Tris Gel 
1.0 mm x 12 well, Cat. No. NP0302BOX, Invitrogen, Germany) in combination with the NuPAGE® 
electrophoresis system. According to Quick Reference Card (NuPAGE ® Bis-Tris Mini Gels), gel was 
fixed in chamber and the inner cassette was filled with 1x MOPS running buffer (20x NuPAGE MOPS 
SDS Running Buffer, Cat. No. NP0001, Invitrogen, Germany). The outer chamber was also filled to 
two-thirds of its volume. The comb was removed and the lanes were purged with a small pipette. 
30 µl of sample was added to 10 µl 4xNuPAGE LDS-Samplebuffer, (Cat. No. NP0007, Invitrogen, 
Germany), 2 µl 1 M DTT (final 50 mM) and incubated at 95°C for 5 minutes. Samples (20 µl/lane) and 
markers ((10 µl/lane) SeeBlue Marker prestained, Cat. No. LC 5625, Invitrogen; (5 µl/lane) 
MagicMark XP anti IgG, Cat.No. LC5602, Invitrogen, Germany) were transferred into the lanes and 
gel was applied at 30 volts for 50 minutes with NuPAGE®electrophoresis system. 
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2.2.2.4    SDS-PAGE and western blot 
SDS-PAGE induced separated proteins were blotted to a methanol-activated nitrocellulose 
membrane according to NuPage protocol for denaturing electrophoresis (NuPAGE®Technical Guide, 
Manual part no. IM1001, Invitrogen, Germany) in a Xcell II Blot-Modul (Invitrogen, Germany) with 
the appropriate reagents. Blotting was conducted in the SDS-PAGE chamber at 30 volt for 50 
minutes. Blotted protein membrane was transferred into a new chamber and washed three times 
for ten minutes in one fold TBS wash buffer (10 fold TBS: 0.5 M Tris-Base, 1.5 M NaCl, pH 7.5) 
followed by five minutes incubation in Ponceau solution (0.1%) for general protein detection. The 
Ponceau solution was discarded and residues were washed away with two times one minute TBS 
wash steps. 
Membrane was blocked for one hour at 20-30°C in 1% blocking solution (Blocking solution: 1/10 
Casein (Roche, Penzberg, Germany), 1x TBS). Subsequently membrane was incubated in primary 
antibody solution (1% Blocking solution + Antibody) at 4°C overnight while shaking. The membrane 
was washed three times in 1x TBST for ten minutes at 20-30°C followed by one minute wash step in 
1x TBS. Membrane was incubated in secondary antibody solution (1% Blocking solution + antibody) 
for 45 minutes at 20-30°C or at 4°C overnight while being agitated. The membrane was washed 
three times in 1x TBST for ten minutes at 20-30°C followed by two times one minute wash step in 1x 
TBS to remove Tween. 
 
Antibody name Dilution (WB) Host Company Cat.no 
H4K16ac-ab 1:5000 Rabbit Millipore 07-329 
Anti GFP 1:2000 Mouse SIGMA G 6539 
Anti Flag 1:1000-10000 Mouse SIGMA F 3165 
Gal4(DBD+O1679 1:100-1000 Rabbit Santa Cruz Biotech Sc-577 
Alpha-tubulin 1:10000 Mouse SIGMA T 9026 
Goat anti rabbit 1:2000 Goat Millipore 12-348 
Goat anti mouse 1:2500 Goat Millipore  
 
Table 11: Western blot antibodies with the used concentration to detect specific proteins. 
 
Detection of Antibody-binding was done with the Lumi-LightPLUS western blotting system (Roche, 
Penzberg, Germany). 
 
64 
 
2.2.3 General methods for working with CHO cell lines 
2.2.3.1    Cryoconservation of CHO cell lines 
1x 10^7 viable cells per sample were centrifuged (500 g, three minutes at 20-30°C) to discard the 
supernatant. Pellet was resuspended in pre chilled 1 ml Cryomedium (Cdm2 Opt 1.1, 10 mM  
L-glutamine, 7.5% DMSO), transferred into cryovial and immediately stored at -80°C in Mr.Frosty 
racks (filled with Isopropanol). Two days later Cryovials were transferred to a liquid nitrogen tank. 
 
2.2.3.2    Thawing of CHO cell lines 
15 ml falcon tubes were prepared with 5 ml of an appropriate medium (Cdm2 Opt 1.1, 10 mM  
L-Glutamine). Cryovials were stored on dry ice until thawing for a maximum of 10 minutes in water 
bath (37°C). Afterwards CHO cells were taken up into prepared falcon tubes and centrifuged for 
three minutes at 500 g to remove residual DMSO. Pellet was resuspended in 5 ml medium and 
propagated in disposable 125 ml vented shake flasks (contain 20 ml appropriate medium) under 
standard humidified conditions (95% rH, 37°C, and 5% to 8% CO2) at a constant agitation rate of 
120 rpm/min to 150 rpm/min. Viability (> 95%) and cell concentration can be tested with Cedex 
HiRes Analyzer (Roche, Germany). 
 
2.2.3.3    Cultivation of CHO cell lines 
Untransfected CHO cells were split every three to four days and seeded with a concentration of 2-3x 
10^5 cells/ml in Cdm2 Opt 1.1 medium (10 mM L-Glutamine). Transfected cells were seeded with 
various concentrations of methotrexate (MTX) or methionine sulfoximine (MSX) as the selection 
agent. After recovery of cell viability (three to four weeks), stably transfected cells were selected in 
thymidine and protein-free medium containing 20 nM to 1,200 nM Methotrexate (MTX) or 140-
160 µM methionine sulfoximine (MSX) as the selection agent. The cells were propagated in 
disposable 125 ml vented shake flasks under standard humidified conditions (95% rH, 37°C, and 5% 
to 8% CO2) at a constant agitation rate of 120 rpm/min to 150 rpm/min. Every three to four days the 
cells were split into fresh mediums with a cell concentration of 2-3x 10^5 cells/ml. Density and 
viability of the cultures were determined using the CASY TT or Cedex HiRes cell counter (Roche 
Innovates AG, Bielefeld, Germany). 
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2.2.3.4    Transient and stable transfection 
Transfection was achieved with the Amaxa® Cell line Nucleofector® Kit V (Lonza, Cologne, Germany) 
and the transfection platforms Nucleofector™2b Device and 96-well Shuttle™System (Lonza, 
Cologne, Germany). 
5x 10^6 CHO cells per transfection were centrifuged (200 g, five minutes) and supernatant was 
discarded. Pellet was resuspended in 100 µl of supplemented Nucleofector Solution V and 1.2 pmol 
of sterile plasmid was added by pipetting up and down. Plasmid was linearized for stable 
transfection, for transient transfection the circular form was maintained. Suspension was mounted 
into bubble-free cuvette and program U-24 was activated for CHO cell line transfection. After pulse 
500 µl of prewarmed media (10 mM L-Glutamine, 0 nM MTX, Mafog In-house platform) was 
mounted into cuvette and whole suspension was transferred in 8 ml prewarmed media. Cells were 
transferred into incubator and cells were ready for first examinations two days after. 
 
2.2.3.5    Cell count with Cellavista 
60 µl of CHO cell suspension was mixed with 60 µl Trypan blue (0.1 µm) in 96 round bottom well and 
incubated at 20-30°C for five minutes. Afterwards treated CHO cell suspension was 1:50 diluted with 
Mafog platform medium and 200 µl were transferred into 96 flat bottom wells (Greiner, Germany). 
Slow centrifugation (500 g, five minutes) resulted in fast sedimentation of cells. 
For a precise cell count pictures from the middle of the well were taken, to avoid display error of 
pictures approaching the edge of each well. The cellavista cell imager (SynenTec, Germany) was used 
for the purpose of cell count with the following parameters. Taken pictures for cell count calculation 
are displayed in green. Leaving out pictures which scraping edge of well will minimize reading error. 
Each sample was done in replicate and the entire ten pictures were used to calculate cell count. 
 
2.2.3.6    Cell count with Cedex HiRes analyzer 
For cell count of a sample number up to 40, the Cedex HiRes Analyzer (Roche, Germany) was used. 
Following this, the CHO cells were diluted at a ratio of 1:5 in HiRes medium and 300 µl were 
transferred to tubes. Cell calculation was done according to manufacturer’s recommendations. 
Samples were analyzed in duplicates to verify the cell number. 
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Doubling time (Korzynska & Zychowicz, 2008) of cell culture was calculated as follows: 
 
 
 
∆t is the time period between split and measurement (~ three days); N is the seeded viable cell 
concentration (N0) and the measured viable cell concentration (N1). 
 
2.2.3.7    CHO cell treatment with 5-aza-2deoxycytidine (DAC) 
Cell cultures were seeded into 96 well plates and DAC dissolved in phosphate buffered saline (PBS) 
were added up to final concentration of 1 µM. Cells were examined on day three after DAC addition, 
comparing reporter gene expression with non-treated cells. 
 
2.2.3.8    Relative quantification of expression with SEAP-assay 
The secreted embryonic alkaline phosphatase (SEAP) catalyzes para-nitrophenylposphate (nNPP) to 
para-nitrophenole (pNP) which results in color changing of the medium from blue to yellow, 
measured at 405 nm. From this it was determined that, as more SEAP is expressed, the faster is the 
color change. 
Transient transfected cell suspensions were seeded in 96 well plates and incubated for five days. 
SEAP concentration was examined in a Tecan-Reader Infinite M200 Pro (Tecan Deutschland GmbH, 
Crailsheim, Germany) by color change of a chemical reaction. 
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CHO-K1 M suspension was transfected with circular plasmid DNA for transient expression of SEAP, 
using the Nucleofector device in combination with the Nucleofector Kit V (Lonza Cologne GmbH, 
Cologne, Germany) in the Amaxa Shuttle 96 well plate (Figure 18 
Figure 18) according to the manufacturer’s protocols. Twelve transient transfected cell suspensions 
per plasmid were seeded in 96 well plates and incubated for fived days. On day two, 5´-Aza-2´-
Deoxycitidine (DAC) was added in four replicates per plasmid to a final concentration of 1 µM to 
demethylate DNA. SEAP concentration was examined using the Tecan-Reader Infinite M200 Pro 
(Tecan Deutschland GmbH, Crailsheim, Germany). 
Code Line 1 2 3 4 5 6 7 8 9 10 11 12   
- A               
GGG B               
GCG C              Transfection with gene of interest 
(plasmid) 
CGC D              Control-transf. with zero volt 
GCC E              Control-transf. with H2O probe 
CCG F              Control-transf. with GFP (Lonza) 
CCC G               
Contr. H         DAC   
 
Figure 18: Amaxa Shuttle 96 well plate for transient transfection of CHO-K1 cell suspension. 
 
Relative concentration of SEAP was examined by the metabolic rate of pNPP  
(para-nitrophenylphosphate) to pNP (para-Nitrophenole) according to the following protocol: 
Diluent 
Charge Amount for 1 assay 
1 mM MgCl2*6H2O 
(Sigma, Cat.No. HM2670-500g MW=203.31 g/mol) 
100 µl 1 M MgCl2*6H2O 
10 mM L-Homoarginine-HCl 
(Sigma, Cat.No H1007-5G, MW 224.69 g/mol) 
224.69 mg 
1 M Diethanolamine 
(Sigma, Cat.No. D-8885, min. 98%,  
MW 105.1 g/mol, conc. 1.1 g/ml) 
9.75 ml 98% 
 ad 90 ml Bidest H2O 
‡ pH to 9.8 with 25-37% HCl 
‡ ad 100 ml Bidest H2O 
Substrate solution 
Charge Amount for 1 assay 
pNPP 
(4-Nitrophenylphosphate, Roche,  
Cat.No. 107905, Lot.No. 10030536) 
74.2 mg in 10 ml bidest H2O 
Table 12: Solutions for SEAP Assay. 
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150 µl of centrifuged cell culture supernatant was diluted 1:3 in multiple steps (Figure 19). 50 µl 
dilutions were added in new 96 well plates and combined with a 50 µl substrate solution. The 
reaction was measured every five minutes at 405 nm wave length with the Tecan-Infinite M200 Pro 
(Tecan Deutschland GmbH, Crailsheim, Germany) until the optical density came up to a value of 2. 
 
 
Figure 19: Procedure of dilution of cell culture supernatant. 
 
The average of eight replicates per plasmid without DAC treatment and the average of four 
replicates per plasmid (Figure 18) with DAC treatment were normalized to control plasmid (p5532). 
 
2.2.3.9    Relative quantification of reporter gene expression with flow cytometry 
Stable transfected cell suspensions expressing eGFP were cultivated over a period of one to three 
months. Intensity of eGFP expression per cell was measured with the Fluorescence Activated Cell 
Sort system (FACS) BD FACS Canto II or BD FACS Calibur (BD, Heidelberg, Germany). Activation, 
inactivation and washing routine were performed according to the manufacturer´s 
recommendations.
150 µl 
Centrifuged cell culture 
supernatant (13.000 rpm, 2 min) 
50 µl 50 µl 50 µl 
1:3 1:9 1:27 
100 µl Diluent 
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The flow cytometry allows simultaneous multi-parameter analysis of single cells by separating cells 
in a tiny stream of fluid, where cells pass the laser light one cell at a time. 10,000 events per sample 
were measured. The cell size was detected as forward scatter (FSC), the granularity of the cell was 
detected as side scatter (SSC). Specific values of FSC and SSC combined, indicated the normal living 
cell population (Figure 20). Gates for living CHO cell suspensions were set in untransfected control 
CHO-K1 cells and transferred to all measured samples.  
 
Figure 20: Living gate of CHO-K1 cells. Granularity (SSC) and cell size (FSC) were plotted in diagram. Living Gate of 
untransfected control CHO-K1 cells was transferred to all examined samples of the same FACS assay. 
 
Relative eGFP expression was compared with the autofluorescence levels of untransfected control 
CHO-K1 cells. Fluorescence of eGFP of the living gate was measured at excitation wavelength of 
488 nm (Alexa Fluor 488 channel). The fluorescent light is filtered so each sensor will detect 
fluorescence only at a specified wavelength. These sensors are called photomultiplying tubes 
(PMTs). The PMT detect light emitted from eGFP at approximately 516 nm wavelength and 
converted this information into an electronic signal. This signal is plotted in a histogram of living gate 
events (Figure 21). 
 
Figure 21: Living gate histogram of eGFP expressing CHO cell population. Values measured at excitation wavelength 488 
nm with the Alexa Fluor 488 channel. Two peaks are displayed representing the two main subpopulation of non eGFP 
expressers (left peak), which is comparable to autofluorescence of untransfected control CHO cells, and high eGFP 
expressers (right peak). 
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Data collection was performed with BD FACS Diva Software v6.12 or Cell Quest Pro Software (BD, 
Heidelberg, Germany). Primary data analysis was performed with FlowJo 7.6.5 EN software 
(TreeStar, Olten, Switzerland). 
 
2.2.3.10    Sample preparation for antibody analysis 
Cell concentration was calculated and 2 ml per sample were centrifuged (500 g, five minutes at  
20-30°C). Supernatant was transferred to new 96 deep well plates and stored at -20°C until use. 
Frozen supernatant was thawed overnight at 4°C, 6x inverted and centrifuged (4,000 rpm, 
30 minutes at 20-30°C). 310 µl were filtered with a multiscreen Millipore plate atop a barcoded 96 
roundwell plate by centrifugation (1,200 rpm, three minutes at 20-30°C). 
 
2.2.3.11    Quantification of antibody production with HPLC 
A chromatographic method was used to quantify the amount of antibody present in a sample. A 
PorosA column was used that binds the Fc-region of the antibody. The antibody binds to the column 
and is subsequently eluted by low pH conditions. Protein concentration was established by 
determining the optical density (OD) at 280 nm, with a reference wavelength of 320 nm, using the 
molar extinction coefficient calculated on the basis of the amino acid sequence. Quantification of 
antibody amount with the chromatographic method was performed in-house by Uta Werner. 
 
2.2.3.12    Quantification of antibody production with ELISA 
The ELISA (Enzyme Linked Immunosorbent Assay) technique is based on the antibody sandwich 
principle. A capture antibody specific to the analyte of interest for instance the Fc part of IgG is 
bound to a microtiter plate (Maxisorp, Inhouse, Roche) to create the solid phase. Following the 
blocking and washing steps, samples, standards (dilution series of reference Ab), and controls are 
then incubated with the solid phase antibody, which captures the analyte. After washing away 
unbound analyte, a conjugated detection antibody (e.g. POD conjugated) is added. This detection 
antibody binds to a different epitope of the molecule being measured, completing the sandwich. The 
BM Chemiluminescence ELISA Substrate POD (Roche, Penzberg, Germany) provides a substrate 
solution of peroxidase-based (POD, HRP) secondary detection system.  
The rate of signal generation in an immunoassay is directly proportional to the amount of marker 
enzyme bound to the solid phase. Antibody concentration was calculated by the slope of standard 
dilution. ELISA assays were performed by Manuela Bernhard. 
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Figure 22: ELISA principle with POD conjugated detection antibody. 
 
2.2.3.13    Generation of recombinant CHO cell lines comprising hCMV-MIE promoter  
   variants or the histone acetyltransferase MOF 
Recombinant cell lines expressing Secreted Alkaline Phosphatase (SEAP: Figure 23), enhanced Green 
Fluorescence Protein (eGFP: Figure 24 & Figure 25) or human antibody constructs of class IgG  
(Figure 26) were generated by transient or stable transfection of CHO-K1 suspension growing cells. 
Used vectors expressing reporter genes under control of hCMV-MIE promoter, comprising C to G 
point mutations, or under control of unmutated hCMV-MIE promoter with an internal ribosomal 
entry sites (IRES EV71), coupled expression of the histone acetyltransferase MOF (Figure 25). Light 
and heavy chain expression cassettes of human immunoglobulin were both under the control of a 
human CMV major immediate-early promoter and enhancer comprising C to G point mutations ( 
Figure 27: Seq ID NO: 01). 
 
Figure 23: Secreted alkaline phosphatase (SEAP) expressing plasmid. SEAP expression is under control of human CMV 
major immediate-early promoter/enhancer. The C to G mutations C-508, C-179 and C-41 of CpG dinucleotides  
(SEQ ID NO 1) within the hCMV-MIE fragment were inserted in various combinations to increase long term stability 
(Table 13). The C to G mutations are identified by their distance to transcription start site. 
p5532-hCMVMIEmut.-SEAP 
 
5548 bp 
UAS sites 
methylation side 
methylation side 
methylation side 
murine DHFR 
origin 
5 UTR human IGHV3-33 
Ampicillin resistance gene 
SV40 early polyadenylation signal 
SV40 early polyadenylation signal shortened 
SV40 promoter and origin 
hCMV MIE Promoter 
UAS sites 
pUC origin 
TATA 
transcription start 
Recomb. SEAP 
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Figure 24: Enhanced Green Fluorescent Protein (eGFP) expressing plasmid. GFP expression is under control of human 
CMV major immediate-early promoter/enhancer (hCMV-MIE). The C to G mutations C-508, C-179 and C-41 of CpG 
dinucleotides (SEQ ID NO 1) within the hCMV-MIE fragment were inserted in various combinations to increase stability 
(Table 13). The C to G mutations are identified by their distance to transcription start site. 
 
 
Figure 25: Enhanced Green Fluorescent Protein (eGFP) expressing plasmid. GFP expression is under control of human 
CMV major immediate-early promoter/enhancer (hCMV-MIE). Histone acetyltransferases MOF is additionally expressed 
to increase stability (Table 13).  
P5532-hCMV MIEmut.-GFP 
5034 bp 
UAS sites 
methylation side 
methylation side 
methylation side 
murine DHFR 
origin 
5 UTR human IGHV3-33 
Ampicillin resistance gene 
SV40 early polyadenylation signal 
SV40 early polyadenylation signal shortened 
SV40 promoter and origin 
hCMV MIE Promoter 
UAS sites 
pUC origin 
TATA 
transcription start 
eGFP-PEST 
P5532 hCMV MIE-GFP-EV71IRES-
GalBD MOF 
8599 bp 
5 UTR human IGHV3-33 
origin 
murine DHFR 
methylation side 
methylation side 
methylation side 
UAS sites 
IRES EV71 
Ampicillin resistance gene 
SV40 early polyadenylation signal shortened 
SV40 early polyadenylation signal 
hCMV MIE Promoter SV40 promoter and origin 
UAS sites 
pUC origin 
TATA 
tramscription start 
GalBD-MOF 
eGFP-PEST 
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Figure 26: Human antibody of class IgG expressing plasmid. Light and heavy chain expression cassette of human 
immunoglobulin were both under the control of a human CMV major immediate-early promoter and enhancer (Figure 
27: Seq ID NO: 01) (hCMV-MIE). The C to G mutations C-508, C-179 and C-41 of CpG dinucleotides (SEQ ID NO 1) within 
the hCMV-MIE fragment were inserted in various combinations to increase the stability (Table 13). The C to G mutations 
are identified by their distance to transcription start site. 
 
The three C to G point mutations C-508, C-179 and C-41 of CpG dinucleotides (Figure 27: SEQ ID NO: 
1) are identified by their distance to transcription start site (TSS) and inserted in various 
combinations (Table 13) with QuikChange Multi-Site-Directed Mutagenesis Kit (Agilent Technologies, 
Waldbronn, Germany). The vector also comprised a nucleic acid sequence encoding murine 
dihydrofolate reductase (DHFR) (Figure 23 - Figure 26). Transfection of cells was performed by 
Amaxa nucleofection system (Lonza Cologne GmbH, Cologne, Germany). 
GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGA
GTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCA
ATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGG
TAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTA
AATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATT
AGTCATCGCTATTAGCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACG
GGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCA
AAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAG
CAGAGCTCCGTTTAGTGAACGTCAGATC 
 
Figure 27: SEQ ID NO 1. Human CMV major immediate-early promoter/enhancer fragment: Grey marked cytosines are 
potentially C to G mutated. CpGs dinucleotides are identified by their distance upstream of transcription start site. The 
names of the three potentially mutated C´s are C-508, C-179 and C-41. The red highlighted tyrosine represents the 
transcription start site. 
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C to G point mutations in human CMV-major immediate-early promoter/enhancer fragment of 
SEAP expressing plasmids 
Plasmid NO.: Code of point 
mutations 
Name of point mutations Position upstream 
of TSS 
 
16100 GGG C-508, C-179, C-41 508, 179, 41  
16101 GCG C-508, C-41 508, 41  
16102 CGC C-179 179  
16103 GCC C-508 508  
16104 CCG C-41 41  
p5532 CCC No mutation   
C to G point mutations in human CMV-major immediate-early promoter/enhancer fragment of 
eGFP expressing plasmids and eGFP expressing plasmids comprising Histone acetyltransferases 
MOF 
Plasmid NO.: Code of point 
mutations 
Name of point mutations Position upstream 
of TSS 
Feature 
16105 GGG C-508, C-179, C-41 508, 179, 41 
Gal4-BD 
binding 
sequence 
UAS 
upstream 
of hCMV-
MIE 
 
16106 GCG C-508, C-41 508, 41 
16107 CGC C-179 179 
16108 GCC C-508 508 
16109 CCG C-41 41 
16111 CCC No mutation 
13134 CCC GalBD control 
13135 CCC GalBD-MOF 
16110 CCC No mutation  
C to G point mutations in human CMV-major immediate-early promoter/enhancer fragment of 
human antibody of class IgG expressing plasmids 
Plasmid NO.: Code of point 
mutations 
Name of point mutations Position upstream 
of TSS 
 
16134 CGG C-179, C-41 179, 41  
16135 CGC C-179 179  
16136 CCG C-41 41  
21504 CCC No mutation   
 
Table 13: Combinations of C to G point mutations of CpG dinucleotides within the human CMV major immediate-early 
promoter/enhancer fragment in the appropriate reporter vectors. GFP expression plasmid with IRES EV71 coupled 
expression of Mof and conrol highlighted in light grey. Target oriented Mof towards UASGal sites. 
 
CHO-K1 suspension was transfected with circular plasmid DNA for transient expression of SEAP or 
with linearized plasmid DNA for stable expression of antibody or eGFP, using the Nucleofector device 
in combination with the Nucleofector Kit V (Lonza Cologne GmbH, Cologne, Germany) according to 
the manufacturer’s protocols. Transient transfected cell suspensions were seeded in 96 well plates 
and incubated for five days. SEAP concentration was examined in a Tecan-Reader Infinite M200 Pro 
(Tecan Deutschland GmbH, Crailsheim, Germany) by color change of a chemical reaction. 
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Stable transfected cell suspensions were seeded in 384 or 6-well plates containing thymidine-free 
medium with 250–1,600 nM methotrexate (MTX) as the selection agent. After three to four weeks, 
eGFP or antibody-expressing cell pools were examined for long term stability over a period of one to 
three months. Intensity of eGFP expression was examined by flow cytometry. Antibodies expressing 
single cell clones were seeded in 384 and 96 well plates. After three weeks, antibody-expressing cell 
lines were identified by measuring antibody titers in the culture medium by ELISA. Growing wells 
were randomly picked and in the interests of long term stability assay cell clones were expanded in 
higher volumes (3 ml per well in six well plates) and antibody concentration was determined by 
protein A HPLC and ELISA at the end of each passage. 
The cells were propagated in disposable 125 ml vented shake flasks or six well plates under standard 
humidified conditions (95% rH, 37°C, and 5% to 8% CO2) at a constant agitation rate of 120 rpm/min 
to 150 rpm/min. Every three to four days the cells were split into fresh mediums. Density and 
viability of the cultures were determined using the Cedex HiRes cell counter (Roche Innovates AG, 
Bielefeld, Germany) or cellavista CV3.1 (Synentech Bio Services GmbH, Munich, Germany). 
 
2.2.3.14    Long-term cultivation and production of CHO cell lines comprising hCMV-MIE  
   promoter variants 
Various CHO cell pools and clones containing CpG point mutations within the hCMV-MIE promoter 
or GalBD-MOF (Table 13) were investigated for long-term productivity. The cells were tested for 
phenotypic (i.e. production), stability for two to three months after transfection in the presence of 
selection agent MTX. The cells were continuously cultivated in vented 125 ml shake flasks containing 
20-40 ml medium or six well plates containing 2-4 ml medium with selection agent and diluted twice 
a week with fresh medium. Seeding density was 2 to 3 *105 cells/ml. Prior to passage, viable cell 
density and viability were determined.  
Antibody concentration of the supernatant (antibody titer) was determined by protein A HPLC and 
ELISA at the end of each passage. From these data, the cell specific productivity (qP) for each 
passage was calculated using the following formula: 
 
 
 
qP [pg/cell/d]: cell specific productivity, 
P1 [µg/ml]: antibody titer at the beginning of the passage, 
P2 [µg/ml]: antibody titer at the end of the passage, 
D1 [cells/ml]: viable cell density at the beginning of the passage, 
D2 [cells/ml]: viable cell density at the end of the passage, 
∆t [d]: duration of the passage. 
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The qP values were plotted against the age of culture at the end of the respective passage in 
generations. A linear trend line was calculated over all qP data points and the alteration of the qP (in 
percent) over the period was calculated in house, according to the following equation: 
 
 
 
∆qP: percentage alteration of qP, 
m [pg/cell/d/generation]: slope of linear trend line, 
a [no. of generations]: age of culture, 
qP0: y-axis intercept of linear trend line. 
 
In regard to the lower number of data points obtained in the stability assay of hCMV-MIE promoter 
variants, for each sample the average of the last three qP values was divided by the average of the 
first two qP values and displayed in percent to obtain ∆qP. ∆qP being the percentual alteration of qP, 
qPstart being the specific productivity at the beginning of the cultivation period and qPend being the 
specific productivity at the end of the cultivation period. 
 
 
 
2.2.3.15    Treatment of recombinant CHO cell lines, used for identification of epigenetic  
   marker 
32 CHO cell lines of two projects were used to identify epigenetic markers, predicting target gene 
expression two months in advance. Both projects were already performed in-house and data 
including antibody concentration, C-179 methylation status of hCMV-MIE promoter and copy 
number had been collected over a period of 60 generations (~ two months).  
Project H comprises 20 CHO-K1 M cell lines expressing a human antibody of class IgG under control 
of hCMV-MIE promoter. The vector further comprises a nucleic acid sequence encoding glutamine 
synthetase, making cells susceptible to methionine sulfoximine (MSX) selection.  
Project T comprises 12 CHO-K1 SV cell lines expressing a human antibody of class IgG under control 
of hCMV-MIE promoter. Those cell lines are prone to methotrexate (MTX) selection because of the 
transgene of the murine dihydrofolate reductase. Frozen start cultures were thawed and cultivated 
in appropriate mediums comprising 250 nM MTX or 140 µM MSX. After two weeks (time point PSB) 
of cultivation cells were harvested and chromatin immunoprecipitation with following antibodies 
was carried out (Table 14). 
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List for project T 
Target Name Company ChIP grade Host Cat.No. Lot 
H3K4me3 ChIPAb+ Trimethyl-
Histone H3 (Lys4)  
millipore v rabbit 
monoclonal 17-614 ng1848343 
H3K27me3 ChIPAb+ Trimethyl-Histone H3 (Lys27)  millipore v 
rabbit 
polyclonal 17-622 dam1850974 
H3K9me3 
Anti-Histone H3 (tri 
methyl K9) 
antibody 
abcam v rabbit 
polyclonal ab8898 gr58934-1 
H3 Anti-Histone H3 antibody abcam v 
rabbit 
polyclonal ab1791 GR103799 
H3ac Anti-acetyl-Histone H3 millipore v 
rabbit 
polyclonal 06-599 2068182 
 
List for project H 
Target Name Company ChIP grade Host Cat.No. Lot 
H3K4me3 Histone H3K4me3 antibody (pAb) activemotif √ 
rabbit 
Polyclonal 39915 14013006 
H3ac Anti-acetyl-Histone H3 Antibody millipore √ 
rabbit 
polyclonal 06-599 2153150 
H3K9me3 ChIPAb+ Trimethyl-Histone H3 (Lys9) millipore v polyclonal 17-625 2190636 
H3K27me3 ChIPAb+ Trimethyl-Histone H3 (Lys27) millipore v 
rabbit 
Polyclonal 17-622 2034145 
H3 Anti-Histone H3 antibody abcam √ 
Rabbit 
polyclonal ab1791 GR135321 
 
Table 14: ChIP grade antibodies specific for Histone or Histone modifications. Antibodies were used for 
immunoprecipitation of specific chromatin fragments. 
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Quantitative PCR was performed with the following primers: 
 
SEQ ID NO: Primer NO: Target Sequence 
08 396 hCMV-MIE forward 1 TACATCAATGGGCGTGGATA 
09 397 hCMV-MIE reverse 1 AAGTCCCGTTGATTTTGGTG 
10 386 Gusb forward 1 CAGGGTGGGATGCTCTTC 
11 387 Gusb reverse 1 GCCGGTTTTCCGAGAAGT 
12 431 Eif3i forward 1 GTTCCCGGCACTGACACT 
13 432 Eif3i reverse 2 ACTTGATCTGCGTGATGGAC 
14 484 Foxa2 forward 1 ATCACCCGTACTGCTGCTCT 
15 485 Foxa2 reverse GAGGCTTCTGGGGATCTCTT 
16 468 Gata5 forward 1 CACCTACCCCATCCTGTCTG 
17 469 Gata5 reverse 1 GAGGAGGTGAAGGCAAAGTCT 
18 388 Rho forward 1 AGCCTCGGTCTCTATTGACG 
19 389 Rho reverse 1 CGTTGGAGAAGGGCACATAA 
20 474 UNC13c forward 1 GGGTGCTTTACGGAAACTGA 
21 475 UNC13c reverse 1 GCTTCTTATGCCCCAGGTTT 
 
Table 15: Primer sequences for real time quantitative PCR. Gusb and Eif3i sequences are close to stable active marks. 
 
2.2.3.16    Generation of eGFP expressing CHO cell pools and preparation of CHO-K1 M cells  
   for the identification of integration sites and chromatin states 
 
 
Figure 28: Exemplified identification of stable integration sites. Combination of chromatin state and integration sites to 
distinguish active and inactive areas of CHO-K1 cell pools. 
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Histone 3 acetylation, H3K4me3, and H3K36me3 as active marker and H3K9me3 as inactive marker 
of wild type CHO-K1-M chromatin were examined by ChIP sequencing. CHO-K1 cell pools were 
randomly transfected with eGFP expressing reporter plasmids, MTX selected and cultivated. After 
one month of cultivation, three independent recombinant cell pools were sorted into subcultures, 
distinguished by high and low levels of eGFP. Inverse PCR of subcultures was conducted to locate 
transgene integration sites. Next generation sequencing of immunoprecipitated chromatin of CHO-
K1 wild type and the integration sites of sorted eGFP pools was performed. 
ChIP sequencing protocol was carried out as described previously in ChIP protocol with the following 
modifications:  
50 µl resuspended dynabeads (Dynabeads® Protein A, Life Technologies GmbH, Darmstadt, 
Germany) per IP were blocked in 1 ml icy PBS (5 mg/ml BSA) for five minutes. Separation of beads 
from liquid was performed by magnets. Blocking step was repeated three times. Beads were 
resuspended in 200 µl PBS/BSA containing 6 µg appropriate antibodies for saturation and incubated 
overnight at 4°C while rotating. Beads were washed three times and resuspended in 100 µl PBS/BSA. 
3.5x 10^7 CHO-K1-M wild-type cells (passage 4) were fixed and sonicated in 3 x 300 µl Nuclei Lysis 
Solution. 700 µl of Nuclei Lysis Solution were added to sonicated cells and cells were 
microcentrifuged for 15 min 4°C at 14,000 rpm. The supernatant contains the chromatin and can be 
stored at -80° for up to two months. Sonification efficiency was tested and protein concentration 
was specified. 200 µl of chromatin solution (1 µg/µl) and 300 µl Dilution buffer were added to 50 µl 
of antibody loaded dynabeads. Incubation was done overnight at -4°C while rotating. After Wash 
and elution steps, crosslink was reversed overnight at 65°C. 200 µl TE buffer were added to each 
tube for SDS dilution. For RNAse digestion, 4 µl RNAse, DNAse (Roche, Mannheim, Germany) free 
solution were added and incubated at 37°C for two hours. Finally 4 µl EDTA (0.5 M Stock) and 4 µl 
Proteinase K (100-200 µg/ml final concentration, Roche, Mannheim, Germany) were added and 
proteins were digested for 1.5 hours at 65°C. DNA was recovered with High Pure PCR Product 
Purification Kit. DNA was stored at -20°C and transferred to GATC for sequencing. 
 
Antibodies 
Target Name Company Cat.No. 
H3K4me3 Anti-trimethyl Histone H3 (Lys4) Millipore CS200580 
H3ac Anti-acetyl Histone H3 Millipore 06-599 
H3K9me3 pAb to histone h3 (tri methyl k9 Abcam Ab8898 
 
Table 16: ChIP grade antibodies. Fishing of active and inactive chromatin areas by immunoprecipitation of specific 
histone modifications. 
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3 Results 
 
3.1 Molecular indicator of production instability 
In order to check whether the degree of histone modifications have similar or even enhanced 
predictive power for the stability of recombinant CHO cell lines, than the DNA methylation 
(Osterlehner et al., 2011), H3ac and H3K4me3 as activation marks and H3K9me3 as well as 
H3K27me3 as repression marks were examined at the sequence from -97 to -200 bp upstream of 
transcription start site of hCMV-MIE to enable the direct comparison with the DNA methylation 
degree at position -179 (Figure 29). 
 
    -603  ATGTTGACAT TGATTATTGA CTAGTTATTA ATAGTAATCA ATTACGGGGT 
    -553  CATTAGTTCA TAGCCCATAT ATGGAGTTCC GCGTTACATA ACTTACGGTA 
    -503  AATGGCCCGC CTGGCTGACC GCCCAACGAC CCCCGCCCAT TGACGTCAAT 
    -453  AATGACGTAT GTTCCCATAG TAACGCCAAT AGGGACTTTC CATTGACGTC 
    -403  AATGGGTGGA GTATTTACGG TAAACTGCCC ACTTGGCAGT ACATCAAGTG 
    -353  TATCATATGC CAAGTACGCC CCCTATTGAC GTCAATGACG GTAAATGGCC 
    -303  CGCCTGGCAT TATGCCCAGT ACATGACCTT ATGGGACTTT CCTACTTGGC 
    -253  AGTACATCTA CGTATTAGTC ATCGCTATTA GCATGGTGAT GCGGTTTTGG 
    -203  CAGTACATCA ATGGGCGTGG ATAGCGGTTT GACTCACGGG GATTTCCAAG 
    -153  TCTCCACCCC ATTGACGTCA ATGGGAGTTT GTTTTGGCAC CAAAATCAAC 
    -103  GGGACTTTCC AAAATGTCGT AACAACTCCG CCCCATTGAC GCAAATGGGC 
     -53  GGTAGGCGTG TACGGTGGGA GGTCTATATA AGCAGAGCTC CGTTTAGTGA 
      -3  ACG  
Figure 29: hCMV-MIE sequence. Underlined sequence spanning a region of -97 to -200 bp upstream of transcription start 
site, which is amplified with the primer pair 396/397 to quantify the degree of histone modifications after chromatin 
immunoprecipitation. Highlighted is the CpG -179 bp upstream of transcription start site, which had been successfully 
used as a prediction marker for stability (Osterlehner et al., 2011). 
 
 
3.1.1 Cell lines and data of literature 
Two Roche cell line development projects (project T and H) were chosen for the identification of 
potential prediction markers. For this purpose frozen cell lines from the start point (PSB) of 
cultivation were thawed and the relative amounts of specified histone modifications close to the 
hCMV-MIE promoter were determined. Project T (Table 17) and project H (Table 18) were 
independently executed and each cell line was cultivated for at least 60 generations under the 
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conditions with (+) and without (-) selection reagent (250 nM methotrexate). Project H ChIP analysis 
was performed by Laura Woltering under my supervision. The data of the hCMV-MIE promoter 
methylation degree (meC-179), the copy number per cell from light chain IgG transgene (PSB) as well 
as the alteration over 60 generations of specific productivity per cell per day (∆qP) were kindly 
provided by the PLPM department. Each cell line was examined once as described previously 
(Osterlehner et al., 2011). 
 
Project T: 12 CHO antibody producing cell lines 
Generated by transfection of CHO-K1-M with Plasmid p5057 
Sample 
No. 
meC-179 [%]  ∆qP (60 generations) in % LC-transgene Copies/Cell  
PSB +MTX -MTX PSB 
T-1 0.44 -35.40 -34.20 4.4 
T-2 2.20 -30.60 -72.00 11.5 
T-3 3.54 -81.60 -96.60 9.4 
T-4 0.92 -23.40 -47.40 4.6 
T-5 4.41 -15.60 -22.20 5.3 
T-6 0.47 -14.40 -20.40 2.6 
T-7 0.22 -16.20 -31.80 1.6 
T-8 52.40 -64.80 -79.20 64.3 
T-9 52.84 -27.60 -49.20 67.5 
T-10 49.61 3.60 1.20 70.5 
T-11 2.02 -10.20 -21.60 4.6 
T-12 61.34 -32.40 -22.80 11.5 
 
Table 17: In house data of 12 cell lines from project T. meC-179 is the mean of percentage methylation of cytosine at 
position -179 upstream of TSS of hCMV-MIE at begin of cultivation phase (PSB). ∆qP is the percentage alteration of 
specific productivity (qP) over a time period of 60 cell generations. The average copy number of the light chain (LC) of 
the IgG transgene was measured at begin of cultivation (PSB). 
 
82 
 
Project H: 20 CHO antibody producing cell lines  
Generated by transfection of CHO-K1-M with Plasmid p7672 
Sample 
No. 
meC-179 (%)  ∆qP (60 generations)(%) LC-transgene Copies/Cell  
PSB +MSX -MSX PSB 
H-1 15.7 -46.80 -80.20 168.8 
H-2 9.9 -71.00 -70.30 2.0 
H-3 16.5 -73.10 -89.60 3.2 
H-4 10.5 -69.30 -69.50 2.9 
H-5 11.0 -40.40 -48.80 1.8 
H-6 7.1 -79.50 -71.70 37.6 
H-7 4.8 -66.20 -81.50 53.0 
H-8 4.4 -67.40 -75.70 30.6 
H-9 23.4 -87.00 -77.00 95.1 
H-10 26.2 -16.40 -73.30 48.8 
H-11 0.2 -43.10 -96.10 3.3 
H-12 0.1 -42.00 -33.00 1.5 
H-13 1.3 8.00 -18.50 1.1 
H-14 0.0 6.80 5.40 1.3 
H-15 0.1 -16.50 -40.40 3.5 
H-16 0.4 16.20 -32.80 3.0 
H-17 1.0 -13.20 -31.30 4.2 
H-18 46.3 -67.50 319.40 8.8 
H-19 16.7 -11.20 2.70 10.1 
H-20 21.8 -40.30 -80.60 4.8 
 
Table 18: In house data of 20 project H cell lines. meC-179 is the mean of percentage methylation of cytosine at position 
-179 upstream of TSS of hCMV-MIE at begin of cultivation phase (PSB). ∆qP is the percentage alteration of specific 
productivity (qP) over a time period of 60 cell generations. The average copy number of the light chain (LC) of the IgG 
transgene was measured at begin of cultivation (PSB). 
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3.1.2 Validation of ChIP antibodies for both projects with one sample each 
In order to ensure the specific immunoprecipitation of histone-DNA complexes, only commercial 
ChIP grade antibodies were used and tested in one randomly chosen cell line for each project. For 
the chromatin immunoprecipitation, viable CHO cells which bear a recombinant gene driven by the 
hCMV-MIE promoter were harvested and protein-DNA interactions were fixed in 3.7% 
formaldehyde. Cells were lysed and chromatin was sonicated up to a fragment size of approximately 
300 bp. Cross-linked histone-DNA fragments were purified with unspecific control beads (Mock) and 
with specific ChIP grade antibodies according to the appropriate histone modification (Table 14). 
Subsequently the accumulated histone-DNA complexes were degraded with proteinase K and DNA 
fragments were eluted.  
To verify the binding of the used antibodies in CHO cells, the accumulation of potential reference 
sequences was compared between the antibody-treated samples and the mock control. The active 
genes Gusb (Abruzzo et al. 2005) and Eif3i (Bahr et al. 2009) were chosen as potential references for 
the expression marks H3ac and H3K4me3. As potential references for H3K9me3 and H3K27me3 the 
assumed inactive genes Foxa2 and Gata5 were investigated. Both genes were not expressed in 
ovary, according to the Tissue-specific Gene Expression and Regulation (TiGER) database (Liu et al. 
2008). 
DNA fragments of antibody-purified samples, mock and untreated input sample were quantified by 
qPCR (2.2.1.11). Primer pairs of potential reference regions (Table 15) were added to each sample 
and qPCR was performed in triplicates. The obtained Cq values were displayed as percentage of the 
input sample (Figure 30) In both projects, the activation marks H3ac and H3K4me3 accumulated at 
the active regions Eif3i and Gusb. In contrast, the silenced region Foxa2 had higher concentration of 
H3K9me3 whereas H3K27me3 accumulated at the Gata5 region. The differences of the control 
regions to each other and to the mock control in project H were not as distinctive as in project T. 
Nevertheless, the different histone modifications matched to the corresponding control regions in 
both projects. 
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Figure 30: Antibody validation within project T and H in one sample each. Reference regions Eif3i, Gusb, Foxa2 and 
Gata5 are displayed as percentage of input sample and are plotted against the specific histone purified with the 
appropriate antibodies. Antibodies for total H3, acetylated H3 (panH3ac), the H3K4me3, H3K9me3 and the H3K27me3 
were tested. Input sample precipitation without antibody is termed mock. For each project, the following could be 
observed: Eif3i and Gusb as proposed active regions, comprising higher levels of H3ac and H3K4me3 compared to mock 
and the Foxa2/Gata5 regions. In contrast the proposed silenced region Foxa2 has higher H3K9me3 values than mock and 
the active regions. The same is true for Gata5 and the H3K27me3. As expected the total H3 level was always high 
compared to mock. Therefore the specificity of each antibody was confirmed. Error bars represent the standard 
deviation of mean of triplicates.  
 
Considering the lower values obtained under mock condition as well as the higher concentration of 
active histone marks in active regions compared to the inactive regions and vice versa, I assume a 
proper binding of the ChIP grade antibodies in both projects. 
 
3.1.3 Validation of reference regions for all cell lines within one project 
In order to enable quantification of the histone modifications and the comparison between cell lines, 
the reference genes need to stably display these modifications at high levels. For this purpose the 
reference regions were checked for the consistency of epigenetic marks. The average Cq values and 
the corresponding coefficients of variation (CV) were calculated for 20 cell lines in project H and for 
twelve cell lines in project T. Calculations were performed for each ChIP condition, the mock 
precipitation and the untreated input sample (Table 3).  
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In the following table the average Cq values and the coefficient of variation (CV) of all cell lines, 
including the three biological replicates are displayed for project T and project H:  
 
Project T: Cq values of ChIP Samples 
Target 
 
H3 H3ac H3K4me3 H3K9me3 H3K27me3 Mock Input Sample 
mean CV mean CV mean CV mean CV mean CV mean CV mean CV 
Eif3i 431 28.24 0.01 27.57 0.02 25.45 0.02 34.35 0.03 35.11 0.03 35.80 0.03 22.38 0.01 
Gusb 386 27.16 0.01 26.73 0.02 24.64 0.02 33.38 0.03 33.90 0.03 35.76 0.04 22.32 0.02 
Foxa2 484 26.32 0.01 36.43 0.05 36.20 0.05 31.54 0.02 33.60 0.02 34.64 0.04 21.31 0.03 
Gata5 468 25.49 0.02 33.34 0.03 34.98 0.03 32.96 0.04 30.70 0.03 34.61 0.04 21.72 0.01 
Rho 388 27.29 0.02 35.56 0.02 36.66 0.03 35.17 0.03 35.15 0.02 36.26 0.02 22.91 0.02 
Unc13c 474 26.81 0.01 35.40 0.03 36.35 0.05 32.01 0.02 34.03 0.02 34.73 0.18 22.50 0.01 
Project H: Cq values of ChIP Samples 
Target  
 
H3  H3ac  H3K4me3  H3K9me3  H3K27me3  Mock  Input Sample 
mean CV mean CV mean CV mean CV mean CV mean CV mean CV 
Eifi 431 26.41 0.02 27.81 0.02 27.88 0.03 35.66 0.06 34.34 0.05 35.55 0.06 22.94 0.02 
Gusb 386 25.98 0.02 27.65 0.03 27.85 0.03 34.96 0.06 33.69 0.04 35.01 0.06 22.63 0.03 
Foxa2 484 25.96 0.02 34.98 0.06 35.45 0.07 34.69 0.06 30.86 0.03 35.46 0.08 22.96 0.03 
Gata5 468 25.75 0.02 33.61 0.05 35.30 0.07 35.16 0.07 30.09 0.03 34.88 0.06 22.62 0.03 
Rho 388 27.08 0.02 34.79 0.04 35.91 0.06 35.82 0.06 33.05 0.03 36.10 0.06 23.90 0.03 
Unc13c 474 26.70 0.02 35.02 0.05 35.03 0.06 34.79 0.05 31.50 0.02 35.12 0.05 23.55 0.03 
 
Table 19: Test of reference regions in project T and H. The averages and the appropriate coefficient of variation (CV) of 
Cq values of all ChIP Samples including the biological triplicates were calculated for both projects. The rows display the 
different reference regions within the genome. The columns contain the specific histone modifications. The chosen 
control regions for the appropriate epigenetic modifications are marked as green cells. In both projects, the activation 
marks H3ac, H3K4me3 as well as total histone 3 are stable at the Gusb and the Eif3i regions (CV of 2 %). The lower Cq 
values suggests Gusb as the reference for activation marks. Also the repression mark H3K27me3 was in both projects 
stable at the Gata5 control region. In contrast, the investigation of project H cell lines leads to the conclusion that the 
Foxa2 region has different H3K9me3 amounts as it was observed in Project T. Unc13c and Rho were potential inactive 
regions, but both sequences obtained higher Cq and CV values compared to Foxa2 and Gata5.  
 
The active regions Gusb and Eif3i consistently displayed high levels (i.e. low Cp values) of H3ac and 
H3K4me3 whereas H3K9me3 and H3K27me3 were at background level. The inactive region Gata5 
was consistently marked with H3K27me3 whereas the activity markers H3ac and H3K4me3 were 
low. Surprisingly the reference region Foxa2 of project T loses the H3K9me3 mark in project H. 
Therefore the H3K9me3 levels can only be analyzed in project T through the normalization to Foxa2 
whereas in both projects Gusb and Eif3i are suitable reference genes for H3ac and H3K4me3 and 
Gata5 can be used to normalize H3K27me3 levels .  
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3.1.4 Normalization of the different histone modifications at the hCMV-MIE 
promoter 
The absolute amount of a certain histone modification at the hCMV-MIE promoter/enhancer is 
influenced by the number of transgene copies, e.g. a cell line with two transgene copies will display 
twice the amount of H3ac than a cell line with just on copy of the same status. Furthermore, the H3 
density can differ between the cell lines and therefore the non-normalized modifications are also 
influenced by the histone density per promoter. In order to compensate for these biases we 
normalized H3 modifications to the level of H3 and looked for a reference gene for H3 as well. 
However H3 levels were constant in all cell lines with all reference genes suggesting that each of 
them can be used as reference gene for H3 (Table 19). 
For a robust relative quantification of a target DNA by qPCR it is desirable to use target and 
reference primer pairs that have high and comparable amplification efficiencies. Therefore, the 
amplification efficiencies of hCMV-MIE and reference gene primers were determined by employing 
the LinReg PCR software, version 2014.5 (Ruijter et al., 2009). All amplification efficiencies were 
greater than 1.9 and differed by less than 2% (Table 20). Consequently, we were able to apply the 
simple ∆∆Cp or Livak method (2.2.1.11) to calculate relative levels of H3 modifications at the hCMV-
MIE promoter enhancer. H3 modifications were normalized to H3 levels (H3ac/H3; H3K4me3/H3; 
H3K27me3/H3 and H3K9me3/H3).  
 
Amplification efficiency with LinReg PCR 
Project T Project H 
Primer pairs mean stdev Primer pairs mean stdev 
CMV 396/397 1.909 0.033 CMV 396/397 1.919 0.032 
Gusb 386/387 1.923 0.036 Gusb 386/387 1.935 0.037 
Eif3i 431/432 1.893 0.036 Eif3i 431/432 1.923 0.034 
Foxa2 484/485 1.925 0.029 Foxa2 484/485 1.946 0.031 
Gata5 468/467 1.914 0.033 Gata5 468/467 1.934 0.034 
Rho 388/389 1.876 0.036 Rho 388/389 1.902 0.037 
Unc13c 474/4745 1.904 0.032 Unc13c 474/4745 1.927 0.034 
 
Table 20: Determination of primer efficiencies in project T and H. Amplification Efficiencies in project T and H were 
determined for all cell lines including biological triplicates. Because of a later detected point mutation within hCMV-MIE 
of project H cell lines a new primer pair (396/397) was used. For this purpose the qPCR raw data were applied to the 
LinRegPCR software, version 2014.5 and efficiencies were calculated. Rows are distinguished by the different primer 
pairs. The mean column contains the average amplification efficiencies of each primer-template pair and the stdev 
column contains the appropriate standard deviation. Distances between all amplification efficiencies are less than 2%. 
Thus the Livak method was used for normalization. 
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The normalization by Livak comprises two normalization steps: 
∑ In the first step, the amount (Cq) of H3 modification close to the hCMV-MIE promoter is 
normalized to the amount (Cq) of H3 modification at the reference region. ‡ ∆Cq 
∑ In the second step, the normalized H3 modification is set to the normalized total H3 close to 
the hCMV-MIE promoter. ‡ ∆∆Cq 
 
This finally displays the relative amount of modification per H3 close to hCMV-MIE promoter! 
 
In any case both parameters, H3 and H3 modification, were determined relative to the same 
reference gene. This minimizes variation within the normalization process. For all further studies 
Gusb was used as reference for H3ac and H3K4me3 whereas Gata5 was used for H3K27me3. Foxa2 
was used for H3K9me3 in project T only. For instance, the relative histone acetylation per histone 3 
can be normalized to the control region Gusb, as long as the Gusb region comprises a stable amount 
of the modified histone and the total H3. The following formula was used for calculation: 
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3.1.5 Effect analysis of potential prediction markers 
After establishment of the CHIP assay to measure histone 3 modifications proximal to the hCMV-
MIE, the abundance of these epigenetic marks and the alteration of their specific productivity ∆qP 
over 60 generations of the affected cell lines were correlated. In addition the recorded data of 
methylation of hCMV-MIE at C-179 (meC-179) and the plasmid copy numbers of one biological 
replicate were also analyzed. Before the correlations were performed, all values were screened for 
outliers employing the jackknife technique (Riu and Bro 2003). The distance for each observation is 
calculated with estimates of the mean, standard deviation, and correlation matrix that do not 
include the observation itself. By performing the analysis, two outliers were found above the upper 
confidence limit (UCL) in project H (Figure 31). ∆qP of cell line H-18 (Figure 31 A) in the absence of 
MSX was strikingly different as compared to all other cell lines (threefold increase in ∆qP) and one 
biological replicate of cell line H-3 (Figure 31 B) showed unusual high H3ac. Consequently, the third 
biological replicate of cell line H-3 as well as cell line H-18 were excluded from further effect 
measurements. 
 
 
Figure 31: Jackknife outlier analysis of project H. The distance for each observation was calculated with estimates of the 
mean, standard deviation, and correlation matrix that do not include the observation itself. ∆qP- of cell line H-18 (A) and 
H3ac/H3 of the third biological replicate of cell line H-3 (B) were way above the upper confidence limit (UCL) and 
therefore excluded from the following effect measurements 
 
The magnitude of the effects of epigenetic marks proximal to hCMV-MIE as well as the  
plasmid copies on stability were examined with a standard least squares fit model. To this end  
the software JMP10 (JMP®10.0.1 Release: 2, 64-bit edition; SAS Institute Inc.) was used.  
The significance levels were set to 0.05 (5%), 0.005 (0.5%) and 0.0005 (0.05%) and effects with lower 
p-values are described as significant, very significant and extremely significant inspired by the 
definition used in the GraphPad software. In addition to the copy number and the DNA methylation, 
the histone modifications H3ac, H3K4me3, H3K9me3 and H3K27me3 normalized to H3 as well as H3 
alone were tested separately (Table IV and Figure 2).  
In addition mock per H3 (Mock/H3) was considered as the unspecific effect of background noise per 
H3. To obtain a linear relation between stability and markers, all marker values were  
log-transformed. Thus, the adjusted R_squares were increased in each case and a higher 
89 
 
symmetrical distribution for the residuals was observed. The adjusted R_square is also termed the 
coefficient of determination and describes the strength of the effect. 
Significant effects were detected in project H but not in project T. Project T comprises a  
smaller number of cell lines, with a lower variability of ∆qP values accompanied by a general higher 
stability than the cell lines of project H. Conceivably, the used prediction markers might be  
not accurate enough to distinguish between cell lines with almost similar values. In addition  
the project T cell lines were quite stable and a certain degree of instability might be needed for  
the correlation with specific histone modifications. Therefore the focus was set on project H  
to identify the best prediction mark. 
In project H the most significant effect on ∆qP with and without selection agent was observed for 
H3ac normalized to H3 (H3ac/H3). The adjusted R_square also indicates H3ac/H3 as the most 
powerful effect (Table 21). The second strongest effect was observed for H3K4me3/H3, which 
confirms the coincidence of positive markers. Significant effects were observed for all histone 
markers. However I propose that H3 has a dominant influence on the combined effect, through the 
influence of the plasmid copy number as well as the histone density. The significant p-values for 
Mock/H3 support this hypothesis. In line with this assumption only H3ac/H3 as the most significant 
and strongest effector was taken into account as a potential prediction marker. In addition the 
effects obtained for the plasmid copy number and the DNA methylation were only significant for 
plasmid copy number in project H. Nevertheless, the DNA methylation correlates notably with the 
stability of cell lines in the presence of selection pressure in project H. The data for transgene 
copies/cell and meC-179 were compiled once. Because only one biological replicate was measured, 
the lower number of observations led to higher p-values. 
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 Single effect leverage model:  
P-values for an epigenetic effect 
 Project T Project H 
 ∆qP+ ∆qP- ∆qP+ ∆qP- 
Epigenetic marks P-values P-values P-values Rsquare Adj P-values Rsquare Adj 
log H3  0.6078 0.7737 0.0005 0.18 0.0015 0.15 
log Mock/H3 0.7050 0.4594 0.0020 0.15 0.0034 0.13 
log H3ac/H3 0.9801 0.7571 <0.0001 0.35 <0.0001 0.24 
log H3K4me3/H3 0.6993 0.4909 <0.0001 0.30 0.0013 0.16 
log H3K27me3/H3 0.9843 0.8354 <0.0001 0.27 0.0009 0.17 
log H3K9me3/H3 0.3664 0.3639 n.d.    
       
log copies/cell 0.2806 0.2800 0.0404 0.19 0.0289 0.21 
log me C-179 (%) 0.3885 0.6994 0.0743 0.13 0.1779 0.05 
 
Table 21: Effect measurement of epigenetic modifications on long term stability in project T and H. P-values as indicator 
of significance and R_square adjusted as indicator of strength of epigenetic effects on ∆qP with (+) and without (-) 
selection pressure (250 nM MTX) are displayed in the columns. All epigenetic effects were log normalized and measured 
close to hCMV-MIE promoter. Effects of normalized H3, background noise per histone 3 (Mock/H3) and modifications 
per histone 3 (H3ac/H3, H3K4me3/H3, H3K27me3/H3 and H3K9me3/H3) were calculated in a standard least square 
model with software JMP10. Significant effects in project H cell lines but not in project T were observed. In project H, 
acetylation per histone 3 (H3ac/H3) has a highly significant effect on ∆qP. Also Mock/H3, H3K4me3, H3K27me3 and H3 
events resulted in moderate to extremely significant effects. 
 
It had been reported previously that hCMV-MIE methylation at C-179 and the number of transgene 
copies predicted a subsequent decrease in productivity (Osterlehner et al., 2011). Both parameters 
were measured in this study in order to determine their effect on production stability and to use it 
as a benchmark for the suitability of histone marker based prediction. It was observed that the 
plasmid copies and the DNA methylation correlate notably well with the loss of stability. Hence the 
strong effect of H3ac/H3 was remarkably significant (Figure 32 A-B), whereas the high copy number 
and high DNA methylation occurs predominantly in unstable cell lines (Figure 32 C-F). 
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Figure 32: Correlation studies of log transformed plasmid copy number and epigenetic effects on ∆qP with and without 
selection agent. The alteration of qP over 60 generations (∆qP) with (left) or without (right) MSX were plotted against 
H3 acetylation levels normalized to total H3 (A and B), copy number (C and D) as well as the DNA methylation at position 
C-179 (E and F) at hCMV-MIE. Production stability data from 19 cell lines and three biological ChIP replicates are shown. 
The p-values of the effect leverage plot are indicated. 
 
Several studies propose an interplay between epigenetic marks and mechanisms (Feller et al., 2015; 
Murr, 2010). For this reason the correlation of plasmid copy number, histone 3 acetylation and DNA 
methylation at the hCMV-MIE promoter/enhancer was investigated. As expected, the degree of DNA 
methylation contrasted to histone 3 acetylation (Figure 33 A). This is plausible since acetylation of 
H3 is an activation mark, whereas DNA methylation is associated with inactivation. It has been 
reported previously that CMV-MIE methylation often coincides with elevated transgene copies, 
which could be confirmed in this study (Figure 33 B). Consequently histone 3 acetylation was 
increased in cell lines that have less transgene copies (Figure 33 C). Summing up, these correlations 
demonstrate the consistency of the data. 
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Figure 33: Interplay of epigenetic effects and the plasmid copy number. Histone 3 acetylation inversely correlates with 
promoter methylation and integrated plasmid copies. 19 cell lines were analyzed and p-value was calculated for the 
linear regression model of the effect leverage plot. (A) Methylation at C-179 (me of C-179 (%)) of hCMV-MIE was plotted 
against the H3ac/H3 values for three biological replicates per cell line. (B) The number of integrated plasmid copies was 
plotted against percent methylation at C-179. (C) The number of integrated plasmid copies was plotted against H3ac/H3. 
The degree of DNA methylation and copy number were contrary to histone 3 acetylation, which demonstrates the 
reliability of our data. 
 
3.1.6 Exclusion of unstable producers by threshold setting for H3ac/H3 and meC-179  
Amongst all parameters, the strongest correlation was observed in project H for ∆qP and H3ac/H3 in 
the presence of methotrexate. From this, H3ac/H3 was re-analyzed to identify a threshold that 
allows distinguishing between stable and unstable cell lines most effectively. To this end a LogWorth 
statistic was performed using the Jmp 10 software (Sall 2002), which led to the identification of the 
best split node. The LogWorth is calculated as log10 (p-value), where the adjusted p-value is 
calculated regarding the myriad number of different ways splits can occur (Sall, 2002). In this case 
the best split was found at 0.47 acetylation per H3. To minimize false positive values, filter was set to 
0.5 H3ac/H3 and this filter setting was applied in project H and T to exclude bad producers. 
In addition, the published threshold of 5% for hCMV-MIE promoter methylation (meC-179 (%)) was 
also applied to the recorded methylation data Table 17 and Table 18) as a benchmark for  
the predictive power of H3ac/H3. In this way samples with more than 5% DNA methylation or less 
than 0.5 acetylation per histone 3 at the hCMV-MIE promoter were excluded in separate 
examinations. 
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The average of ∆qPs of the remaining cell lines was calculated for both filter settings separately and 
compared with the unfiltered samples (Figure 34). 
For project H, the average loss in qP over 60 generations was significantly decreased from 39% to 
15% with MSX and from 55% to 38% without MSX employing the H3ac/H3 filter, whereas for the 
meC-179 [%] filter the average loss in qP decreased significantly from 39% to 24% with MSX. Also at 
the absence of selection agent the ∆qP decreased from 55% to 45% but without reaching significant 
difference between the two subpopulations (Figure 34). Therefore, H3ac/H3 appears to be more 
effective than meC-179 to pick cell lines with stable productivity. 
 
 
Figure 34: Application of filter settings. 0.5 is a suitable threshold for H3ac/H3 to exclude unstable producer cell lines in 
project H. The bar charts show the distribution of biological samples by ∆qP over 60 generations with (upper row) or 
without MSX (lower row), either without filtering (left column), after filtering for samples with less than 5% methylation 
at C-179 (meC-179: middle column) or after filtering for samples with more than 0.5 H3ac/H3 (right column). The 
average ∆qP of unfiltered and filtered samples is indicated below the charts. The percentage of samples before and after 
filtering is indicated in the lower row. The highest increase of stability was obtained for the H3ac/H3 filter settings. The 
H3ac/H3 filter results in a significant improved stability of sorted cell lines. Also the DNA methylation filter results in a 
significant accumulation of stable cell lines at the presence of MSX. The box plot shows the 1st and 3rd quartile 
indicated by the ends of the box, whereby the horizontal line within the box represents the median sample value. The 
end of the box has extended lines which represent the whiskers. The confidence diamond contains the sample means in 
the middle and the upper and lower 95% of the mean indicated by the top and bottom points. The bracket outside 
identifies the most dense 50% of the observations. 
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The application of the same filter settings in project T results in almost the same improved stabilities 
after H3ac/H3-dependent cell sort, which was significant in the presence of selection (Figure 35). 
 
 
Figure 35: Transferred threshold settings from project H to project T. The bar charts show the distribution of biological 
samples by ∆qP over 60 generations with (upper row) or without MSX (lower row), either without filtering (left column), 
after filtering for samples with less than 5% methylation at C-179 (meC-179: middle column) or after filtering for samples 
with more than 0.5 H3ac/H3 (right column). The average ∆qP of unfiltered and filtered samples is indicated below the 
charts. The number of samples before and after filtering is also given. The H3ac/H3 filter at the presence of selection 
agent results in a significant improved stability of sorted cell lines. The box plot shows the 1st and 3rd quartile indicated 
by the ends of the box, whereby the horizontal line within the box represents the median sample value. The end of the 
box has extended lines which represent the whiskers. The confidence diamond contains the sample means in the middle 
and the upper and lower 95% of the mean indicated by the top and bottom points. The bracket outside identifies the 
most dense 50% of the observations. 
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3.2 Alteration of epigenetic landscape of CHO-K1 cell lines to circumvent the 
silencing of recombinant genes 
Loss of productivity in CHO cell lines poses a serious risk in cell line development. In addition to the 
loss of copy number, epigenetic mechanisms like promoter methylation (Osterlehner et al., 2011; 
Yang et al., 2010b) or histone modifications (Mutskov & Felsenfeld, 2004; Paredes et al., 2013)  
are proposed repressors of productivity. Following this, reducing the accumulation of repression 
signals or an accumulation of activation marks close to the gene of interest might hinder epigenetic 
silencing effects. As described in the introduction, the acetylation of histone H3 and H4 is  
mainly associated with the activation of transcription. In particular, acetylation of lysine 16 at 
Histone 4 (H4K16ac) promotes an open chromatin formation (Corona et al., 2002). Inversely, CpG 
promoter methylation correlates strongly with transcriptional silencing of production cell lines 
(Smith & Meissner, 2013). Consequentially, targeting H4K16 acetylation to the promoter that drives 
the gene of interest and reduction of CpG methylation sites might stabilize the productivity of 
recombinant CHO cells. 
In order to check whether H4K16 hypoacetylation results in higher productivity, the histone 
acetyltransferase MOF was fused to a DNA binding domain. MOF was coexpressed with eGFP 
reporter and targeted to the corresponding cis element upstream of the promoter. Stably 
transfected CHO pools were cultivated and fluorescence intensity was measured. 
Furthermore, I generated various CHO cell lines which contain reporter genes driven by hCMV-MIE 
variants. The promoter variants contain up to three C to G conversions of specific CpG sites. The 
influence of the mutations on promoter strength and expression stability was assessed using 
reporter gene assays after transient and stable transfection of suitable constructs. 
 
3.2.1 Coupled expression of target gene and the specific histone acetyltransferase 
MOF, proposing open chromatin formation. 
It has been shown in Drosophila that Gal4-BD MOF can be targeted to the UAS binding sites, which 
leads to H4K16 acetylation of adjacent regions (Corona et al., 2002; Prestel et al., 2010), which in 
turn promotes the expression of the adjacent reporter gene (Schiemann et al., 2010). I aimed for 
evaluating this concept in CHO cells. Therefore I fused the histone acetyltransferase MOF to a  
Gal4-BD, which is able to bind the yeast upstream activating sequence (UASGal). A plasmid was 
generated, comprising 5x UAS sites in front of the hCMV-MIE promoter. This promoter is supported 
by the IRES element EV71 to drive the simultaneous expression of the reporter gene eGFP and  
Gal4-BD MOF.  
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In addition a control plasmid expressing unfused Gal4-BD was also generated. CHO cells were 
transfected with the appropriate plasmids in triplicates and stable transfectants were selected using 
the DHFR/MTX system. After 34 days of selection, the CHO pools were cultivated for additional 90 
days at a constant MTX concentration (250 nM).  
During the cultivation period cell pools were examined every week for their eGFP expression by flow 
cytometry with the BD FACS Canto II (BD, Heidelberg, Germany) (2.2.3.9). The geometrical mean of 
fluorescence intensity of living cell pool was calculated for each measurement and plotted against 
the time of cultivation (Figure 37).  
During the cultivation the CHO pools with GalBD-MOF plasmid (plasmid no. 16125) had lower eGFP 
expression than the control pools (plasmid no. 16124) (Figure 36 and Figure 37).  
 
Gal4-BD control Gal4-BD MOF 
  
 
Figure 36: Histogram of fluorescence intensity (x-axis) of CHO pools, 52 days after transfection. 10,000 events (y-axis) per 
pools were measured. Gal4-BD MOF expressing CHO pools one (red), two (blue) and three (orange) had fewer events 
with high fluorescence intensity than the Gal4-BD control pools one (red), two (blue) and three (orange). 
Autofluorescence of CHO-K1 wild type cells are displayed in green.  
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Figure 37: Geometrical means of FACS measurements over time. Gal4-BD MOF pools have lower eGFP signals overall 
compared to control pools 16124. High expressers of Gal4-BD control have a strong loss of eGFP signal over time, but 
expression was still higher than in the Gal4-BD MOF pools (plasmid no. 16125).  
 
In addition to the eGFP expression the global H4K16 acetylation was measured. To this end, the 
membrane/cytoplasmic and nuclear fraction of all cell pools were prepared 52 days after 
transfection (Figure 38) according to Misawa et al. (2006).  
After transfection the same amount of nuclear proteins of each cell pool was analyzed in two 
independent SDS-PAGE assays. The Western blot was conducted with three independent MOF and 
control CHO cell pools and the global acetylation of histone 4 at lysine 16 was measured with the 
appropriate antibody.  
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 α-tubulin and H4K16 acetylation 
Gal4-BD control Gal4-BD MOF 
α-tubulin- 
 
H4K16ac-  
 
Figure 38: Western blot of the nuclear fraction of three independent MOF and control CHO pools. Acetylation of H4K16 
was measured with an appropriate antibody, 52 days after transfection. Thereby global H4k16 acetylation was 
noticeably higher in all MOF expressing pools than in the control pools.  
 
Although the eGFP expression of MOF comprising cell pools was very low (Figure 36), the  
global H4K16 acetylation was noticeably higher compared to controls (Figure 38). To avoid  
over-interpretations of H4K16 acetylation by a small fraction of high producers, pools were sorted 
50 to 57 days after transfection for high eGFP expressers. Sorted pools were cultivated for 45 days 
and eGFP expression was recorded. A shift of eGFP expression was observed in most of the  
CHO pools, especially one MOF pool did not remain stable (Figure 39).  
eGFP positive sorted cells with and without MOF. 66 days after transf.  
97 days after transf.  
CHO control wt  
Gal4-BD control 1 Gal4-BD control 2 Gal4-BD control 3 
   
Gal4-BD MOF 1 Gal4-BD MOF 2 Gal4-BD MOF 3 
   
 
Figure 39: Histogram of fluorescence intensity (x-axis) of eGFP positive sorted CHO pools. 10,000 events (y-axis) per pool 
were measured. After recovery of sort, pools were cultivated for one month and start (red) as well as end (blue) of new 
cultivation was displayed in the histograms. Autofluorescence signal of CHO-K1 wild type cells is displayed in orange. 
Gal4-BD MOF and Gal4-BD control CHO pools tend to lose eGFP expression over time. Particularly Gal4-BD MOF CHO 
pools have a rapid decrease of eGFP signal. 
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The concurrent appearance of eGFP and Gal4-BD or Gal4-BD MOF transcripts is ensured by the IRES-
coupled expression. Furthermore, the global increase of H4K16 acetylation demonstrates the 
presence of a functional expressed MOF protein. Nevertheless, low eGFP expression of MOF pools 
was observed. To exclude the possibility of over interpretation of acetylation signal by a small 
fraction of highly hyperacetylated cells, pools were eGFP positive sorted and cultivated. Thereby a 
MOF dependent effect on stability was not detected. Unfortunately, I wasn´t able to detect MOF 
either in a western blot or in a chromatin immunoprecipitation assay. Considering this, the effect of 
MOF close to the reporter gene could not be analyzed. 
However, these preliminary results suggest that at least a global hyperacetylation of H4K16 does not 
promote stable expression of recombinant genes. In regard to the strength of the used IRES and the 
eGFP positive sort the presence of MOF is very probably but the hypoacetylation of H4K16 might not 
have the assumed effect. The additional expression of MOF might rather hinder stable expression by 
overburden of cell metabolism by his additional expression. 
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3.2.2 Point mutation of CpGs within the hCMV-MIE promoter to improve production 
stability 
Osterlehner et.al. (2011) have reported that specific CpG sites within the hCMV-MIE promoter are 
frequently methylated in unstable CHO cell lines. This suggested that these sites may play a 
prominent role in silencing of the hCMV-MIE promoter. To test this hypothesis different hCMV-MIE 
promoter variants which comprise cytosine to guanine mutation of those specific CpG sites were 
generated. The resulting effects were measured in different reporter plasmids by the expression of 
secreted embryonic alkaline phosphatase (SEAP), eGFP and an IgG antibody-cytokine fusion protein 
(Figure 40). The cytosine to guanine conversions were performed at location -508, -179 and -41 
upstream of transcription start site of hCMV-MIE. In doing so I chose methylation-susceptible CpGs 
from the enhancer (-508 bp), the proximal promoter (-179 bp) and the core promoter (-41 bp) 
region, which in addition are not involved in known transcription factor binding. Furthermore, I 
engineered C to G conversions to maintain the overall GC content without the recreation of new 
CpG sites (Figure 40 B). The used promoter variants were abbreviated with a three letter code, 
starting from C-508 over C-179 to C-41 (Figure 40 C). Each point mutation within the hCMV-MIE is 
indicated by a G instead of a C. All point-mutated constructs were compared to the unmutated 
control CCC. Plasmid variants were used for transient and stable transfection of CHO-K1-M cells.  
 
 
Figure 40: hCMV-MIE: Effects of C to G conversions at position-508, -179 and -41 upstream of transcription start site was 
measured with the expression pattern of the reporters SEAP, eGFP and IgG-cytokine fusion protein (A). CpG sites 
susceptible for methylation were mutated without the changing known transcription factor binding sites marked in grey 
and without creating of new CpG sites. C to G mutations are highlighted with a black background. putative transcription 
factor binding sites are highlighted with a grey background. Those sites were identified by employing software PROMO 
3.0 for species cricetidae which uses the TRANSFAC database version 8.3 (B). Various point mutations were combined in 
several hCMV-MIE promoter variants and examined in different reporter vectors. Promoter variants are identified by a 
three letter referring to the nucleotides at positions -508, -179 and -41 (C). 
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3.2.2.1    Transient transfection: Investigation of promoter strength in CHO pools 
During the selection phase, CHO cells are highly stressed (Chusainow et al., 2009), which results in 
unreliable expression of target genes. Considering that the expression of transgenes in the early 
selection phase is not consistent, the direct promoter strength of hCMV-MIE variants were 
investigated to ensure comparability of constructs. 
To this end CHO cells were transiently transfected with reporter vectors carrying SEAP under the 
control of a specific hCMV-MIE promoter variant. The expression level of SEAP was examined by 
measuring the metabolic rate of para-nitrophenylphosphate to para-nitrophenole on day five after 
transfection, (2.2.3.8).  
The averages of the resulting optical densities were normalized to those obtained after transfection 
of the unmutated control plasmid (CCC). The mock controls are duplicates of water-transfected 
CHO-K1 cells. Two independent experiments were performed, denoted in Figure 41 as assay 1 and 2. 
 
 
Figure 41: Transient transfection of CHO cells with SEAP expression plasmids under the control of hCMV-MIE promoter 
variants. The optical densities obtained by ELISA assay were normalized to unmutated control CCC. Mock is the 
untransfected control. Error bars represent the standard deviation of eight replicates. The diagram shows the result of 
two independent transient transfection experiments. Differences between mutants and control CCC were tested with 
the Tukey HSD test and significance was set to p< 0.05. Significant differences are marked with an asterisk.  
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The hCMV-MIE promoter variants especially with multiple mutations showed noticeable differences 
to the OD of the unmutated control (CCC) (Figure 41). For a statistical evaluation, means of 
replicates were tested with the Tukey honest significant difference (HSD) test (Table 22) (Abdi, 
2010). The significance level was set to 0.05 (Figure 41). The SEAP expression of GGG and CGC 
mutants was significantly lower in one experiment whereas expression by GCG was significantly 
lower in both assays. In general the CpG mutations rather led to a reduced than enhanced direct 
promoter strength. 
 
P values of Tukey HSD test, comparing SEAP expression of mutants to control 
Code of promoter mutant DAC untreated DAC treated 
 Assay 1 Assay 2 Assay 1 Assay 2 
GGG 0.126 0.016 0.985 0.999 
GCG 0.006 <0.0001 0.348 0.76 
CGC 0.049 0.424 0.098 0.578 
GCC 0.446 0.856 0.076 0.521 
CCG 0.334 0.984 0.578 0.989 
 
Table 22: P-values of Tukey HSD Test as an indicator of different promoter strength of mutants to the unmutated 
control. Normalized OD´s of the SEAP assays were used for comparison. Point mutations are ordered in rows and the 
average of eight replicates in DAC untreated and the average of four replicates in DAC treated condition were compared 
with the average of unmutated control. The columns comprise the Tukey HSD calculated P-values of the two assays with 
and without DAC treatment. The significance level was set to 0.05 (5%). Only GCG point mutations results in significant 
lower OD values in both assays in absence of DAC. 
 
3.2.2.2    Stable transfection: Investigation of stable eGFP expression in CHO pools 
With the knowledge about the direct promoter strength of promoter mutants I was able to analyze 
the influence on long term stability. Consequently I examined, whether hCMV-MIE promoter 
variants influence the expression stability of stable transfected CHO cells during long term 
cultivation. For this purpose eGFP was chosen as reporter gene to enable the measurement of 
fluorescence intensity of each individual cell in the suspension (Table 23). 
Four replicates per hCMV-MIE promoter variant were generated by transfection of CHO-K1-M cells. 
Two days following transfection, selection was started by adding MTX. After the reduction of the 
overall cell viability to < 20 %, the value was maintained for one week followed by slow recovery 
over one month until a viability of > 97% was obtained. Stable transfected cell suspensions 
expressing eGFP were cultivated over a period of one to three months. The intensity of eGFP 
expression was measured with BD FACS Canto II (BD, Heidelberg, Germany) and primary data 
analysis was performed with the FlowJo 7.6.5 EN software (TreeStar, Olten, Switzerland). The 
geometrical means of the fluorescence intensity of 10,000 events per measurement were calculated 
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for each living cell pool and plotted on a logarithmic scale against the time of cultivation (2.2.3.9). 
The start and end point of cultivation was compared to identify high and stable expressers (Figure 42 
A). 
 
hCMV-MIE promoter variants in eGFP reporter gene plasmids (Figure 24)  
Plasmid No.: Code of promoter mutant Point mutations Feature 
16105 GGG G-508, G-179, G-41 Gal4-BD binding 
sequence UAS 16106 GCG G-508, G-41 
16107 CGC G-179 
16108 GCC G-508 
16109 CCG G-41 
16111 CCC No mutation 
 
Table 23: eGFP reporter plasmid list: Code of promoter mutant describes the C to G point mutations within the hCMV-
MIE promoter located -508, -179 and -41 base pairs upstream of transcription start site. CCC is the code for the 
unmutated control with UAS sites. 
 
I found that the CHO pools with the CGC or CCG mutation yielded distinctively higher eGFP values 
than the control at the beginning of the cultivation phase. Although consistent eGFP expression over 
time suggested an enhanced stability of CGC pools, no significant difference (significance level 0.05) 
to control was determined with the Tukey HSD test. Therefore, I performed a power analysis in 
order to calculate the minimal number of samples required to obtain a significant difference of 
promising CGC (G-179) and CCG (G-41) mutants to the control. At least eight replicates per construct 
were suggested and a second experiment was pursued. 
Stable transfected CHO cell pools with eight replicates of CGC promoter mutants (two losses by 
contamination) and ten replicates of CCG and CCC promoter mutants were selected, cultivated and 
analyzed as described previously (Figure 42 B). The CGC and CCG mutants showed moderately to 
extensively higher eGFP values than the control at the beginning of the cultivation phase. During 
cultivation an increase of eGFP expression was observed in some CCG mutants, suggesting higher 
stability. The Tukey HSD test showed that the eGFP expression in CCG mutants were significantly 
higher than in the control on day 42 after transfection. However a decrease of eGFP expression over 
time was seen in CCG as well as CGC mutants, which might be caused by evolutionary pressure 
within the complex CHO pools.  
In addition to eGFP measurements, the copy number per cell as well as the hCMV-MIE promoter 
methylation was determined for each CHO pool 42 and 69 days after transfection (Figure 42 C and 
D). The average copy number per pool was calculated as described previously (Osterlehner et al., 
2011) and were compared between mutants and control by employing the Tukey HSD test. Although 
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no significant difference was obtained, the G-179 (CGC) mutants have less transgenes compared to 
the control and the G-41 (CCG) mutants. The promoter methylation was examined after bisulfite 
conversion of gDNA, the amplification of hCMV-MIE and the library preparation followed by 
sequencing employing the TrueSeq Nano Kit and the MiSeq system (Illumina, Inc., San Diego, USA). 
The average CpG methylation of hCMV-MIE was calculated with the Bismark software (Krueger & 
Andrews, 2011). Similar to the tendencies obtained for the copy numbers, the G-179 (CGC) mutants 
are less methylated compared to the control and the G-41 (CCG) mutants. 
 
 
Figure 42: eGFP expression of stable transfected CHO cell pools. Promoter mutants were compared to unmutated 
control (CCC). The progression of eGFP expression is exemplified for begin and end of the cultivation phase. N indicates 
the number of replicates. (A) Prominent eGFP expression was observed in CGC and CCG pools at begin of cultivation 
phase. However significant difference to control was not obtained. (B) Assay was repeated for CCC, CCG and CGC with a 
higher replicate number indicated by the symbol N. Again higher eGFP expression was observed in CCG and CGC 
mutants at begin of cultivation phase, whereat the eGFP expression of CCG pools seems to be maintained over time. In 
addition the CCG pools had significantly higher eGFP expression than the control 42 days after transfection. Neither the 
copy numbers (C) nor the methylation of hCMV-MIE (D) of the appropriate eGFP pools from (B) were not significantly 
different between the promoter variants. 
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The methylation coverage for each CpG was also calculated with the Bismarck software and the 
methylation patterns for all pools are displayed in Figure 43. I found the unmutated CpG at position -
179 upstream of TSS prominently methylated in comparison to all other CpG sites. Furthermore, it 
could be observed that the mutation of CpG -179 and -41 did not result in an altered methylation 
pattern across the CMV promoter. However, a general lower methylation of methylation-susceptible 
CpGs could be observed in both mutants and in particular for the CGC promoter variant. For this 
reason the average methylation of hCMV-MIE (Figure 42 D) describes a reliable value for further 
analysis. 
 
 
Figure 43: hCMV-MIE methylation pattern of CpGs. Methylation of GFP expressing pools were examined for promoter 
variants CCG, CGC and control CCC 42 and 69 days after transfection. 
 
Although only CCG pools yielded significantly higher eGFP values, both point mutations followed the 
trend towards higher eGFP expressions observed, in two independent experiments (Figure 42 A and 
B). Considering the high variability of pools I assume that the mutation effect might be masked by 
the increased evolutionary competition within the cell suspensions. As a consequence, the promoter 
mutants CGC and CCG were investigated in clonal cell lines to reduce variability. Furthermore, these 
effects were measured in conditions as close as possible to the standard cell line development 
(Figure 44). Therefore, both mutations alone as well as in combination (CGG) were examined as IgG-
cytokine fusion protein expressing clonal CHO cell lines. In consideration of the copy number 
similarity of the different CHO pools, I propose the same bias in clonal cell lines.  
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3.2.2.3    Stable transfection: Investigation of stable IgG-Cytokine fusion protein expressing 
monoclonal CHO cell lines 
IgG plasmids with CGG, CGC, CCG promoter mutants and the unmutated control of hCMV-MIE 
promoter were generated (Table 24 and Figure 44). The CGG mutation was constructed to assess 
potential additive effects of both single mutations. As reporter the IgG-cytokine fusion protein  
(Table 23) was chosen to measure expression and stability. Furthermore, the IgG-cytokine fusion 
protein is a pipeline product of Roche, which enables effect measurements close to the standard cell 
line development. To generate monoclonal cell lines, CHO-K1-M cells were transfected with the 
appropriate plasmid, isolated in 384 well plates and kept under high selection pressure for three 
weeks. In order to assess cell viability, cultures were continuously expanded until 41 days after 
transfection. 30 clonal cell lines per construct were randomly picked and transferred into six well 
plates for long term cultivation. During the cultivation phase some cell lines were discarded as a 
result of contamination or reduced viability. 22 to 30 clones per construct were examined for two 
months. 
 
C to G point mutations in human CMV-major immediate-early promoter/enhancer 
fragment of human antibody of class IgG expressing plasmids (Figure 26) 
Plasmid No.: Code of promoter mutant Point mutations 
16134 CGG G-179, G-41 
16135 CGC G-179 
16136 CCG G-41 
21504 CCC No mutation 
 
Table 24: IgG reporter plasmid list: Code of promoter mutant describes the C to G point mutations within the hCMV-MIE 
promoter located -179 and -41 base pairs upstream of transcription start site. CCC is the code for the unmutated control. 
IgG expression is driven by the appropriate hCMV-MIE promoter. 
 
The antibody concentration was kindly examined by Manuela Bernhard using ELISA technology and 
antibody titer (µg/ml) and qP was calculated (2.2.3.12). Measurements of the beginning and the end 
of the cultivation phase were displayed to visualize the difference of mutants to control and 
alteration of expression during cultivation. The titers at the end of cultivation phase were found 
noticeably higher in single mutants than in the control cell lines (Figure 44 A). In particular the  
CGC (G-179) mutant obtained significantly higher titer during the cultivation phase than the control. 
Significant difference was tested again with the Tukey HSD test. To reduce potential propagation 
effects, the time of cultivation and the concentration of cells were considered. For this purpose the 
qP of mutants and control were compared during the whole cultivation phase (Figure 44 B). 
Furthermore to reduce errors which might occur during the estimation of qPs like miscounting of 
cells or dilution errors, the specific productivity of the first two (Start = 68 & 83 days after 
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transfection) and the last three (End = 124, 127 & 131 days after transfection) qP values of each cell 
line were averaged. The performance of qP values at the beginning and the end of the cultivation 
phase matched the respective titers. The difference of CGC mutants to unmutated control increases 
over time and at the end of cultivation the specific productivity of CGC mutants were tremendously 
higher than the control.  
Taking into account the slightly reduced direct promoter strength of mutants, the comparable copy 
number values obtained in the previous assay as well as the higher specific productivity of mutants, 
I conclude about a stabilizing effect of the point mutations G-179 and G-41. To verify this hypothesis, 
I calculated the alteration of the specific productivity ∆qP of antibody expressing cell lines during the 
cultivation phase (Figure 44 C). Therefore, I only chose cell lines which produce antibodies from the 
beginning of the cultivation phase. In the following formula the ∆qP being the percental alteration of 
qP, qPstart being the specific productivity at the beginning of the cultivation period and qPend being 
the specific productivity at the end of the cultivation period. 
 
 
 
The comparison of all ∆qP values shows that one control sample had an uncommonly high ∆qP 
value, indicating a more than six fold higher increased productivity than the average (Figure 44 C: 
left plot). In light of this exceptional high ∆qP value of one control, a jackknife outlier analysis was 
performed, which led me to exclude sample CCC-13. qP values were plotted again and the averages 
were compared with the Tukey HSD Test. Hence the monoclonal cell lines with the CGC and CCG 
promoter mutants obtained a significantly higher stability than the unmutated control cell lines 
(Figure 2 C right). In particular the G-179 point mutation results in remarkable expression stability 
over time. 
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Figure 44: Generation of stable transfected clonal CHO cell lines which express antibodies under the control of CCC, CCG, 
CGC and CGG promoter variants. Comparisons of mutants and control were performed with the Tukey HSD Test. A) 
Antibody titer (µg/ml) of CCG, CGC and CGG cell lines were compared to unmutated control (CCC), employing the Tukey 
HSD test. The titer from the beginning (left) and the end (right) of the cultivation phase are displayed for all cell lines. 
Higher titers were obtained for the CGC and the CGG mutant at the start of cultivation. At the end of cultivation all 
mutants obtained higher antibody titer than the control. B) The specific productivities (qP) of all cell lines were 
calculated as pg/cell per day and were averaged for the beginning (left) and the end (right) of the cultivation phase. CGC 
cell lines have significantly higher qP values at the end of cultivation phase. C) The percentage alteration of specific 
productivities was compared between control and mutants. After exclusion of outlier cell line CCC-13 by employing the 
jackknife technique, the CGC and CCG mutation resulted in significant higher stability compared to the unmutated 
control cell lines (CCC). 
 
Taken together, the single point mutations G-41 and G-179 have a positive effect on expression 
stability in CHO pools as well as in clonal cell lines. The observed effect in CHO pools was not as 
distinctive as in clonal cell lines, which might be linked to the high variability of pools and the 
subsequent evolutionary competition within the suspension. However, the examination of antibody-
expressing clonal cell lines shows the tremendous effect of G-179. Interestingly combined mutations 
enhance the stability neither in eGFP cell pools (e.g. GGG) nor in antibody clonal cell lines (CGG). This 
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indicates that the number and the position of point mutations are more important than a general 
depletion of CpG sites within the hCMV-MIE. Considering that the initiation of transgene silencing 
depends not only on the sequence of transgene, but also on the tendency to form tandem repeats 
upon integration, and the integration site into the host genome (Kaufman et al., 2008) I propose a 
dominant effect of DNA methylation on gene expression. 
 
3.3 Epigenetic Landscape of CHO-K1-M cells and potential stable integration 
sites 
Transfection of CHO cells with expression vectors followed by selection and cultivation phases is a 
common method to obtain high titer of a recombinant protein. However, many cell lines are prone 
to lose productivity over time. During the transfection and the selection phase the expression 
vectors integrate randomly into the genome. It seems plausible that the integration of transgenes 
within active, highly transcribed regions promotes the transcription of the transgene. A randomly 
transfected cell pool most likely contains high expressers with frequently integrated transgenes in 
active regions and low expressers with transgenes predominantly located in inactive regions of the 
genome. 
 
3.3.1 Chromatin state of CHO-K1 wild type 
In order to enable the segmentation of the CHO-K1 genome in active and inactive regions, a ChIP 
sequencing experiment, monitoring of well-known marks was performed. To this end, chromatin 
was immunoprecipitated with chip grade antibodies against specific diagnostic histone modifications 
and the enrichment over input sample was determined by qPCR. The H3K4me3, H3ac and 
H3K36me3 modifications are mainly present in active euchromatin whereas H3K9me3 is known as a 
repressive signal (Zentner & Henikoff, 2013; Zhou, Goren & Bernstein, 2011). I performed the ChIP to 
enriched chromatin for H3K4me3 and H3K9me3 with two biological replicates (2.2.3.16). For qPCR 
the control primers for Gusb, Gata5 and Foxa2 sites were used and enrichment was normalized to 
the input sample. Thereby a strong accumulation of H3K4me3 on Gusb site and moderate 
enrichment H3K9me3 at the Foxa2 site was observed in both biological replicates (Figure 45 A  
and B). Consequently, samples were transferred to GATC (GATC-biotech, Konstanz, Germany) for 
sequencing. The ChIP sequencing for H3ac as well as H3K36me3 was performed by Active motif  
(La Hulpe, Belgium) from a provided sample of CHO-K1 chromatin. For this purpose I prepared 
chromatin as described for ChIP sequencing and send the sample to Active motif on dry ice. Active 
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motif completed the H3Ac and H3K36me3 ChIP reactions using 25 μg of Chinese hamster ovary cell 
chromatin and 5 μl of H3Ac antibody (Active Motif, cat # 39139) and 4 μg of H3K36me3 antibody 
(Active Motif, cat # 61101). The qPCR was performed using positive control primers that were 
designed for CHO cells based on conserved sites in human and mouse, as well two negative control 
primer pairs that amplify regions in gene deserts (Untr87, Untr99). Results were normalized to input 
values and to 1000 cells. The signal for H3Ac binding is strong at the Gapdh site. In the case of 
H3K36me3, signals were strong on Gapdh and Actb in both biological samples (Figure 45 C and D).  
 
 
Figure 45: Enrichment of histone modification on specific genomic regions analyzed by qPCR. Accumulation of H3K4me3 
and H3K9me3 were examined in house as % of Input sample (A and B). In contrast, Active Motif normalized the 
enrichment to the input values and the number of cells (C and D). Strong enrichment was observed for H3K4me3 on 
Gusb, for H3ac on Gapdh and for H3K36me3 on Actb. Moderate enrichment was observed for H3K9me3 on Foxa2. 
 
Sequencing was done with the Illumina, HiSeq (Single Read, 50 bp; GATC) and Illumina, NextSeq 500 
instruments (Single Read,75 bp; Active Motif). 
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Encode suggests for mammalian broad-source histone marks more than 20 million uniquely mapped 
reads with a non-redundant fraction of greater than 0.8 million (Landt et al., 2012). Alignment of 
reads and mapping was kindly performed by Matthias Barann. Reads of the integration sites, 
generated by inverse PCR, and the ChIP sequencing reads for H3K36me3, H3ac, H3K4me3 and 
H3K9me3 were aligned to the CHO-k1 genome (genBank Assembly ID GCA_000223135.1), employing 
the Burrow-Wheeler alignment tool BWA (Li & Durbin, 2009). In doing so, the quality criteria of 
Encode could be respected for the ChIP sequencing results. 
 
Histone 
modification 
Sequencing 
Service 
# of all reads # of mapped reads % of all reads 
1_H3K36me3 Active Motif 33167150 26117120 78.74% 
2_H3K36me3 Active Motif 40764874 23992326 58.86% 
1_H3ac pan Active Motif 31233220 21303019 68.21% 
InputControl A Active Motif 29208305 22008294 75.35% 
1_H3K4me3 GATC 51681788 27614201 53.43% 
1_H3K9me3 GATC 34733630 26931375 77.54% 
2_H3K4me3 GATC 51434453 33773785 65.66% 
2_H3K9me3 GATC 37975834 28716974 75.62% 
InputControl B GATC 65239893 55050603 84.38% 
 
Table 25: BWA mapping report of ChIP sequencing reads. More than 20 million reads were obtained and mapped to the 
CHO-K1 genome. 
 
Peak calling of the aligned reads was performed with the Model-based Analysis tool for ChIP 
Sequencing termed MACS2 (Zhang et al., 2008b). Hence H3K36me3 and H3K9me3 were investigated 
with the broad peak model, whereas narrow peaks were called for H3ac and H3K4me3. 
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3.3.2 Validation of integration sites 
For the investigation of location-dependent effects on integrates, I examined transfected CHO pools 
with random integration sites of transgenes and compared their productivity with the location of the 
transgenes and the surrounding chromatin state of the CHO-K1 wild type. CHO cell were transfected 
with an eGFP reporter plasmid and three independent high variable cell pools were selected for one 
month. After selection phase, eGFP expressing CHO-K1 cell pools were sorted into two subcultures 
of high and low eGFP expressers. Cells were harvested and stored two weeks after sort while high 
eGFP expressing pools were still cultivated to verify the long term stability of eGFP expression 
(Figure 46). Sorted cell pools 2.3 and in particular 1.7 could be clearly distinguished by their eGFP 
expression. Even five weeks after sorting the eGFP expression of high eGFP expressing pools 
remained stable as it can be seen in the stability control. The eGFP expression in the low eGFP 
expressing pool 4.6 (-) might compromise the discrimination of integration sites that support stable 
or variegated expression in these pools. Therefor further analysis of pool 4.6 was done with a note of 
caution. 
 
 
Figure 46: Subcultures of eGFP expressing CHO-K1 pools. Two weeks after sorting into high and low eGFP expressing 
pools, cells were analyzed employing flow cytometry and genomic DNA was stored for inverse PCR. The stability control 
of high eGFP expressers was analyzed five weeks after sort to confirm stability of expression. 
 
Inverse PCR of subcultures was conducted to locate transgene integration sites of sorted cell pools. 
For this purpose the stored genomic DNA of CHO pools was digested with the 4 bp cutting enzymes. 
The chosen enzymes did not cut between the primer binding sites and the linearization site of the 
vector. The enzymes cut statistically every 256 bp in the genome, which should result in small 
fragmented DNA. After self-ligation only fragments with the appropriate primer binding sites are 
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able to be amplified. Only the 5´iPCR of MseI and MluCI cutted fragments results in amplification 
without an unspecific band in control CHO-K1 wild type (Figure 47). For this reason the 5´amplicons 
of each sample were combined and purified with High Pure PCR Purification Kit (Roche, Penzberg, 
Germany) in 40 µl Elution buffer. The sequencing of fragments was done by GATC-Biotech (Konstanz, 
Germany). 
 
Figure 47: 5`iPCR of stable CHO pools after eGFP sort. Pools were randomly transfected with eGFP reporter plasmid and 
MTX selected. After one month of cultivation, pools were positive and negative eGFP sorted and integration sites were 
examined with iPCR. No unspecific amplifications were obtained in untransfected CHO control cells using 5´integration 
site primers.  
 
For the alignment of the amplicons the BWA software (Li & Durbin, 2009) was used. Unfortunately 
only a small proportion of reads could be aligned to the CHO-K1 genome (Table 26). 
 
Pools Sequencing 
Service 
# of all reads # of mapped reads % of all reads 
1,7 minus GATC 3114808 31670 1.01% 
1,7 plus GATC 10680020 128682 1.20% 
2,3 minus GATC 4344334 105701 2.43% 
2,3 plus GATC 1964838 26851 1.36% 
4,6 minus GATC 2786248 151038 5.42% 
4,6 plus GATC 3916138 167914 4.28% 
 
Table 26: BWA report of amplicon alignment on CHO-K1 genome. Only a small fraction of reads could be aligned. 
 
In light of the low number of aligned reads, the specific amplification by inverse PCR primers was 
verified (Table 27). To this end all reads were scanned for the primer sequence and known vector 
sequences, which revealed that 80% to 96% of all reads containing the primer sequence also 
contained the adjacent vector sequence. This implies in the most cases a correct primer annealing 
and amplification. The low number of mapped reads might be a result of a large number of tandem 
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repeats or viral infection, which suggests that further analysis should be interpreted with caution. 
The mapped integration sites were compared with activation and inactivation marks of the ChIP 
sequencing. 
 
Sequence files of sorted eGFP pools % of reads 
containing primer 
sequence 
% of reads containing 
primer & adjacent vector 
sequence 
1_7_gfp_minus_lib32736_1894_1_1.fastq.gz 35% 85% 
1_7_gfp_minus_lib32736_1894_1_2.fastq.gz 27% 80% 
1_7_gfp_plus_lib34418_1923_1_1.fastq.gz 47% 85% 
1_7_gfp_plus_lib34418_1923_1_2.fastq.gz 40% 83% 
2_3_gfp_minus_lib32738_1862_1_1.fastq.gz 32% 95% 
2_3_gfp_minus_lib32738_1862_1_2.fastq.gz 34% 95% 
2_3_gfp_plus_lib32737_1923_1_1.fastq.gz 44% 94% 
2_3_gfp_plus_lib32737_1923_1_2.fastq.gz 38% 91% 
4_6_gfp_minus_lib32740_1862_1_1.fastq.gz 40% 96% 
4_6_gfp_minus_lib32740_1862_1_2.fastq.gz 36% 95% 
4_6_gfp_plus_lib32739_1862_1_1.fastq.gz 46% 95% 
4_6_gfp_plus_lib32739_1862_1_2.fastq.gz 41% 94% 
 
Table 27: Specificity of primer binding: Most of the reads did not contain the primer sequence. However most of the 
primer sequence containing reads have also the following 16 bp vector sequence before the linearization site PvuI. 
 
3.3.3 Combined analysis of chromatin state and integration sites 
Until now the CHO-K1 genome has not been fully annotated. For this reason all investigated 
software tools such as ChromHMM are not able to cluster the genome in predominately active and 
inactive regions with respect to the histone modifications H3K4me3, H3ac, H3K36me3 and 
H3K9me3. Furthermore, the most overlapping sequence data (contigs) are very small, which 
impedes the full analyses of the regions. Accordingly, I was not able to perform a general analysis of 
all integration sites with a chromatin map, segmented in active and inactive areas.  
To circumvent this problem, Matthias Barann scripted a small program, in which all peaks within 
6,500 bp around an integration site were counted and listed. The table 28 displays for every pool the 
number of peaks of the investigated histone modification 6,500 bp around each integration site. The 
coverage of an integration site is the average number of reads representing a given nucleotide in the 
reconstructed sequence. This read depth should correlate with the frequency of the specific 
integration site within the examined pool.  
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To assure comparability I excluded all contigs, which are smaller than 13,000 bp, and all Integration 
sites, which are closer than 6,500 bp to one end of the appropriate contig. Taking into consideration 
that the H3K36me3 and H3K9me3 are the most promising histone modifications to distinguish 
between active and inactive chromatin states, I excluded all contigs, which do not contain at least 
one of those marks. In regard to the poor mapping results for integration sites, I only analyzed 
integration sites with coverage of more than 100x. Unfiltered integration sites with coverage of >0 
are depicted as control. With the threshold of >100x coverage, the total number of integration sites 
and the appropriate contigs reduces drastically to 57 integration sites for low eGFP expressers and 
33 integration sites for high eGFP expressers. Following the assumption that silenced integration 
sites should mainly occur in inactive regions and vice versa, I calculated the ratio of H3K9me3 to 
H3K36me3 peaks for the integration sites of low and high eGFP expressers, and the statistical ratio 
for the whole genome of CHO-K1 wild type as control (Table 28). This analyses show that the portion 
of H3K9me3 increases close to integration sites compared to the statistical ratio of 3.25 
H3K9me3/H3K36me3. In particular the low eGFP expressers obtained a notably higher value for 
H3K9me3 close to their highly covered integration sites. However, a significant difference of 
unfiltered negative and positive sites with respect to the number of H3K9me3 peaks could not be 
demonstrated. For this reason those data must be treated with caution.  
 
Integration sites  Peaks of histone modifications 
H3K9me3 H3K36me3 H3panAc H3K4me3 H3K9me3/ 
H3K36me3 
low (-)eGFP pools with 100x 
coverage 
114 18 5 2 6.33 
high (+) eGFP pools with 100x 
coverage 
71 17 3 2 4.17 
(-) eGFP pools with coverage >0 920 215 82 37 4.27 
(+) eGFP pools with coverage >0 3182 741 244 120 4.29 
close to all integration sites 4000 943 321 154 4.24 
global 150496 46214 37998 24822 3.25 
 
Table 28: Peaks count of histone modifications located 6,500 bps around integration sites. Peaks were counted for high 
covered (>100x coverage), low covered (>0x coverage) and all integration sites. In addition all peaks were counted 
independent of integration sites. The ratio of the most prominent inactive marker H3K9me3 and active marker 
H3K36me3 were calculated. 
 
Due to the unreliability of a general analysis and under the assumption that the coverage correlates 
with the frequency of the integration sites within the examined pool, single integration sites with the 
highest coverage were examined. The three most prominent integration sites for each pool were 
chosen (Table 29) and displayed with the IGV genome browser (Figure 48) (Robinson et al., 2011). To 
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facilitate discrimination of active and inactive regions, the integration sites of low eGFP (-) 
expressing pools are red and the integration sites of high eGFP (+) expressing pools are green.  
In addition the inactivation mark H3K9me3 is painted in purple whereas the activation marks 
H3K4me4, H3ac and H3K36me3 are painted in green (Figure 48). Hence it could be observed that all 
integration sites of low eGFP expressing pools are surrounded by the inactivation mark H3K9me3 
(Figure 48 A-C). In contrast to this the integration sites of the high eGFP expressing pools were 
encircled by active as well as inactive marks (Figure 48 D-F). The 1.7 (+) pool obtained the best 
association of integration sites and activation marks followed by the 2.3 (+) pool, whereas no 
activation mark could be observed close to the most prominent integration sites of the high eGFP 
expressing 4.6 (+) pool. This suggests that many silenced transgenes also exist in high expressers. 
The lower eGFP expression and the reduction over time in the 4.6 (+) pool support this theory 
(Figure 46). 
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Figure 48: IGV genome browser pictures of the three highest covered integration sites of each pool. The integration sites 
of the low eGFP expressing pools 1.7 (-), 2.3 (-), and 4.6 (-) are displayed as red columns in A, B and C whereas the 
integration sites of the high eGFP expressing pools 1.7 (+), 2.3 (+), and 4.6 (+) are pictured in D, E, and F as green 
columns. The inactivation peaks of H3K9me3 are portrayed as purple bars. The activation peaks for H3K4me3, H3ac and 
H3K36me3 are portrayed as green bars. All integration sites of low eGFP expressing pools are surrounded by H3K9me3 
peaks. The integration sites of high eGFP expressing pools predominantly encircled by activation marks in particular in 
1.7 (+) pool. 
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Pools Integration 
site 
start end contig contig 
length 
1.7 (-) 1 33710 33879 gi|529736278|gb|APMK01209506.1| 61339 
2 27820 28038 gi|529632532|gb|APMK01259496.1| 34698 
3 17844 18011 gi|529542894|gb|APMK01299512.1| 28254 
2.3 (-) 1 9560 9732 gi|529755684|gb|APMK01200188.1| 18950 
2 33177 33363 gi|530129180|gb|APMK01019987.1| 48062 
3 12592 12772 gi|529840071|gb|APMK01159973.1| 24537 
4.6 (-) 1 9329 9392 gi|529543284|gb|APMK01299321.1| 44147 
2 15923 16036 gi|529899463|gb|APMK01129909.1| 29170 
3 8008 8136 gi|529695444|gb|APMK01229803.1| 24501 
1.7 (+) 1 11339 11522 gi|529983619|gb|APMK01090275.1| 21655 
2 14892 14989 gi|529899456|gb|APMK01129916.1| 28873 
3 28880 28977 gi|530129135|gb|APMK01020008.1| 43344 
2.3 (+) 1 14549 14753 gi|529879688|gb|APMK01139946.1| 26816 
2 7600 7740 gi|529542165|gb|APMK01299870.1| 19894 
3 33062 33224 gi|529961879|gb|APMK01099785.1| 52446 
4.6 (+) 1 12833 12999 gi|529899487|gb|APMK01129885.1| 30233 
2 39673 39872 gi|530149103|gb|APMK01009994.1| 56793 
3 9333 9506 gi|530147711|gb|APMK01010668.1| 18622 
 
Table 29: Position of the three highest covered single integration sites of each pool. High eGFP expressing pools are 
indicated by (+) and low eGFP expressing by (-). 
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4 Discussion 
 
4.1 Molecular Indicator of Production Instability 
Epigenetic marks are well known to alter the expression of genes and specific marks correlate with 
an open or a closed formation of specific chromatin regions (Chen & Dent, 2014). Most therapeutic 
proteins are produced in large fed-batch cultures of CHO cells. Late stage reduction of therapeutic 
protein expression levels, caused by epigenetic alterations can therefore be very cost intensive. To 
minimize that risk, epigenetic markers were investigated at an early stage to distinguish stable from 
unstable production cell lines. On account of this, the epigenetic modifications of cell lines were 
measured at the start point of cultivation and compared to the alteration of stability over 60 
generations.  
It was demonstrated that the level of histone H3 acetylation at hCMV-MIE can be used to screen for 
stable cell lines and exclude unstable ones from further development early on. The results suggest 
that cell lines, which are highly acetylated at H3, are less prone to transgene silencing than others. In 
line with this, hypoacetylation of H3 has been shown to accompany loss of productivity in unstable 
CHO cell lines (Paredes et al. 2013; Spencer et al. 2015) suggesting that H3 hypoacetylation plays a 
major role in silencing of transgenes in CHO cells. 
Considering the moderate predictive power indicated by the adjusted R², I aimed to identify a 
threshold of H3ac/H3 which appears to be optimally suited to separate unstable from stable 
producers. It appeared that most cell lines with H3ac/H3 > 0.5 have above average production 
stability whereas most cell lines with H3ac/H3 < 0.5 have below average production stability. After 
applying this filter most selected cell lines lose not more than 40% of their specific productivity over 
60 generations with and without selection agent, which we consider as the critical limit. 
Furthermore I was able to demonstrate in two independent cell line development projects that the 
subpopulations filtered by H3 acetylation are significantly more stable than the unfiltered 
populations, employing the Tukey HSD test. 
The selection of cell lines by acetylation of H3 at the heterologous hCMV major immediate early 
promoter and enhancer appears to be more reliable and effective than using DNA methylation as a 
marker. According to the general model of gene silencing, activating histone modifications disappear 
and inactivating histone modifications occur before the DNA is permanently ‘locked’ into the silent 
state by methylation (Smith and Meissner 2013; Yin et al. 2012). This sequence of events may 
explain why the early occurring H3 acetylation is better suited as early indicator of production 
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stability or instability than promoter methylation. Both, H3 acetylation and production stability 
generally anti-correlate with methylation of hCMV-MIE as well as the number of transgene copies, 
which demonstrates the consistency of the data. 
It seems obvious that the H3 acetylation levels of low copy number cell lines might be primarily 
influenced by the location of transgenes, particularly by the position effect, which can influence the 
stability of recombinant gene expression (Lattenmayer et al. 2006; Yin et al. 2012). For this reason I 
propose that the degree of H3 acetylation close to the transgene is not only a sign of activation but 
also an indicator of stable integration sites. 
 
4.1.1 Limitation of prediction marker 
As already noted in the result section, the differences of the effect analyses between project H and 
project T indicates the limitations of H3 acetylation as a predictive marker. The high stability 
combined with the low variability between cell lines in project T demonstrates that the marker is 
able to distinguish roughly between stable and unstable subpopulations, but does not allow for a 
more precise prediction. For this reason I aimed to identify a general threshold. Project H 
outperforms project T in terms of the number of cell lines and the variance of expression changes 
and was therefore chosen for the definition of the threshold. Applying the threshold of 0.5 H3ac to 
project T led to a significant discrimination of stable and unstable cell lines. However, the suitability 
of this marker might diminish with the development of more stable cell lines. To this end I compared 
the average stability of the examined projects H and T with data from other in-house projects  
(Figure 49). The average stability in project T was noticeably higher than in most other projects. 
From this I assume that the prediction marker H3ac will also be of great benefit in the current 
development of CHO cell lines. 
 
 
Figure 49: Comparison of differences of in-house cell line projects according to their average stability. Stability (∆qP) was 
examined over 60 generations in the presence (+) and absence (-) of selection pressure. Project T cell lines were more 
stable compared to the other projects.  
 
On closer inspection of each examined cell line, there were some which were remarkably stable with 
H3ac/H3 values below the threshold (false negatives) and others with H3ac/H3 values above the 
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threshold that were unstable (false positives). The unstable cell lines with high H3ac/H3 values were 
predominantly observed in absence of selection agent. This leads to the assumption that the 
alteration of selection condition influences the chromatin stability, which will be discussed in more 
detail later. 
Histone acetylation and deacetylation are highly dynamic processes (Zentner & Henikoff, 2013), 
which is why the status of H3 acetylation at a certain point in time cannot absolutely anticipate the 
future evolution of productivity. 
One source of error is the fact that our assays measure the average modification of all transgenes of 
a specific cell line. The same is true for DNA methylation measurement. A population with mixed 
modification status may gradually shift towards deacetylation. Otherwise, in a stable cell line, strong 
acetylation of one active transgene can be masked by multiple non-acetylated inactive transgenes. 
Similarly, DNA methylation of multiple silenced transgenes can conceal one unmethylated active 
copy. This underestimation of activation signals and the overestimation of repression signals likely 
results in a decreased predictive power as the number of copies increases. For instance, cell line H-
19 is quite stable although it contains ten integrated plasmid copies, H3ac/H3 is very low and DNA 
methylation is above five percent. Similar effects were observed for cell line H-10 with 50 plasmid 
copies at the presence of selection agent (Supplement Table 18). Conceivably, a minority of these 
copies is responsible for most of the production, whereas the majority contributes to the 
modification status. In this context it may be quite relevant whether all copies are integrated in one 
locus as tandem repeats or present as several independent integrates. Furthermore, we assume that 
some false predictions may result from subsequent alterations of plasmid copy number or from 
posttranscriptional mechanisms (Kim et al., 2011; Li & Rana, 2014). 
The variety of different lysines per H3 which can be acetylated might also decrease the 
discrimination by the marker. The chip-graded antibodies for H3ac recognize all acetylated lysines at 
the N terminus of histone three. Although H3 can be acetylated on the lysines 4, 9, 14, 18, 23 and 27 
in different combinations, it was shown that the activation effect of these residues is in general 
redundant (Martin et al., 2004). Consequently the acetylation of each residue is predominantly 
associated with transcription (Dawson & Kouzarides, 2012). Furthermore it was shown recently that 
the histone acetylation degree remained constant even upon depletion of individual 
acetyltransferases. This indicates the global role of histone acetylation in the stability of nuclei 
(Feller et al., 2015). From this I conclude that the general acetylation of H3 is a reliable and 
consistent mark for activation  
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4.1.2 Effect of copy number on stability at begin of cultivation phase  
It has been demonstrated previously that multi-copy integrates are more susceptible to methylation 
and silencing (Osterlehner et al., 2011). In addition to the absolute copy number, the different 
location of copies and the number of tandem repeats influences the expression (Garrick et al., 1998; 
He et al., 2012; Mauro et al., 2015). The phenomenon of repeat-induced gene silencing was first 
observed in transgenic organisms as a highly conserved mechanism from plants to mammals. 
(Rosser & An, 2010). A recent study has shown the association of expanding natural tandem repeats, 
with DNA methylation and repression of adjacent genes, which suggest that repeat-induced gene 
silencing (RIGS) also occurs as a natural mechanism (Brahmachary et al., 2014). Cell lines with a high 
copy number have a naturally increased chance for tandem repeat formation, which in turn 
increases the possibility for repeat-induced gene silencing. Our studies are consistent with the idea 
that RIGS is a dominant inducer of transgene silencing in recombinant mammalian cell lines and 
confirms the value of strategies that aim to avoid multiple tandem integrates. 
In addition I propose that the location of the first integrated transgenes influence the copy number 
variation during selection phase and in consequence the stability of selected cell lines. Taking into 
account that transfected CHO cells contain the same transgenic sequence, the copy number 
variation and location of transgenes might be the major triggers. A recent study has asserted that 
the acetylation in single copy CHO cell lines is associated with the expression of transgenes (Spencer 
et al. 2015). This leads to the assumption that the site-specific effects are dominant at low copy 
number. Due to the nature of random integration during transfection, plasmids may integrate in 
active and less active regions. The subsequent selection pressure forces cell lines with less active 
transcription of transgenes to compensate their lack of resistance, for example through the 
amplification of transgenes (Chusainow et al., 2009; Schimke et al., 1978).  
Although a strong gene amplification is no longer preferred in the cell line development, a recent 
study has shown that even a low selection pressure of 250 nM MTX can lead to notably higher copy 
numbers of control plasmid when compared with a plasmid with ubiquitous chromatin opening 
elements which are proposed to maintain the open state of chromatin (Betts, Croxford & Dickson, 
2015). Furthermore, the copy number variation was frequently found in heterochromatin regions 
(Aldrich & Maggert, 2014; Hastings et al., 2009). Considering the high selection pressures present 
during the selection phase, it seems plausible that gene amplification occurs predominantly in less 
active transgenes, probability accumulated in heterochromatin regions. After the primary selection 
phase cells are selected by their ability to produce antibody levels above a specific detection 
threshold. In doing so, cell lines with a low copy number need to be predominately active whereas 
producers with a high copy number may have a plethora of different epigenetic states that define a 
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wide range of activities of each individual transgene, provided that the sum of the transcripts 
exceeds the detection level.  
Consequently, the interplay between the activity of the first integration sites and the early selection 
steps during the cell line development supports the formation of two different cell line types; either 
predominantly active at low copy number or with tendencies to silencing at high copy number. 
Hence cell lines with a high copy number have an increased chance of originating from weak 
producers, which were forced to compensate the evolutionary drawback as a result of the high 
selection pressure. 
Assuming that the moderate selection pressure during cultivation phase still influences and maintain 
the copy number, those copies should have a greater effect on the stability in the absence of 
selection agent than in the presence of selection agent. To verify whether this speculation bears 
substance, the copy number from the beginning of the cultivation phase was plotted against the 
production stability of cell lines in the presence or absence of selection agent in project H. The 
predictive power of copy number was slightly better in the absence of selection agent (Figure 32 A 
and B), which is different from the case of epigenetic marks.  
 
4.1.3 Effect of selection agent on stability 
In general the examined cell lines showed an accelerated decline of stability in the absence of 
selection agent. By contrast, the cell line H-18 showed a different behavior (Table 2). A possible 
explanation might be a major structural alteration of chromosomes. Given the fact that the 
expression of transgenes leads to a higher metabolic burden, subpopulations of cells with lower 
transgene expression are proposed to have an evolutionary benefit. During constant selection 
pressure this evolutionary benefit is abrogated by the vital need to express sufficient amounts of 
glutamine synthetase. The subsequent absence of selection agent promotes a selective amplification 
of subpopulations with susceptibility to silencing depending on their evolutionary benefit. The 
reduction of transgene mRNA is either promoted by loss of copy number, epigenetic silencing or 
both (Chusainow et al. 2009; Kim et al. 2011; Paredes et al. 2013). Local epigenetic silencing or 
activation can influence adjacent or even distant regions (Almouzni and Probst 2011; Cheutin and 
Cavalli 2014; Vempati et al. 2010; Wang et al. 2014) which might lead to formation of new foci 
whereas the copy number variation can result into a chromosomal rearrangements, resulting in 
juxtaposition of previously separated chromosomal regions (Hastings et al. 2009). Considering this I 
assume that structural changes can lead to exceptional reactivation of previously silenced transgene, 
which would explain the tremendous increased specific productivity of cell line H-18.  
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4.1.4 Perspectives 
My study proposes that a high plasmid copy number correlates with transgene silencing in 
recombinant mammalian cell lines. Hence the high plasmid copy number might be induced by 
location dependent effect of the first integrated transgenes or vice versa. This confirms the value of 
strategies that aim to avoid tandem integrates and multiple copies in favor of single integrates. 
Lentiviral vectors (Overbeck et al., 2011), transposase-mediated transfection (Matasci et al. 2011) 
and targeted integration approaches such as genome editing (Krämer et al., 2010) and recombinase-
mediated integration or cassette exchange (Kito et. al., 2002; Zhou et al. 2010; Turan et al., 2011; 
Crawford et al., 2013) have been applied and discussed as alternatives to random integration of 
transfected plasmids. The recent development of the CRISPR/Cas9 system for genome editing will 
offer exciting new opportunities in this field (Mali et al., 2013; Ran et al.,2013). However, there are 
applications were cell lines containing several copies of transfected plasmids are desirable, e.g. if 
proteins with several different subunits such as asymmetric, bispecific antibodies need to be 
expressed (Schäfer et al.,2011). For proper composition of these products the subunits need to be 
expressed at the optimal molar ratio. This can easily be accomplished by adjusting gene doses if the 
different subunits are expressed from different plasmids. The plasmids are mixed at the optimal 
molar ratio and the mixture is transfected into cells. This is usually more convenient than 
engineering a multi-gene plasmid with each gene under the control of a promoter of distinct 
strength.  
Nevertheless, due to the evolutionary principles within cell cultures silencing remains a serious risk 
even in improved cell lines. Especially the unstable genome of CHO cells, which has a tendency for 
chromosome rearrangements and loss (Cao et al. 2012; Derouazi et al. 2006) might promote an 
accelerated selection of cell lines towards producers, which are stable, primarily under selection 
pressure. Considering this, the ability to predict stability is important, regardless of enhanced vector 
design or integration sites. Screening generated cell lines for production stability using a predictive 
marker can reduce the drawback of instability with this approach. 
Histone acetylation is performed by a variety of histone acetyltransferases (Feller et al., 2015). 
Therefore the localization of those HATs close to the hCMV-MIE might be an even better prediction 
marker, because of their upstream position in the epigenetic cascade. However, the large number of 
potential targets makes it extremely difficult to choose a general signal of activation. Furthermore, 
the depletion of HATs did not result in an altered acetylation pattern (Feller et al., 2015). This 
obvious redundancy of some lysine acetyltransferases even increases the complexity of target 
definition. 
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Considering the fast turnover of histone acetylation at promoters (Zheng, Thomas & Kelleher, 2013), 
even the observation of a HAT, which is consistently related to gene activity might not increase the 
predictive power remarkably. Therefor the detection of the general histone acetylation appears to 
be the most reliable prediction marker in a variable system. 
Finally I suggest two modifications to the standard procedure of cell line selection. In the first step 
cells should be selected based on to their production titer followed by the expansion of low copy 
number cell lines as long as quality and titer are not affected. In the second step the H3 acetylation 
should be determined once the number of candidate cell lines has been narrowed down to about 20 
based on productivity and product quality. 20 cell lines can be evaluated within two days so that 
timelines are not affected too much. The cell lines that pass the filter would proceed to fermentation 
evaluation. 
 
4.2 Alteration of epigenetic landscape of CHO-K1 cell lines to circumvent 
silencing of recombinant genes 
Different methods are published to overcome the location-dependent effect by targeted 
integrations (Inao et al., 2015; Lee et al., 2015; Matasci et al., 2011). Nevertheless the random 
integration of transfected plasmids is a common method to obtain high titer of recombinant 
proteins. For this reason I aimed to identify vector modifications, which are able to overrule the 
location and copy number effects. 
 
4.2.1 Coupled expression of target gene and the histone acetyltransferase MOF to 
promote open chromatin formation. 
To improve long-term stability of different production cell lines I aimed to maintain the open 
chromatin state at the integration sites. For this purpose a plasmid was designed, which contains a 
IRES EV 71 coupled expression of the reporter eGFP and the histone acetyltransferase MOF or a 
control. The histone acetyltransferase MOF was fused to Gal4-BD, a yeast protein which binds to a 
yeast upstream activation sequence (UAS). This enables the recruitment targeting of UAS sites 
located upstream of the hCMV-MIE. MOF is well known for his role as a transcription activator and it 
was shown that the hyperacetylation of H4K16 by MOF results in an open chromatin formation 
(Corona et al., 2002; Prestel et al., 2010; Schiemann et al., 2010). Furthermore, MOF is the enzymatic 
subunit of the MSL and the NSL complex. The MSL complex in mammals is the main HAT acetylating 
H4K16 in murine embryonic stem cells. NSL binds exclusively at promoters mostly of housekeeping 
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genes and regulates proliferation and cellular homeostasis (Ravens et al., 2014). Therefore I 
assumed activating effects if MOF is directed to the hCMV-MIE. 
CHO pools were generated and the expression of eGFP was measured over three months. The 
results did not show an enhanced expression or an improved stability in MOF CHO pools. To exclude 
the possibility that MOF containing cells are only the subpopulation of high eGFP producers which 
tend to be overgrown, all pools were sorted for high eGFP expression and production stability was 
recorded. However, the additional sort did not result in enhanced production stability. 
Unfortunately, neither the binding of MOF to hCMV-MIE by ChIP nor its general presence by 
Western blot could be detected. However, the present eGFP signal in combination with the nature 
of IRES coupled expression strongly suggests the expression of MOF. In addition, a global 
hyperacetylation within the unsorted MOF pools was observed. Both facts lead to the assumption 
that MOF is expressed and induces the acetylation of H4K16. From this it can be concluded that a 
global hyperacetylation of H4K16 did not influence the expression stability of recombinant genes in 
CHO cells. On the other hand I wasn´t able to examine a direct interaction of MOF and hCMV-MIE 
and a conclusion about target oriented H4K16 acetylation cannot be derived at this point. 
Paredes et al. (2013) showed that the general H4 acetylation degrees did not differ between stable 
and unstable clones, producing IgG. This suggests that the level of general H4ac is not correlated 
with production stability. Furthermore, it was observed that the H4K16 acetylation level close to the 
CMV promoter in eGFP expressing transgenic pigs did not correlate with the transgene expression. 
Even after combined treatment with 5-Aza-dC and TSA no significant alteration of H4K16 acetylation 
close to CMV promoter could be observed (Yin et al., 2012). In addition it was shown that the 
functionality of H4K16ac differs according to the model system (Horikoshi et al., 2013). Taken 
together, the effect of H4K16 acetylation in mammals depends on the cell type and the genomic 
location. Considering the higher eGFP expression levels of the Gal4-BD control, MOF might perturb 
balanced acetylation levels and thus lead to a decreased proliferation of the cells that contain the 
expression vector (Shogren-Knaak et al., 2006). 
Although it seems that MOF might not have an activation potential for hCMV-MIE under the chosen 
conditions other target oriented activators were shown to be effective. Gal4-VP16 fusion protein 
was described over two decades ago as an potent activator of transcription in CHO cells (Sadowski et 
al., 1988). VP16 recruits interacting proteins which lead to large scale decondensation of chromatin 
and stable transcription (Carpenter et al., 2005). Also the overexpression of targeted histone 
acetyltransferase p300 resulted in higher expression. However, the transgene obtained only a 
slightly increased stability compared to control (Kwaks et al., 2005). A recent study presents a 
CRISPR-Cas9-p300core fusion protein, which enables highly specific, targeted activation of 
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promoters (Hilton et al., 2015). Hence they showed a promising tool for epigenome editing. 
Complementary to the methods which aimed at hyperacetylation, methods were developed to avoid 
histone deacetylation. For instance the compound sodium butyrate is well known for his role as 
histone deacetylase inhibitor. For this reason butyrate was extensively investigated in different cell 
lines (Choi, 2006; De Leon Gatti et al., 2007; Li & Li, 2006; Lu et al., 2008; Yee et al., 2008) often 
resulting in a down-regulation of cell cycle proteins and an arrest in the G1 or G2 phase (Hendrick et 
al., 2001). At a concentration of 1 mM sodium butyrate a decline of cell viability was observed 
accompanied by a decreased productivity, whereas a lower concentration of 0.5 mM induces a 
slightly increased productivity. The usage of a general and unspecific inhibitor like butyrate can 
result in the deregulation of many genes (Birzele et al., 2010).  
Considering the variety of effects and the amount of sodium butyrate which will be needed in large 
batch culture, the usage in the standard cell line project might be complicated.  
 
4.2.2 Point mutation of CpGs within the hCMV-MIE promoter to improve production 
stability 
4.2.2.1    Different effect strength of CpG point mutations between CHO pools and CHO cell 
lines 
To improve transgene expression over time I aimed to diminish repressive chromatin marks by the 
reduction of methylation-susceptible CpG islands within the promoter. In so doing, I observed 
notably effects in CHO pools and in CHO cell lines after mutation of cytosines to guanine located 179 
and 41 bp upstream of transcription start site of the hCMV-MIE. Especially in clonal CHO cell lines a 
tremendous effect was observed for the G-179 constructs. By contrast, in CHO pools the highest 
reporter gene expression was obtained for the G-41 mutation.  
However the observed differences in CHO pools were not as significant as observed in CHO cell lines. 
In contrast to clonal cell lines, CHO pools contain cells with broadly different characteristics after 
transfection (Mariati et al., 2014). The higher variability and consequently the increased evolutionary 
pressure in CHO pools might explain the difference between the G-179 and G-41 expression levels as 
well as the lower difference to control. In turn the effect measurement in clonal cell lines is 
accompanied by less disturbing variability, which makes the results more reliable. For this reason I 
propose that the G-179 mutation is more potent than the G-41 mutation. 
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The notably lower copy number of G-179 constructs in CHO pools might mask the higher activity per 
each transgene considering that the number of copies influences the expression levels (Mauro et al., 
2015; Pruner et al., 2014). At the same time the lower CMV methylation for G-179 constructs  
(Figure 42 D) suggests a higher activity per transgene. Considering this, the low number of 
transgenes might be a direct result of the potent G-179 mutation. A functional crosstalk between 
promoters is well known and can be divided into activating promoter-promoter interaction (Li et al., 
2012) and repressive promoter interference. Bidirectional promoter interference is accompanied by 
an impaired expression of both promoters (Curtin et al., 2008). Promoter interference is a well-
studied phenomenon and was also found between the CMV promoter and the Simian virus 40 early 
promoter (West, 2014). The SV40 originated from polyomavirus and was firstly discovered in Rhesus 
monkey cells (Sweet & Hilleman, 1960). In my vector, the part that contributes the promoter 
variants contains the SV40 which is located 11 bp upstream of hCMV-MIE and drives the DHFR 
expression in antisense direction (Figure 11). Therefore, it seems plausible that the activity of hCMV-
MIE might influence the activity of SV40 by positive neighboring effects like a regional 
decondensation.  
As discussed for the prediction marker (4.1.2), I propose that the degree of DHFR expression at 
constant selection pressure directly influences the evolutionary benefit of each cell. Hence cells with 
lower expression of DHFR need to overcome this disadvantage by gene amplification, as it was 
observed in Betts et al., (2015). Following the assumption that G-179-containing CHO pools have an 
improved activity and stability per transgene as was observed for the cell lines, the lower copy 
number might be a consequence of lower evolutionary pressure. However in addition to the 
compensatory effect of gene amplification, the increase of copy numbers correlates with the 
reduction of transgene mRNA either by loss of copies or by epigenetic silencing mechanisms (Mauro 
et al., 2015; Osterlehner et al., 2011). I propose that the constant selection pressure decelerates the 
growth of subpopulations with reduced amount of transgene mRNA. 
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In conclusion, cells with a higher copy number should have a generaly higher doubling time, 
balancing the adverse loss of transgene mRNA. To this end I performed the Pearson and the 
Spearman correlation, employing the Jmp10 software (Figure 50). This was done for all eGFP-
expressing CHO cell pools at the beginning of the cultivation with the copy number and the doubling 
time T2 of all cell cultures (Korzynska & Zychowicz, 2008).  
The resulting low correlation was significant in the parametric and the non-parametric model. This 
led to the assumption that high copy number pools partly tend to lose transgene mRNA which in 
turn results in an overall higher doubling time of the stable high expressers. 
 
 
Figure 50: Correlation study of copy number and doubling time of cell culture. Pairwise correlation was calculated with 
the parametric Pearson test, whereas the Spearman calculation was used for the non-parametric test. Both correlations 
were low to moderate but significant. 
 
4.2.2.2    Copy number and CMV promoter methylation 
With regard to the correlation of copy number and CMV promoter methylation (Figure 42 C and D), 
I investigated the time-dependent alteration of both markers. For this purpose the methylation and 
copy number values obtained 42 and 69 days after transfection were plotted for each promoter 
variant in an outlier boxplot (Figure 51). It could be clearly observed that in general the copy number 
declines whereas the methylation of hCMV-MIE increases over time. This confirms the association of 
high copy numbers with the reduction of copies and the increase of DNA methylation (Mauro et al., 
2015; Osterlehner et al., 2011). The coincidence of these events led to the assumption that primarily 
unmethylated transgenes are even more prone for loss of copies by their higher accessibility (Lay et 
al., 2015).  
Following this I propose that G-179 results in a stable expression over time whereas the less stable 
promoter variants compensate the selection disadvantage with gene amplification. This gene 
amplification in turn promotes the promoter methylation and a declined copy number. Hence the 
inverse behavior of both marks might be enforced by a primarily reduction of unmethylated 
transgenes. 
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Figure 51: Box plot of the average CMV methylation and transgene copy number of GFP expressing pools. The alteration 
of both markers were compared for promoter variants CCG (N=10), CGC (N=8) and the control CCC (N=10). Hence a 
general reduction of copy numbers and an increase of CMV methylation could be observed. The box plot shows the 1st 
and 3rd quartile indicated by the ends of the box, whereby the horizontal line within the box represents the median 
sample value. The end of the box has extended lines which represent the whiskers. 
 
Besides the point mutations, no general alteration of the methylation patterns was observed 
between the promoter variants. However the G-179 construct tended to have a general lower CMV 
promoter methylation, which can be seen at the other predominately methylated CpGs. This might 
be either a direct effect of the point mutation or an indirect effect due to the lower number of 
transgene copies. Control and G-41 pools are highly methylated in particular at position -179 
upstream of TSS. This confirms previous results (Osterlehner et al., 2011) and indicates the 
importance of this specific CpG site within the silencing mechanisms of transgenes. 
 
4.2.2.3    General different effect strength of point mutations 
Osterlehner et al (2011) proposed that the degree of methylation of single CpGs is an indicator  
of stability. Especially the methylation degree of C-179 can be used to predict stability of monoclonal 
cell lines. It seems plausible that the mutation of the CpG site with the highest susceptibility  
for methylation also results in the most prominent effect compared to control. In fact, the 
expression and stability was outstanding in clonal cell lines containing the G-179 constructs. Among 
the various factors that affect transgene silencig like the copy number, the number of tandem 
repeats, the sequence and location of the transgene, I propose that G-179 mutation elicits a 
dominant role. 
In addition to the possibility of CpG methylation (Brooks et al., 2004; Kim et al., 2011; Yang et al., 
2010a), CpG richness itself may attract protein complexes which promote accumulation of H3K4me3 
(Thomson et al., 2010) and H3K27me3 (Mendenhall et al., 2010). Furthermore, a gradually increasing 
GC skew might promote stable expression as it was observed in highly transcribed prototypical 
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housekeeping genes (Ginno et al., 2013). It was shown that a general depletion of CpGs around the 
transcription start site of a promoter can reduce silencing (Swindle, Kim & Klug, 2004). However my 
results indicate that the combined mutations do not enhance the stability in eGFP cell pools (GGG) 
nor in antibody clonal cell lines (CGG) at least not to levels that were observed for single mutations, 
in particular the C to G conversion of the most methylated cytosine located -179 bp upstream of TSS 
resulted in the most stable cell lines. This illustrates the importance of the methylation degree at 
each individual CpG site as it was proposed previously (Nile et al., 2008). Furthermore, I propose that 
the underlying epigenetic mechanism is highly sensible for alterations of each CpG and precise 
adjustment of the promoter methylation pattern might be more effective than a general depletion 
of CpGs. 
 
4.2.2.4    Presumable influence of G-179 mutation in the cell line development after 
screening for high producers. 
The comparison of CHO pools and clonal cell lines indicate that factors like copy number can 
influence the expression to compensate lower activity per transgene even at low selection pressure 
(Figure 42). Depending on the intensities of the selection pressure this effect might be also seen  
in clonal cell lines, which will reduce the direct benefit of G-179 mutation over unmutated control. 
The additional screening step for high producers will further reduce the direct advantage of  
the promoter variant. However, these selection steps only mask the advantage of G-179 by 
enforcing the accumulation of unmutated producers with higher copy numbers. In large batch 
cultures the selection agent will be removed and consequently the evolutionary pressure which 
keeps unstable producers stable disappears. From the previous results I presume that the  
G-179 constructs might lead to more stable producers with a lower number of copies after 
screening. 
 
4.3 Epigenetic landscape of CHO-K1-M cells and potential stable integration 
sites 
4.3.1 Location of integration sites of randomly transfected CHO-K1 pools 
The mapping of histone modification with the broad peak modus of MACS2 led to a coverage of 
8.2% for H3K36me3 and 6.7% for H3K9me3 all over the CHO-K1 genome. However more peaks were 
detected for H3K9me3 with 150496 peaks compared to the 46214 peaks of the H3K36me3. This 
implies that the H3K36me3 modification covers larger areas than H3K9me3 and has broader peaks. 
For this reason the peak counting around integration sites must be considered with caution and the 
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inspection of single integration sites and the appropriate chromatin marks was essential to estimate 
the activity of the regions. The analysis of the H3K9me3/H3K36me3 ratios was done to enable a 
generalized statement about predominantly active and inactive regions. For this reason the 
statistical ratio of 3.25x H3K9me3 per H3K36me3 peaks was calculated by the inclusion of all 
mapped H3K9me3 and H3K36me3 peaks and compared to the ratios obtained for peaks +/- 6500 
bps around of integration sites. Hence a general increase of H3K9me3 close to the integration sites 
could be observed (Table 28). From this I propose that the integration or that the following gene 
amplification is not truly random and occurs frequently in H3K9me3 dense regions (Aldrich & 
Maggert, 2014). To enable stable integration, plasmids were enzymatically linearized. The resulting 
non-homologous ends of the linearized plasmids should be consequently integrated by the non-
homologous end joining mechanism (NHEJ). From this it was proposed that in euchromatin the NHEJ 
preferably occurs in inactive H3K36me3 depleted regions whereas homologous recombination (HR) 
was predominantly found in actively transcribed regions (Aymard et al., 2014). For this reason the 
integration might preferably occur in accessible but inactive euchromatin regions, whereupon the 
moderate activity might be compensated by gene amplification and subsequent 
heterochromatinization. 
Without threshold settings for the integration sites, the histone modification ratios were higher than 
the statistical ratio but similar between high eGFP and low eGFP expressing cell pools. Considering 
that the low eGFP expressing pools should mainly correspond to inactive integration sites, the 
relatively high proportion of H3K36me3 indicates the presence a second class of active integration 
sites. The heterogeneity lead to an implausible modification ratio. For this reason, integration sites 
were sorted for their read coverage and those sites with less than 100x coverage were excluded. As 
a result, integration sites of the eGFP negative sorted pools, obtained a notably higher ratio 
compared to the positive sorted pools. The fraction of H3K9me3 was twice as much as was 
calculated for the general statistical ratio.  
Furthermore the counting of all integration sites showed that the high eGFP expressing pools (except 
4.6), yielded more integration sites than the low eGFP expressing pools. This seems plausible 
considering that a loss of copy number is associated with a declined productivity (Osterlehner et al., 
2011). The higher eGFP intensity observed in the 4.6 (-) pool might explain the contrasty high 
number of integration sites within this sort. For comparison, the copy number per pool was 
determined as described previously. Hence the same tendencies were observed within each pool 
sort (1.7 +/-) as was seen for all unsorted integration sites. This suggests that the most of the 
integration sites are not unspecific background reads. However most of the integration sites are 
infrequently as it is indicated by the coverage. Those integration sites might not have a great 
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influence on the general expression level of eGFP, which would explain the similar 
H3K9me3/H3K36me3 ratios although the eGFP expression levels between low and high eGFP 
expressing pools were different. 
 
 Positive sorted eGFP pools Negative sorted eGFP pools 
pool identification 1.7 (+) 2.3 (+) 4.6 (+) 1.7 (-) 2.3 (-) 4.6 (-) 
# of Integration sites 8452 1855 1621 976 502 1945 
# of Integration sites >100x coverage 19 4 11 4 13 39 
copy number per cell 50 13 5 4 5 9 
 
Table 30: Number of integration sites per pool before and after sort for integration sites with a coverage of higher than 
100x. Copy number of transgenes per cell was calculated. The same trend between negative and positive sorted pools 
was seen for copy number as well as for all integration sites. 
 
4.3.2 Discrimination of active and inactive integration sites 
The ratio H3K9me3/H3K36me3 for the unfiltered integration sites (coverage > 0) was similar 
between high eGFP and low eGFP expressing pools (Table 28). This illustrates the challenge of 
defining the right and plausible threshold for the integration sites. Similar to “omics” studies the 
small number of samples and the high number of analytes can result in a high number of false 
positive or negatives (Dietmair, Nielsen & Timmins, 2012). However, all mapped integration sites 
might be specific as the similarity between the alteration of copy numbers and the number of 
unfiltered integration sites within one pool sort suggests. But under the chosen experimental 
conditions I was not able to correlate any single integration site to the appropriate expression 
stability. However the simultaneous investigation of many different cells enables the identification 
of overall histone modification patterns which describe general associations between expression and 
location of transgenes.  
Following the assumption that the integration sites that were covered most are also the most 
prominent integration sites, the three single integration sites per pool with the highest coverage 
were chosen for the visual analyses of the adjacent region (Figure 48). This way the background 
integration sites were excluded as well as those integration sites which might only have minor 
contributions to the overall transgene expression. For all low eGFP expressing pools the most 
prominent single integration sites were surrounded by the inactivation mark H3K9me3. This seems 
plausible considering that the absence of eGFP signal follows the complete silencing of all 
transgenes. The most prominent integration sites of the high eGFP expressing pools are surrounded 
by H3K36me3 in five out of nine cases. The Pool 1.7 with the clearest difference between the high 
and low eGFP expressing subpopulations (Figure 46) also showed the strongest association of active 
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chromatin status and integration sites that support transgene expression (Figure 48). In contrast, the 
2.3 (+) in one case and in particular the high eGFP expressing pool 4.6 (+) revealed integration sites 
with repressive H3K9me3 marks. However both pools neither reached the same eGFP expression 
levels nor a comparable sharpness as was seen for the high eGFP expressing pool 1.7. Considering 
this I propose that the broader peaks correspond to a higher variability of cells with different 
integration sites. In conclusion the highest coverage might not belong to most stable integration site 
within the variable pools. In addition, not all the integration sites of high eGFP expressing pools are 
necessarily in active regions as long as some integration sites are active. Hence the chance that the 
prominent integration sites of high eGFP expressing pools support stable expression, increases with 
the number of adjacent active marks. 
 
4.3.3 Perspective 
My preliminary results lead me to propose an influence of the chromatin state on the stability of the 
integration site. To confirm this hypothesis I suggest two different approaches. Initially and directly I 
suggest to explore the targeted integration of transgenes expressing the reporter eGFP by employing 
the CRISPR/Cas9 technology (Lee et al., 2015). If the results are promising the assay should be 
repeated with an antibody reporter. 
For this purpose the integration site must be well chosen. Many of the aligned integration sites were 
found in small contigs of the CHO-K1 genome, closer than 6,500 bps to one contig end or in the 
absence of any histone modification. Therefore the chosen filter settings exclude many potentially 
stable integration sites. For this reason I reviewed whether the three highest covered integration 
sites per pool are also highly covered compared to all possible integration sites. I found that in the 
high eGFP expressing pool 1.7 (+), the highest covered integration site close to histone modifications 
in contig gi|529983619|gb|APMK01090275.1| was ranked place four according to the coverage  
of all integration sites (Table 31). As a consequence both sites should be investigated as  
potentially active ones. The integration site of low eGFP expressing pool 1.7 (-) within the  
contig gi|529840071|gb|APMK01159973.1| is surrounded by heterochromatin and therefore is 
suitable for use as a negative control. From this approach I expect production stabilities and 
expression degrees which confirm the selection of the chosen locations.  
contig start end cov chromatin state expression 
gi|529983619|gb|APMK01090275.1| 11339 11522 1640 active  yes 
gi|529537223|gb|APMK01302182.1| 2250 2473 3106 no mark yes 
gi|529840071|gb|APMK01159973.1| 24537 12592 1160 inactive no 
 
Table 31: Integration sites or target oriented integration. First integration site is encircled by active histone marks in an 
eGFP expressing pool. The second integration sites is the highest covered site, but without any surrounding marks. The 
third negative sorted integration site is in a heterochromatin region and can be used as negative control. 
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In the second approach the identification of integration sites of random integrations after 
transfection of CHO-K1 cells should be repeated. At least five replications should be investigated to 
increase the significance. Furthermore, the eGFP sorting window should be tightly focused to 
promote the development of a well-defined subpopulation, comparable to the high eGFP expressing 
pool 1.7 (+). From this I expect the reduction of background integration sites and facilitated analyses 
of stable and unstable locations. The extension of cultivation time, followed by resorting will also 
support the formation of an isolated subpopulation and is strongly recommended.  
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5 Appendix 
 
5.1 Supplement tables 
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Cell line 
me of C-179 in % ∆qP (60 generations) in % Plasmid copies/cell 
H3 H3ac/H3 H3K4me3/H3 H3K27me3/H3 
biol. replicate biol. replicate biol. replicate biol.  replicate 
PSB +MSX -MSX PSB 
1 2 3 1 2 3 1 2 3 1 2 3 
H-1 15.7 -46.80 -80.20 168.8 54.44 53.69 59.58 0.19 0.01 0.03 0.02 0.02 0.03 1.35 1.72 1.28 
H-2 9.9 -71.00 -70.30 2.0 2.41 1.08 1.55 0.17 0.11 0.35 0.19 0.19 0.38 3.11 2.07 5.53 
H-3 16.5 -73.10 -89.60 3.2 2.08 2.15 2.27 0.21 0.12 222.35 1.02 1.75 0.35 2.36 2.17 4.88 
H-4 10.5 -69.30 -69.50 2.9 2.71 2.54 2.23 0.36 0.25 0.09 0.28 0.05 0.09 7.08 3.29 2.62 
H-5 11.0 -40.40 -48.80 1.8 2.09 2.02 2.21 0.11 0.04 0.39 0.33 0.05 0.07 5.92 2.24 7.33 
H-6 7.1 -79.50 -71.70 37.6 27.60 32.60 30.63 0.01 0.06 0.02 0.03 0.01 0.02 1.11 2.64 2.04 
H-7 4.8 -66.20 -81.50 53.0 44.84 44.12 49.98 0.01 0.02 0.03 0.02 0.03 0.02 1.21 2.43 2.03 
H-8 4.4 -67.40 -75.70 30.6 37.44 28.77 36.50 0.02 0.03 0.04 0.01 0.03 0.10 1.57 1.56 1.84 
H-9 23.4 -87.00 -77.00 95.1 67.96 60.83 60.13 0.01 0.05 0.02 0.01 0.04 0.06 1.71 2.91 2.16 
H-10 26.2 -16.40 -73.30 48.8 46.31 45.05 36.50 0.01 0.12 0.02 0.01 0.09 0.04 1.31 3.97 1.51 
H-11 0.2 -43.10 -96.10 3.3 0.21 9.43 0.54 0.70 1.48 1.82 15.62 1.40 3.47 4.30 10.14 13.78 
H-12 0.1 -42.00 -33.00 1.5 0.11 4.95 0.19 2.41 2.22 2.42 6.54 3.72 1.44 7.34 17.07 8.28 
H-13 1.3 8.00 -18.50 1.1 1.14 4.90 0.35 0.21 0.98 2.23 0.29 3.92 9.21 9.92 103.97 16.00 
H-14 0.0 6.80 5.40 1.3 0.12 8.04 0.25 2.29 1.19 2.98 2.46 4.12 1.16 200.16 15.33 2.65 
H-15 0.1 -16.50 -40.40 3.5 0.29 9.83 0.45 0.85 1.33 1.87 0.40 0.97 1.47 2.44 3.71 38.23 
H-16 0.4 16.20 -32.80 3.0 0.12 6.12 0.50 1.14 2.12 1.84 1.88 3.93 4.85 25.78 7.35 12.35 
H-17 1.0 -13.20 -31.30 4.2 0.42 5.19 0.29 0.59 1.84 4.31 1.47 2.15 0.56 7.03 8.33 4.06 
H-18 46.3 -67.50 319.40 8.8 3.08 6.98 2.65 0.37 2.28 0.17 0.21 1.88 0.12 2.64 11.38 2.17 
H-19 16.7 -11.20 2.70 10.1 4.44 6.93 4.36 0.13 0.85 0.09 0.19 1.13 0.15 2.51 3.67 2.27 
H-20 21.8 -40.30 -80.60 4.8 0.61 3.82 0.32 0.38 1.55 1.20 0.70 4.14 1.78 22.21 43.51 1.62 
 
Table 32: Data of normalized histone3 and histone3 modification, DNA methylation, plasmid number and stability of 20 CHO cell lines of project H. Transgene LC and HC copy numbers are 
comparable. LC transgene copy number was used for the effect measurements and is here described as plasmid copies/cell. Highlighted cells are described in results or discussion. 
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Cell 
line 
me of C-
179 in % 
∆qP (60 
generations) in % 
Plasmid 
copies/cell 
H3 H3ac/H3 H3K4me3/H3 H3K27me3/H3 H3K)me3/H3 
biol. replicate biol. replicate biol. replicate biol.  replicate biol.  replicate 
PSB +MSX -MSX PSB 
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
T-1 0.44 -35.40 -34.20 4.4 0.70 0.38 0.33 0.27 0.19 0.47 0.09 0.22 0.15 8.30 14.04 19.74 151.52 19.38 20.92 
T-2 2.20 -30.60 -72.00 11.5 0.98 1.38 1.16 0.17 0.12 1.40 0.09 0.05 0.05 11.75 3.16 6.13 8.72 4.62 8.66 
T-3 3.54 -81.60 -96.60 9.4 0.87 0.61 0.77 0.20 0.24 0.21 0.12 0.13 0.38 6.48 6.30 16.60 8.03 3.66 5.66 
T-4 0.92 -23.40 -47.40 4.6 0.48 0.27 0.41 0.17 0.47 1.79 0.15 0.19 0.15 17.19 45.25 195.81 23.86 530.06 94.35 
T-5 4.41 -15.60 -22.20 5.3 0.11 0.06 0.40 0.99 2.66 0.59 0.18 0.32 0.28 38.23 6.62 16.49 321.42 13.96 10.27 
T-6 0.47 -14.40 -20.40 2.6 0.26 0.09 0.36 0.51 1.24 0.33 0.12 0.23 0.49 25.99 7.62 44.74 14.83 4.29 34.78 
T-7 0.22 -16.20 -31.80 1.6 0.51 0.58 0.88 0.32 0.31 0.11 0.13 0.03 0.06 193.56 7.43 11.63 9.96 4.78 7.98 
T-8 52.40 -64.80 -79.20 64.3 265.64 186.97 212.31 0.00 0.00 0.00 0.00 0.00 0.00 0.63 0.67 0.96 1.62 1.56 1.74 
T-9 52.84 -27.60 -49.20 67.5 142.68 91.14 83.87 0.00 0.00 0.00 0.00 0.00 0.00 0.40 0.54 1.03 0.98 1.81 1.84 
T-10 49.61 3.60 1.20 70.5 82.71 109.39 75.06 0.00 0.00 0.01 0.00 0.00 0.00 0.85 0.43 1.21 1.79 1.51 1.47 
T-11 2.02 -10.20 -21.60 4.6 3.46 5.07 3.57 0.06 0.02 0.06 0.01 0.01 0.01 5.19 0.96 2.14 156.86 3.67 1.90 
T-12 61.34 -32.40 -22.80 11.5 15.60 13.77 11.06 0.01 0.01 0.02 0.00 0.00 0.01 0.87 1.78 2.07 1.59 3.00 2.70 
 
Table 33: Data of normalized histone3 and histone3 modification, DNA methylation, plasmid number and stability of twelve CHO cell lines of project T. Transgene LC and HC copy numbers 
are comparable. LC transgene copy number was used for the effect measurements and is here described as plasmid copies/cell 
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5.2 Abbreviations 
A Adenine 
Amp Ampicillin 
BSA Bovine Serum Albumin 
C Cytosine 
ChIP Chromatin Immunoprecipitation 
CHO Chinese Hamster Ovary 
CHO-K1 cell Chinese Hamster Ovary cell line K1 
CMV Cytomegalovirus-Promoter 
CpG Cytosine-phosphat-Guanine 
DAC 5-Aza-2-Deoxycytidine 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic Acid 
DNMT DNA Methyltransferase 
dNTP Deoxynucleotidethriphosphate 
DTT Dithiothreitol 
EDTA Ethylendiaminetetraacetate 
eGFP enhanced Green Fluorescent Protein 
EGTA Ethylenglycol-bis(2-aminethyl)-N,N,N,N-tetraacetic acid 
Eif3i Eukaryotic translation initiation factor 3, subunit I 
EtBr Ethidiumbromide 
F Forward 
Foxa2 Forkhead box A2 
Gata5 Gata binding protein 5 
Gusb Glucuronidase, beta 
G Guanine 
h hour 
H2A Histone 2 A 
H3 Histone 3 
H3ac acetylated Histone 3 
H3K4me3 trimethylated lysine 4 at Histone 3 
H3K9me trimethylated lysine 9 at Histone 3 
H3K27me3 trimethylated lysine 27 at Histone 3 
HAT Histone Acetyltransferases 
HDAC Histone Deacetylase 
HEPES (N-(2-Hydroxyethyl)piperazine-H´-(2-ethanesulfonic acid) 
HMT Histone Methyltransferase 
HP1 Heterochromatin protein 1 
HRP Horseradish Peroxidase 
Ig Immunoglobulin 
IP Immunoprecipitation 
kb Kilobase 
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kDA Kilo Dalton 
M Molar 
min minute 
ml milliliter 
mM Millimolar 
MNase Micrococcal Nuclease 
mRNA Messenger RNA 
OD Optical Densitiy 
PAGE Polyacrylamide Gel Electrophoresis 
PBS Phosphate Buffered Saline 
PcG Polycomb Group 
PCR Polymerase Chain Reaction 
PEST Proline (P), Glutamic acid (E), Serine (S), and Threonine (T) rich 
PFA Paraformaldehyde 
PMSF Phenylmethanesulfonyl Fluoride 
PTM Posttranslational Modification 
PVDF Polyvinylidene Fluoride 
qP specific Productivity (pg/cell/day) 
∆qP percentual alteration of qP 
rCN relative Copy Number 
R Reverse 
Rho Rhodopsin 
RNA Ribonucleic acid 
RT Room Temperature 
SDS Sodiumdodecylsulfate 
T Thymine 
Temed N,N,N,N-Tetramethylethylenediamine 
UAS Upstream Activating Sequence 
UHRF1 Ubiquitin-like plant Homeodomain and RING Finger domain 1 
Unc13c Unc-13 homolog C (C. elegans), transcript variant X1 
UV Ultraviolet 
V Volt 
v/v Volume per volume 
WT Wild Type 
w/v Weight per volume 
µg Microgramm 
µl Microliter 
µM Micromolar 
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